0001558370-21-006266.txt : 20210506 0001558370-21-006266.hdr.sgml : 20210506 20210506163903 ACCESSION NUMBER: 0001558370-21-006266 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NextCure, Inc. CENTRAL INDEX KEY: 0001661059 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475231247 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38905 FILM NUMBER: 21898511 BUSINESS ADDRESS: STREET 1: 9000 VIRGINIA MANOR ROAD, SUITE 200 CITY: BELTSVILLE STATE: MD ZIP: 20705 BUSINESS PHONE: 240-399-4900 MAIL ADDRESS: STREET 1: 9000 VIRGINIA MANOR ROAD, SUITE 200 CITY: BELTSVILLE STATE: MD ZIP: 20705 10-Q 1 nxtc-20210331x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

⌧	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2021

◻	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to .

Commission File Number: 001-38905

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware	04-5231247
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

9000 Virginia Manor Road, Suite 200 Beltsville, Maryland	20705
(Address of principal executive offices)	(Zip Code)

(240) 399-4900

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered:
Common Stock, $0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻	Accelerated filer ◻
Non-accelerated filer ⌧	Smaller reporting company ⌧
	Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ◻ No ⌧

As of May 5, 2021, the registrant had 27,609,863 shares of common stock, par value $0.001 per share, issued and outstanding.

Table of Contents

NextCure, Inc.

Form 10-Q

For the Quarter Ended March 31, 2021

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
	Condensed Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020	1
	Unaudited Condensed Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2021 and 2020	2
	Unaudited Condensed Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and 2020	3
	Unaudited Condensed Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020	4
	Notes to Unaudited Condensed Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	23
Item 4.	Controls and Procedures	23
Part II. OTHER INFORMATION		24
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3.	Defaults Upon Senior Securities	26
Item 4.	Mine Safety Disclosures	26
Item 5.	Other Information	26
Item 6.	Exhibits	27
SIGNATURES		28

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

NEXTCURE, INC.

CONDENSED BALANCE SHEETS

(unaudited, in thousands, except share and per share amounts)


	March 31,		December 31,
	2021		2020
Assets
Current assets:
Cash and cash equivalents	$	36,527	$	32,772
Marketable securities		231,709		250,676
Restricted cash		1,706		1,706
Prepaid expenses and other current assets		3,109		2,824
Total current assets		273,051		287,978
Property and equipment, net		15,470		15,809
Other assets		2,438		2,857
Total assets	$	290,959	$	306,644
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	2,017	$	3,901
Accrued liabilities		4,295		4,627
Deferred rent, current portion		209		130
Term loan, current portion		1,667		1,667
Total current liabilities		8,188		10,325
Deferred rent, net of current portion		2,223		792
Term loan, net of current portion		1,389		1,806
Total liabilities		11,800		12,923
Stockholders’ equity:
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020		—		—
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at March 31, 2021 and December 31, 2020; 27,604,417 and 27,568,802 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		28		28
Additional paid-in capital		413,122		410,551
Accumulated other comprehensive income		179		779
Accumulated deficit		(134,170)		(117,637)
Total stockholders’ equity		279,159		293,721
Total liabilities and stockholders’ equity	$	290,959	$	306,644

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share amounts)


	Three Months Ended
	March 31,
	2021		2020
Revenue:
Revenue from former research and development arrangement	$	—	$	22,378

Operating expenses:
Research and development		12,386		10,578
General and administrative		4,848		3,588
Total operating expenses		17,234		14,166
(Loss) income from operations		(17,234)		8,212
Other income, net		701		1,521
Net (loss) income	$	(16,533)	$	9,733
(Loss) earnings per share:
Basic	$	(0.60)	$	0.35
Diluted	$	(0.60)	$	0.33

Shares used in the calculation of (loss) earnings per share:
Basic		27,597,426		27,506,927
Diluted		27,597,426		29,348,615
Comprehensive (loss) income:
Net (loss) income	$	(16,533)	$	9,733
Unrealized loss on marketable securities		(600)		(543)
Total comprehensive (loss) income	$	(17,133)	$	9,190

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited, in thousands, except share data)




	Stockholders’ Equity
				Additional
	Common Stock			Paid-in		Accumulated Other		Accumulated		Stockholders’
	Shares	Amount		Capital		Comprehensive Income (Loss)		Deficit		Equity
Balance as of December 31, 2020	27,568,802	$	28	$	410,551	$	779	$	(117,637)	$	293,721
Stock-based compensation	—		—		2,508		—		—		2,508
Issuance of common stock	35,615		—		63		—		—		63
Unrealized loss on marketable securities, net of tax $0	—		—		—		(600)		—		(600)
Net loss	—		—		—		—		(16,533)		(16,533)
Balance as of March 31, 2021	27,604,417	$	28	$	413,122	$	179	$	(134,170)	$	279,159




	Stockholders’ Equity
				Additional
	Common Stock			Paid-in		Accumulated Other		Accumulated		Stockholders’
	Shares	Amount		Capital		Comprehensive Income (Loss)		Deficit		Equity
Balance as of December 31, 2019	27,499,260	$	27	$	402,529	$	(38)	$	(81,034)	$	321,484
Stock-based compensation	—		—		1,008		—		—		1,008
Issuance of common stock	17,142		1		36		—		—		37
Unrealized loss on marketable securities, net of tax $0	—		—		—		(505)		—		(505)
Net income	—		—		—		—		9,733		9,733
Balance as of March 31, 2020	27,516,402	$	28	$	403,573	$	(543)	$	(71,301)	$	331,757

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)


	Three Months Ended
	March 31,
	2021		2020
Cash flows from operating activities:
Net (loss) income	$	(16,533)	$	9,733
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization		1,105		751
Stock-based compensation		2,508		1,008
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(285)		606
Accounts payable		(1,884)		402
Accrued liabilities		(332)		(812)
Deferred rent		1,510		96
Deferred revenue		—		(22,378)
Net cash used in operating activities		(13,911)		(10,594)
Cash flows from investing activities:
Maturities of marketable securities		56,786		30,349
Purchases of marketable securities		(38,420)		(23,531)
Purchase of property and equipment		(766)		(1,445)
Net cash provided by investing activities		17,600		5,373
Cash flows from financing activities:
Proceeds from issuances of common stock		63		37
Payments of the term loan		(417)		(277)
Net cash used in financing activities		(354)		(240)
Net increase (decrease) in cash, cash equivalents and restricted cash		3,335		(5,461)
Cash, cash equivalents and restricted cash — beginning of period		36,284		39,130
Cash, cash equivalents and restricted cash — end of period	$	39,619	$	33,669

Supplemental disclosures of cash flow information:
Cash paid for interest	$	36	$	35
Cash paid for income taxes	$	—	$	—

Supplemental disclosures of noncash investing and financing activities:
Purchase of property and equipment included in accrued liabilities	$	—	$	156

The accompanying notes are an integral part of these unaudited condensed financial statements.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

1. Nature of the Business

Organization

NextCure, Inc. (“NextCure” or the “Company”) was incorporated in Delaware in September 2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (“FIND-IO”) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company’s product candidates, building and optimizing the Company’s manufacturing capabilities and conducting discovery, research and development activities for the Company’s product candidates, discovery programs and its FIND-IO platform.

Liquidity

The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through March 31, 2021, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company’s former agreement with Eli Lilly and Company, which was terminated in March 2020 (see Note 6). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.

Risks and Uncertainties

COVID-19

In March 2020, the World Health Organization declared the novel coronavirus disease 2019 (“COVID-19”), outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities, including clinical trial sites. However, the Company’s laboratories have continued operations throughout the pandemic mostly without interruption.

The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company’s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of “lockdown,” “social distancing” and “shelter in place” directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic initially placed significant strain on the Company’s clinical trial sites, have raised concerns around monitoring patient safety, and caused enrollment to slow in the Phase 2 portion of the ongoing Phase 1/2 monotherapy clinical trial of the Company’s lead product candidate, NC318. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company’s planned activities.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

2. Summary of Significant Accounting Policies

There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Basis of Presentation

The unaudited condensed financial statements include the accounts of NextCure and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”).

Unaudited Financial Information

In the opinion of management, the information furnished reflects certain adjustments, all of which are of a normal and recurring nature and are necessary for a fair presentation of the Company’s financial position as of the reported balance sheet date and of the Company’s results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.

Recently Issued Accounting Pronouncements

The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 (Topic 842), Leases (“ASC 842”). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

periods under previous lease accounting guidance. The Company is currently evaluating the impact of adopting this guidance on the Company’s financial statements. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the total assets and total liabilities that it reports relative to such amounts presented prior to adoption.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s financial statements.

The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company’s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations.

3. Restricted Cash

The Company is required, as a condition of its $5.0 million term loan (the “Term Loan”), to maintain cash collateral on deposit in a segregated money market bank account equal to the principal portion of the Term Loan, as determined on a quarterly basis. The bank may restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The required Term Loan reserve totaled $3.1 million and $3.5 million as of March 31, 2021 and December 31, 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying condensed balance sheets.

The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the condensed statement of cash flows:


	March 31,		December 31,
(in thousands)	2021		2020
Cash and cash equivalents	$	36,527	$	32,772
Restricted cash (including $1,386 and $1,806 in other assets as of March 31, 2021 and December 31, 2020, respectively)		3,092		3,512
Total	$	39,619	$	36,284

4. Marketable Securities

Marketable securities consist of the following:


	March 31, 2021
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
(in thousands)	Cost		Gain		Loss		Fair Value
Corporate bonds	$	231,530	$	337	$	(158)	$	231,709
Total	$	231,530	$	337	$	(158)	$	231,709

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)


	December 31, 2020
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
(in thousands)	Cost		Gain		Loss		Fair Value
Corporate bonds	$	242,900	$	854	$	(75)	$	243,679
Commercial paper		6,997		—		—		6,997
Total	$	249,897	$	854	$	(75)	$	250,676

The Company uses the specific identification method when calculating realized gains and losses. For the three months ended March 31, 2021 and 2020, respectively, the Company recorded approximately $54,000 and $64,000 in realized gains on available-for-sale securities, which is included in other income, net on the condensed statements of operations.

The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.

The following table summarizes maturities of the Company’s investments available-for-sale as of March 31, 2021:


	March 31, 2021
			Fair
(in thousands)	Cost		Value
Maturities:
Within 1 year	$	115,920	$	116,233
Between 1 to 2 years		115,610		115,476
Total investments available for sale	$	231,530	$	231,709

The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying condensed balance sheets based on the highly-liquid nature of these investment securities and because these investment securities are considered available for use in current operations.

5. Fair Value Measurements

The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

Level 1—Quoted market prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy as of March 31, 2021 and December 31, 2020:


	March 31, 2021
					Significant
			Quoted Prices in		Other
			Active Markets or		Observable		Significant
			Identical Assets		Inputs		Unobservable
(in thousands)	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	19,185	$	19,185	$	—	$	—
Marketable securities:
Corporate bonds		231,709		—		231,709		—
Total	$	250,894	$	19,185	$	231,709	$	—


	December 31, 2020
					Significant
			Quoted Prices in		Other
			Active Markets or		Observable		Significant
			Identical Assets		Inputs		Unobservable
(in thousands)	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	11,155	$	11,155	$	—	$	—
Marketable securities:
Corporate bonds		243,679		—		243,679		—
Commercial paper		6,997		—		6,997		—
Total	$	261,831	$	11,155	$	250,676	$	—

The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March 31, 2021 and 2020.

6. Former Agreement with Eli Lilly and Company

On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the “Lilly Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which the Company agreed to use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly terminated the Lilly Agreement without cause.

The Company recognized revenue under the Lilly Agreement of $22.4 million for the three months ended March 31, 2020. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company.

7. Stock-Based Compensation

Employee Equity Plans

The NextCure, Inc. 2015 Omnibus Incentive Plan (the “2015 Plan”) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

The NextCure, Inc. 2019 Omnibus Incentive Plan (the “2019 Plan”) became effective on May 8, 2019, the date on which the Company’s Registration Statement on Form S-1 filed in connection with the IPO was declared effective (the “Effective Date”). The Company’s board of directors (the “Board”) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company’s officers, employees, non-employee directors and other key persons (including consultants).

The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan automatically increase each January 1st during the term of the 2019 Plan by 4% of the number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or such lesser number of shares determined by the Board.

As of March 31, 2021, 2,589,208 shares were reserved for future grant under the 2019 Plan.

Stock options granted under the 2015 Plan and 2019 Plan (together, the “Plans”) to employees generally vest over four years and expire after ten years.

A summary of stock option activity for awards under the Plans is presented below:


	Options Outstanding and Exercisable
				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value⁽¹⁾
	Shares	Price		Life (Years)	(in thousands)
Outstanding as of December 31, 2020	3,112,376	$	16.95	8.2	$	10,810
Granted	1,313,150	$	12.49
Exercised	(35,615)	$	1.78
Forfeited	(49,776)	$	29.26
Outstanding as of March 31, 2021	4,340,135	$	15.59	8.6	$	8,779
Vested and expected to vest as of March 31, 2021	4,340,135	$	15.59	8.6	$	8,779
Exercisable as of March 31, 2021	1,521,940	$	10.77	8.4	$	6,689

(1)	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at March 31, 2021 and December 31, 2020.

The weighted average grant date fair value of stock options granted to employees for the three months ended March 31, 2021 was $8.57. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $0.3 million. As of March 31, 2021, there was $31.1 million of total unrecognized compensation expense related to unvested options under the Plans that will be recognized over a weighted-average period of approximately 2.7 years.

The aggregate grant date fair value of stock options and restricted stock vested during the three months ended March 31, 2021 and 2020 was approximately $6.4 million and $30.3 million, respectively.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

Stock-based compensation expense was classified on the statements of operations as follows for the three months ended March 31, 2021 and 2020:


	Three Months Ended
	March 31,
(in thousands)	2021		2020
Research and development	$	958	$	452
General and administrative		1,550		556
Total stock-based compensation expense	$	2,508	$	1,008

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:


	Three Months Ended
	March 31,
	2021		2020
Expected term	6.1	years	6.1	years
Expected volatility	79.7	%	69.7	%
Risk free interest rate	0.8 - 1.4	%	0.6 - 1.0	%
Expected dividend yield	—	%	—	%

8. Net (Loss) Income Per Share Attributable to Common Stockholders

(Loss) Earnings per share

The computation of basic (loss) earnings per share ("EPS") is based on the weighted-average number of common shares outstanding, without consideration for dilutive common stock equivalents. The computation of diluted EPS is based on the weighted-average number of common shares outstanding and dilutive potential common shares, which include shares that may be issued under the stock option plan, as determined using the treasury stock method.

The computation for basic and diluted EPS were as follows (in thousands, except share and per share data):


	Three months ended
	March 31,
	2021		2020
(Loss) income (Numerator):
Net (loss) income for basic and diluted EPS	$	(16,533)	$	9,733
Shares (Denominator):
Weighted-average number of common shares outstanding		27,597,426		27,506,927
Effect of dilutive common stock equivalents		—		1,841,688
Weighted-average shares for diluted EPS		27,597,426		29,348,615

Basic EPS	$	(0.60)	$	0.35
Diluted EPS	$	(0.60)	$	0.33

For the three months ended March 31, 2020, options to purchase 3,000 shares of the Company's common stock were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:


	March 31,
	2021		2020
Outstanding options to purchase common stock		4,340,135	3,000
Total		4,340,135	3,000

9. Income Taxes

The Company did not record a provision or benefit for income taxes during the three months ended March 31, 2021 and 2020. The Company continues to maintain a full valuation allowance against its deferred tax assets.

The Company has evaluated the positive and negative evidence involving its ability to realize its deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of any commercially ready products. It has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Management reevaluates the positive and negative evidence at each reporting period.

Under the provisions of Sections 382 and 383 of the Internal Revenue Code (“IRC”), certain substantial changes in the Company’s ownership may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that can be used to reduce future income taxes. We have not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of credits attributable to periods before the change and could result in a reduction in the total credits available.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act includes various income and payroll tax provisions. The Company has analyzed the tax provisions of the CARES Act and determined they have no significant financial impact to the Company’s condensed financial statements. On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed financial statements.

10. Commitments and Contingencies

Legal Proceedings

On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021 and discovery is stayed pending resolution of that motion.

Table of Contents

NEXTCURE, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(unaudited)

by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys’ fees and costs, declaratory relief, corporate governance changes, and restitution. The deadline to respond to the Complaint is May 24, 2021 but we anticipate either stipulating to, or moving for, a stay of proceedings pending resolution of the Ye Zhou action.

The Company intends to vigorously defend the Ye Zhou and Liu actions and believes these cases are without merit. Based on the Company’s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto included in this Quarterly Report and the audited financial information and related notes, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and other disclosures, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, or our 2020 Annual Report. Some of the statements contained in this discussion and analysis or set forth elsewhere in this Quarterly Report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “should,” “due,” “estimate,” “expect,” “intend,” “hope,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “target,” “towards,” “forward,” “later,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements include, but are not limited to, statements about:

●

our expectations regarding the timing, progress and results of preclinical studies and clinical trials for NC318, NC410, NC762 and any other product candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;

●

the impact of the COVID-19 pandemic (including the emergence of variant strains) on the initiation, progress or expected timing of our clinical trials and the timing of related data, our efforts to adjust trial-related activities to address the impact of the COVID-19 pandemic, and other future impacts of the COVID-19 pandemic on the economy, our industry and our financial condition and results of operations;

●

the timing or likelihood of regulatory filings for NC318, NC410, NC762 and any other product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;

●

the identification, analysis and use of biomarkers and biomarker data;

●

development of patient selection assays and companion or complementary diagnostic for NC318, NC410, NC762 or any other product candidates we develop;

●

our manufacturing capabilities and strategy, including the scalability of our manufacturing methods and processes;

●

our expectations regarding the potential benefits, activity, effectiveness and safety of NC318, NC410, NC762 and any other product candidates we develop;

●

our intentions and ability to successfully commercialize our product candidates;

●

our expectations regarding the nature of the biological pathways we are targeting;

●

our expectations for our FIND-IO platform, including our ability to discover and advance product candidates using our FIND-IO platform;

●

the potential benefits of and our ability to maintain our relationships and collaborations with Yale University and Dr. Lieping Chen;

Table of Contents

●

our estimates regarding our expenses, future revenues, capital requirements, our needs for or ability to obtain additional financing and the period over which we expect our current cash, cash equivalents and marketable securities to be sufficient to fund our operations;

●

our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party manufacturers;

●

our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;

●

developments and projections relating to our competitors and our industry, including competing therapies; and

●

the impact of current and future laws and regulations.

Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic (including the emergence of variant strains) on our business, including our clinical trials, third parties on which we rely and our operations; positive results in preclinical studies may not be predictive of the results of clinical trials; our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on our FIND-IO platform; and dependence on key personnel. More detailed information on these and additional factors that could affect our actual results are described under the heading “Risk Factors” in our 2020 Annual Report and in our other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this report, and we assume no obligation to update any forward-looking statements, even if expectations change.

Overview

We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or “FIND-IO”, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition, for these patients.

Our lead product candidate NC318 is a first-in-class immunomedicine against a novel immunomodulatory receptor called Siglec-15, or “S15”. In October 2018, we initiated a Phase 1/2 clinical trial of NC318 in patients with advanced or metastatic solid tumors. We completed enrollment of the Phase 1 portion of this trial in August 2019, and preliminary data from the Phase 1 portion were presented at the Society for Immunotherapy of Cancer annual meeting in November 2019 and updated data were announced in December 2020.

We began enrolling patients in the Phase 2 portion of the Phase 1/2 clinical trial of NC318 trial in October 2019. In this portion, we planned to enroll up to 100 patients with tumor types that have been shown to have elevated S15 expression, including non-small cell lung cancer, or “NSCLC”, ovarian cancer, head and neck squamous cell carcinoma, or “HNSCC”, and triple-negative breast cancer, or “TNBC”. In July 2020, we reported a confirmed partial response in a head and neck squamous cell carcinoma patient. In addition, we reported at the time that we would not progress the NSCLC and ovarian cancer cohorts to the second stage of the Simon 2-stage trial. In December 2020, we completed a retrospective analysis of S15 expression in biopsy samples collected from the Phase 2 patients at their initial screening. Of the evaluable biopsies collected, 13% of the patients enrolled had S15-positive tumors. These biopsies showed that the selection criterion

Table of Contents

did not result in enough S15-positive patients for us to effectively evaluate the activity of NC318 in S15-positive tumors. We are modifying the Phase 2 portion of the trial for S15 selection and expect to begin pre-selecting patients for enrollment, based on S15 expression in the second quarter of 2021 in order to assess response rates in patients selected for S15 positivity. In addition, we believe that scientific evidence supports a combination of NC318 with anti-PD-1 therapy, and we plan to study that combination in NSCLC patients.

Our second product candidate, NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors after a temporary delay due to the COVID-19 pandemic. The Phase 1 dose-escalation portion of this open-label trial is designed to evaluate the safety and tolerability of NC410 in patients with advanced or metastatic solid tumors and determine its pharmacologically active and/or maximum tolerated dose. After a recommended dose for the Phase 2 portion of the trial is determined, the efficacy of NC410 will be evaluated in select tumor types. We expect to announce data from the Phase 1 portion of this trial in the second half of 2021.

Our third product candidate, NC762, is an immunomedicine targeting an immunomodulatory molecule called human B7 homolog 4 protein, or B7-H4. We submitted our investigational new drug application, or IND, to the FDA in the first quarter of 2021, which has been cleared. We intend to initiate a Phase 1/2 clinical trial of NC762 in patients with lung cancer, HER2+ breast cancer, ovarian cancer or potentially other tumor types in the second quarter of 2021. The Phase 1 dose-escalation portion of this open-label trial is being designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. After a recommended dose for the Phase 2 portion of the trial is determined, the efficacy of NC762 will be evaluated in select tumor types.

COVID-19

Financial Overview

Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing capabilities, and conducting discovery, research and development activities for our product candidates, discovery programs and FIND-IO platform.

We have not generated any revenue from product sales and only limited revenue from other sources. As a result, with the exception of the three months ended March 31, 2020, for which we reported a profit due to recognition of deferred

Table of Contents

revenue in connection with the termination of our former research and development collaboration agreement with Eli Lilly and Company, or “Lilly”, we have never been profitable and have incurred net losses since the commencement of our operations. Our net loss for the three months ended March 31, 2021 was $16.5 million and our net income for the three months ended March 31, 2020 was $9.7 million. As of March 31, 2021, we had an accumulated deficit of $134.2 million, primarily as a result of research and development and general and administrative expenses. We do not expect to generate product revenue unless and until we obtain marketing approval and commercialize a product candidate, and we cannot assure you that we will ever generate significant revenue or profits.

We have funded our operations to date primarily with proceeds from public offerings of our common stock, with private placements of our preferred stock and with upfront fees received under our former research and development collaboration agreement with Lilly, or the “Lilly Agreement,” which was terminated in March 2020. From our inception through March 31, 2021, we received gross proceeds of $164.4 million through private placements of preferred stock.

In November 2018, we entered into the Lilly Agreement to use our FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by us and Lilly. We received an upfront payment of $25.0 million in cash and an equity investment of $15.0 million from Lilly upon entering into the Lilly Agreement, and we were eligible for quarterly research and development support payments during a portion of the term of the Lilly Agreement. Effective March 3, 2020, Lilly terminated the Lilly Agreement without cause.

On May 13, 2019, we closed our initial public offering, or “IPO”, in which we sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for aggregate gross proceeds of $86.3 million. The net offering proceeds to us were approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million.

On November 19, 2019, we completed an underwritten public offering, in which we issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for total net proceeds to us of approximately $160.9 million, after deducting underwriting discounts and commissions of approximately $10.3 million and offering expenses of approximately $1.0 million.

As of March 31, 2021, we had cash, cash equivalents and marketable securities, excluding restricted cash, of $268.2 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into the second half of 2023. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.

We expect to incur substantial expenditures in the foreseeable future as we advance our product candidates through clinical development, the regulatory approval process and, if approved, commercialization, and as we expand our pipeline through research and development activities related to our FIND-IO platform and discovery programs. Specifically, in the near term, we expect to incur substantial expenses relating to our ongoing Phase 1/2 clinical trial and planned Phase 2 clinical trial of NC318, our ongoing Phase 1/2 clinical trial of NC410, and our planned Phase 1/2 clinical trial for NC762, and other research and development activities. We expect to continue to incur significantly increased costs as a result of operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.

We will need substantial additional funding to support our continuing operations and to pursue our development strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through a combination of public and private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.

Table of Contents

Components of Our Results of Operations

Revenue

Through March 31, 2021, we have not generated any revenue from product sales.

For additional information about our revenue recognition policy, see Note 2 of the Notes to Financial Statements in our 2020 Annual Report.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our discovery efforts, research activities, development and testing of our product candidates as well as for clinical trials, including:

●

salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions;

●

expenses incurred under agreements with third parties, including agreements with third parties that conduct research, preclinical activities or clinical trials on our behalf, such as our corporate sponsored research agreement, or “SRA,” and our license agreement with Yale University, or “Yale”;

●

costs of outside consultants, including their fees, stock-based compensation and related travel expenses;

●

the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; and

●

facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

We expense research and development costs as incurred. Our expenses related to clinical trials are based on actual costs incurred and estimates of other incurred costs. These estimated costs are based on several factors, including patient enrollment and related expenses at clinical investigator sites, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clinical trials on our behalf. We generally accrue estimated costs related to clinical trials based on contracted amounts applied to the level of patient enrollment and other activity according to the protocol. If future timelines or contracts are modified based on changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis. Historically, any such modifications have not been material.

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we advance our product candidates through development and expand the number of trials we are conducting and the patients enrolled in those trials, as we utilize our current good manufacturing practice, or “cGMP”, manufacturing capacity, including to provide drug supply of NC318, NC410 and NC762 for future clinical trials, and as we expand our pipeline through research and development activities related to our FIND-IO platform and discovery programs.

Table of Contents

We cannot determine with certainty the duration and costs of future clinical trials of NC318, NC410, NC762 or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we may obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of NC318, NC410, NC762 and any other product candidate we may develop will depend on a variety of factors, including:

●

the scope, progress, results and costs of clinical trials of NC318 and NC410 and NC762, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;

●

the impact of the COVID-19 pandemic, including delays and slowdowns as a result of strain on our clinical trial sites and concerns about patient safety;

●

uncertainties in selection of indications, clinical trial design and patient enrollment rates;

●

the probability of success for our product candidates, including safety and efficacy, early clinical data, competition, ease and ability of manufacturing and commercial viability;

●

significant and changing government regulation and regulatory guidance;

●

the timing and receipt of any development or marketing approvals; and

●

the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of a product candidate could lead to a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time to complete clinical development for any such product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel-related costs, including payroll and stock-based compensation, for personnel in executive, finance, human resources, business and corporate development and other administrative functions, professional fees for legal, intellectual property, consulting and accounting services, rent and other facility-related costs, depreciation and other general operating expenses not otherwise classified as research and development expenses. General and administrative expenses also include all patent-related costs incurred in connection with filing and prosecuting patent applications, which are expensed as incurred.

We anticipate that our general and administrative expenses will increase substantially during the next few years as a result of staff expansion and additional occupancy costs, higher legal and accounting fees, investor relations costs, higher insurance premiums and other compliance costs.

Other Income, Net

Other income, net consists primarily of interest income earned on marketable securities and payment of interest on our term loan with a commercial bank, or the “Term Loan”.

Table of Contents

Results of Operations

Comparison of the Three Months Ended March 31, 2021 and 2020

The following table summarizes our results of operations for the periods indicated (in thousands):


	Three Months Ended
	March 31,
	2021		2020		Change
Revenue:
Revenue from former research and development arrangement	$	—	$	22,378	$	(22,378)

Operating expenses:
Research and development		12,386		10,578		1,808
General and administrative		4,848		3,588		1,260
(Loss) income from operations		(17,234)		8,212		(25,446)
Other income, net		701		1,521		(820)
Net (loss) income	$	(16,533)	$	9,733	$	(26,266)

Revenue from Research and Development Arrangement

Revenue was $0 and $22.4 million for the three months ended March 31, 2021 and 2020, respectively. The decrease in revenue for the three months ended March 31, 2021 compared to the same period in 2020 is related to the recognition of all of the deferred revenue under the Lilly Agreement as of the Lilly Termination Date. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company.

Research and Development Expenses

The following table summarizes our research and development expenses by product candidate for the periods indicated (in thousands):


	Three Months Ended
	March 31,
	2021		2020			Change
External research and development expenses:
NC318	$	1,441	$	2,946	$	(1,505)
NC410		1,228		409		819
Programs in discovery and preclinical development		3,876		3,055		821
Total external research and development expenses		6,545		6,410		135
Total internal research and development expenses		5,841		4,168		1,673
Total research and development expenses	$	12,386	$	10,578	$	1,808

We do not allocate personnel-related costs, including stock-based compensation costs, or other indirect costs to specific programs, as they are deployed across multiple projects under development and discovery and, as such are separately classified as internal research and development expenses in the table above.

Research and development expenses for the three months ended March 31, 2021 increased by $1.8 million to $12.4 million compared to $10.6 million for the three months ended March 31, 2020. The increase was driven primarily by $1.3 million in personnel-related costs, offset by timing of clinical supply and costs associated with our NC318 trials. Other significant components of the increase in research and development expenses included costs related to advancing NC410 and our other development programs.

Table of Contents

General and Administrative Expenses

General and administrative expenses for the three months ended March 31, 2021 increased by $1.3 million to $4.9 million as compared to $3.6 million for the three months ended March 31, 2020. The increase was driven primarily by $1.0 million in personnel-related costs.

Other Income, Net

Other income, net for the three months ended March 31, 2021 decreased by $0.8 million to $0.7 million from $1.5 million for the three months ended March 31, 2020 due to lower investment balances and a reduction in interest rates.

Liquidity and Capital Resources

We have financed our operations primarily with proceeds from public offerings of our common stock, private placements of our preferred stock and upfront fees received under the Lilly Agreement. On May 13, 2019, we closed our IPO, in which we sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for net offering proceeds to us of approximately $77.0 million after deducting underwriting discounts and commissions and offering expenses. On November 19, 2019, we completed an underwritten public offering in which we sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at a public offering price of $36.75. Net offering proceeds to us were approximately $160.9 million after deducting underwriting discounts and commissions and offering expenses. Since inception, we have received aggregate gross proceeds of $164.4 million from the sale and issuance of shares of our preferred stock. In addition, in November 2018, we received an upfront payment of $25.0 million in cash from Lilly pursuant to the Lilly Agreement. Our cash and cash equivalents are held in money market funds.

As of March 31, 2021, we had cash and cash equivalents and marketable securities, excluding restricted cash, of $268.2 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into the second half of 2023.

In April 2016, we entered into the Term Loan to finance laboratory equipment purchases. In January 2019, we amended the Term Loan to increase our borrowing capacity from $1.0 million to $5.0 million. As amended, the Term Loan matures in January 2023. Under the Term Loan, we are obligated to make interest-only payments through January 2020 and 36 equal monthly payments of principal plus accrued interest thereafter through January 2023. As of March 31, 2021, our outstanding borrowings under the Term Loan were $3.1 million.

We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through sale of equity, debt financings, strategic alliances and licensing arrangements. Adequate additional funding may not be available to us on acceptable terms or at all, including as a result of the impact of the COVID-19 pandemic. If we fail to raise capital or enter into such arrangements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates or delay our efforts to expand our pipeline of product candidates.

Table of Contents

Cash Flows

The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):


	Three Months Ended
	March 31,
	2021		2020
Net cash provided by (used in) :
Operating activities	$	(13,911)	$	(10,594)
Investing activities		17,600		5,373
Financing activities		(354)		(240)
Net increase (decrease) in cash and cash equivalents	$	3,335	$	(5,461)

Cash Used in Operating Activities

Net cash used in operating activities was $13.9 million for the three months ended March 31, 2021, which was primarily due to our net loss of $16.5 million. Net cash used in operating activities was $10.6 million for the three months ended March 31, 2020, which was primarily due to the recognition of deferred revenue related to the terminated Lilly Agreement of $22.4 million, partially offset by our net income of $9.7 million and non-cash charges of $1.8 million for share-based compensation and depreciation.

Cash Used in Investing Activities

Cash provided by investing activities for the three months ended March 31, 2021 was $17.6 million, which was primarily due to net proceeds from marketable securities of $18.4 million, partially offset by purchases of property and equipment of $0.8 million. Cash provided by investing activities for the three months ended March 31, 2020 was $5.4 million, which was primarily due to net proceeds from marketable securities of $6.8 million, partially offset by purchases of property and equipment of $1.4 million.

Cash Provided by Financing Activities

Cash used in financing activities was $0.4 million for the three months ended March 31, 2021, which consisted primarily of payments related to the Term Loan. Cash used in financing activities was $0.2 million for the three months ended March 31, 2020, which consisted primarily of payments related to the Term Loan.

Contractual Obligations and Commitments

There have been no material changes outside the ordinary course of business to our contractual obligations during the three month period ended March 31, 2021, as compared to those disclosed in our 2020 Annual Report.

Critical Accounting Policies, Significant Judgments and Use of Estimates

Our condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or “GAAP”. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. The most significant assumptions used in the financial statements are the underlying assumptions used in revenue recognition and valuing share-based compensation, including the fair value of our common stock in periods before our IPO. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.

Table of Contents

During the three months ended March 31, 2021, there were no material changes to our critical accounting policies reported in our 2020 Annual Report.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.

Recent Accounting Pronouncements

See Note 2 to our unaudited condensed financial statements included elsewhere in this Quarterly Report for a discussion of recent accounting pronouncements that may impact our financial position and results of operations.

Emerging Growth Company Status

As an emerging growth company, or “EGC”, under the Jumpstart Our Business Startups Act of 2012, or the “JOBS Act”, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. We have elected to take advantage of the extended transition period for adopting new or revised accounting standards that have different effective dates for public and private companies until such time as those standards apply to private companies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the “Exchange Act”, as of March 31, 2021. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the quarter ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

The information set forth under the heading “Legal Proceedings” in Note 10, Commitments and Contingencies, in Notes to Condensed Financial Statements in Item 1 of Part I of this Quarterly Report, is incorporated herein by reference. In addition, from time to time, we are involved in litigation or other legal proceedings as part of our ordinary course of business. In the opinion of our management, the ultimate disposition of these legal proceedings in the ordinary course of business are not likely to have a material adverse effect on our business.

Item 1A. Risk Factors.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described in the “Risk Factors” section of our 2020 Annual Report together with certain updated risk factors described below and all of the other information in this Quarterly Report, including our financial statements and the related notes and the information described in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. If any of the risks described in our filings with the SEC actually occurs, our business, results of operations, financial conditions, cash flows or prospects could be harmed. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.

The impacts of the COVID-19 pandemic could continue to adversely affect our business.

In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities, including clinical trial sites. While we are considered an essential business under applicable regulations and continue to operate, the impacts of COVID-19 initially placed significant strain on our clinical trial sites, have raised concerns around monitoring patient safety, and caused enrollment to slow in the Phase 2 portion of the ongoing Phase 1/2 monotherapy clinical trial of our lead product candidate, NC318. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. We are continuing to work closely with our clinical partners and have taken steps as necessary to adjust our protocols and timelines due to the impact of the COVID-19 pandemic. Specifically, initial data from the Phase 2 portion of our ongoing Phase 1/2 clinical trial of NC318 was temporarily delayed, and the initial delay of our Phase 2 clinical trial to evaluate NC318 in combination with standard of care chemotherapies was due to COVID-19. In addition, we delayed until July 2020 initiation of the Phase 1 portion of our Phase 1/2 clinical trial of NC410 despite being prepared to begin the trial in March 2020. The impacts of the COVID-19 pandemic could adversely affect our clinical trials and operations in other ways as well. For example, challenges may arise as a result of patients, members of the clinical team, or our employees becoming infected with COVID-19 or otherwise unable or unwilling to participate in trials or come to work, as applicable, as a result of COVID-19, interruptions to the supply chain or manufacturing, site closures, or difficulties in meeting protocol-specified procedures, including difficulties adhering to protocol-mandated visits and testing. The COVID-19 pandemic may also increase the likelihood and severity of other risks discussed in the “Risk Factors” section of our 2020 Annual Report and this Quarterly Report, including but not limited to risks related to the conduct, progress and outcomes of clinical trials, risks related to reliance on third parties, risks related to our operations and dependence on key personnel, and risks related to our need to obtain additional capital.

The COVID-19 pandemic and its impacts continue to evolve, including the emergence of variant strains of the COVID-19 virus. Although vaccines are now available are being distributed globally, we cannot predict the full scope, duration and severity of disruptions resulting from COVID-19 or their impacts on us. Business disruptions for us or the third parties with whom we engage, including the collaborators, contract organizations, third-party manufacturers, suppliers, clinical trial sites, regulators and other third parties with whom we conduct business could materially and negatively impact our ability to conduct our business in the manner and on the timelines presently planned. The extent to which the COVID-19 pandemic may impact our business and financial performance will depend on future developments,

Table of Contents

which are highly uncertain and cannot be predicted with confidence, including the scope and duration of the pandemic and the extent and effectiveness of government restrictions, relief measures and other actions implemented to address the impact of the pandemic, and resulting economic impacts.

Recently announced interim results regarding our NC318 monotherapy Phase 1/2 clinical trial may adversely impact our product development efforts.

In July 2020, we announced that based on the current enrollment criteria and clinical response data, we did not plan at that time to advance the NSCLC and ovarian cancer cohorts of our NC318 Phase 1/2 monotherapy clinical trial into the stage 2 portion of the Simon 2-stage trial. In December 2020, we announced that the initial selection criterion did not result in enough S15-positive patients for us to effectively evaluate the activity of NC318 in S15-positive tumors. We are modifying the Phase 2 portion of the trial for S15 selection and expect to begin pre-selecting patients for enrollment based on S15 expression in the second quarter of 2021, which we anticipate will allow us to assess response rates in patients selected for S15 positivity. The developments in this trial could increase the costs and lengthen the timeline for this trial, adversely impact our ability to enroll patients and impair our ability to gain regulatory approval for and commercialize NC318. We could also make decisions about pursuing particular tumor types based on incomplete facts, resulting in decisions to either pursue indications that we should not pursue, or to not pursue indications that we should pursue. In addition, our former chief medical officer resigned effective August 4, 2020, and a new chief medical officer was appointed effective January 14, 2021. This transition could also delay or otherwise adversely impact our development efforts for NC318 and our other product candidates. Any of these developments could damage our reputation or investor confidence in our company, disrupt our broader research and development, impact our ability to raise capital, or hinder our ability to execute our strategic plans, which could have a material adverse effect on our business, financial condition, operating results and prospects.

We are now and may in the future be subject to securities litigation, which can be expensive and could divert management’s attention.

On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys’ fees and costs, declaratory relief, corporate governance changes, and restitution. For more information regarding these proceedings, please refer to Note 10 to the Company’s Condensed Financial Statements.

We intend to vigorously defend these actions. However, whether or not the claims are successful, litigation is often expensive and can divert management’s attention and resources from other business concerns, which could adversely affect our business. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations.

We may be the target of similar litigation in the future. The market price of our common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. Any future litigation could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business. We maintain liability insurance; however, if any costs or expenses associated with the Ye Zhou action, Liu action or any other litigation exceed our insurance coverage, we may be forced to bear some or all of these costs and expenses directly, which could be substantial.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

The exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, below.


Exhibit No.		Exhibit Description

31.1		Certification of Michael Richman pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Steven P. Cobourn pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Michael Richman and Steven P. Cobourn pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EX-101.INS		XBRL Instance Document

EX-101.SCH		XBRL Taxonomy Extension Schema Document

EX-101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

EX-101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

EX-101.LAB		XBRL Taxonomy Extension Label Linkbase Document

EX-101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NEXTCURE, INC.

Date: May 6, 2021	By:	/s/ Michael Richman
	Name:	Michael Richman
		President and Chief Executive Officer

Date: May 6, 2021	By:	/s/ Steven P. Cobourn
	Name:	Steven P. Cobourn
		Chief Financial Officer

EX-31.1 2 nxtc-20210331ex3115dcb26.htm EX-31.1

EXHIBIT 31.1

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Michael Richman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of NextCure, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 6, 2021


/s/ Michael Richman
Name:	Michael Richman
Title:	President and Chief Executive Officer

EX-31.2 3 nxtc-20210331ex3124a8a29.htm EX-31.2

EXHIBIT 31.2

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Steven P. Cobourn, certify that:

1. I have reviewed this quarterly report on Form 10-Q of NextCure, Inc.;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 6, 2021


/s/ Steven P. Cobourn
Name:	Steven P. Cobourn
Title:	Chief Financial Officer

EX-32.1 4 nxtc-20210331ex3216bda16.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NextCure, Inc. (the “Company”) for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned each hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge, on the date hereof:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: May 6, 2021

	/s/ Michael Richman
	Name:	Michael Richman
	Title:	President and Chief Executive Officer



Dated: May 6, 2021

	/s/ Steven P. Cobourn
	Name:	Steven P. Cobourn
	Title:	Chief Financial Officer

EX-101.INS 5 nxtc-20210331.xml EX-101.INS 0001661059 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001661059 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001661059 us-gaap:RetainedEarningsMember 2021-03-31 0001661059 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001661059 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001661059 us-gaap:RetainedEarningsMember 2020-12-31 0001661059 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001661059 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001661059 us-gaap:RetainedEarningsMember 2020-03-31 0001661059 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001661059 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001661059 us-gaap:RetainedEarningsMember 2019-12-31 0001661059 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001661059 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001661059 nxtc:A2015OmnibusIncentivePlanMember 2020-01-01 2020-03-31 0001661059 nxtc:A2015OmnibusIncentivePlanMember 2020-01-01 2020-12-31 0001661059 nxtc:A2015OmnibusIncentivePlanMember 2020-12-31 0001661059 srt:MinimumMember 2021-01-01 2021-03-31 0001661059 srt:MaximumMember 2021-01-01 2021-03-31 0001661059 srt:MinimumMember 2020-01-01 2020-03-31 0001661059 srt:MaximumMember 2020-01-01 2020-03-31 0001661059 nxtc:ResearchAndDevelopmentCollaborativeAgreementMember 2020-01-01 2020-03-31 0001661059 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001661059 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001661059 nxtc:A2015OmnibusIncentivePlanMember 2021-01-01 2021-03-31 0001661059 nxtc:A2015OmnibusIncentivePlanMember 2021-03-31 0001661059 us-gaap:CommonStockMember 2021-03-31 0001661059 us-gaap:CommonStockMember 2020-12-31 0001661059 us-gaap:CommonStockMember 2020-03-31 0001661059 us-gaap:CommonStockMember 2019-12-31 0001661059 nxtc:EmployeeStockPurchase2019PlanMember 2021-03-31 0001661059 nxtc:OmnibusIncentive2019PlanMember 2019-05-03 0001661059 2020-03-31 0001661059 2019-12-31 0001661059 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001661059 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0001661059 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001661059 us-gaap:CorporateDebtSecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0001661059 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:CorporateDebtSecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-12-31 0001661059 us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0001661059 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001661059 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001661059 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001661059 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001661059 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001661059 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001661059 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001661059 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001661059 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001661059 nxtc:OmnibusIncentive2019PlanMember 2019-05-03 2019-05-03 0001661059 nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember 2021-01-01 2021-03-31 0001661059 2020-12-31 0001661059 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001661059 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001661059 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001661059 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001661059 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0001661059 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001661059 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001661059 2020-01-01 2020-03-31 0001661059 2021-03-31 0001661059 2021-05-05 0001661059 2021-01-01 2021-03-31 iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares false --12-31 Q1 2021 2021-03-31 10-Q 0001661059 27609863 Yes true false Non-accelerated Filer Yes NextCure, Inc. false true Common Stock, $0.001 par value per share NXTC 115610000 115476000 <div> <div> Recently Issued Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies.   In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 (Topic 842), Leases (“ASC 842”). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year.  As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022.  Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. The Company is currently evaluating the impact of adopting this guidance on the Company’s financial statements. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the total assets and total liabilities that it reports relative to such amounts presented prior to adoption.       In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s financial statements. The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company’s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations. <div /></div> </div> 96000 1510000 -22378000 261831000 11155000 250676000 250894000 19185000 231709000 -505000 -505000 -600000 -600000 3500000 3100000 3512000 3092000 1806000 1386000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Maturities: </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Within 1 year </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 115,920 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 116,233 </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Between 1 to 2 years </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 115,610 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 115,476 </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total investments available for sale </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,530 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> </tr> </table></div>   <div /></div> </div> P10Y 0.04

3901000

2017000

4627000

4295000

779000

179000

410551000

413122000

1008000

2508000

1008000

556000

452000

2508000

1550000

958000

3000

4340135

306644000

290959000

287978000

273051000

854000

337000

75000

158000

249897000

6997000

242900000

231530000

231709000

231530000

115920000

116233000

250676000

6997000

243679000

6997000

243679000

6997000

243679000

231709000

250676000

231709000

64000

54000

<div> <div> There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Basis of Presentation The unaudited condensed financial statements include the accounts of NextCure and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”). Unaudited Financial Information In the opinion of management, the information furnished reflects certain adjustments, all of which are of a normal and recurring nature and are necessary for a fair presentation of the Company’s financial position as of the reported balance sheet date and of the Company’s results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. <div /></div> </div>

156000

32772000

36527000

<div> <div> 3. Restricted Cash The Company is required, as a condition of its $5.0 million term loan (the “Term Loan”), to maintain cash collateral on deposit in a segregated money market bank account equal to the principal portion of the Term Loan, as determined on a quarterly basis. The bank may restrict withdrawals or transfers by or on behalf of the Company that would violate this requirement. The required Term Loan reserve totaled $3.1 million and $3.5 million as of March 31, 2021 and December 31, 2020, respectively. These amounts are presented in part as restricted cash and in part as other assets on the accompanying condensed balance sheets. The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the condensed statement of cash flows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="middle" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="middle" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,527 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 32,772 </td> </tr> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash (including $1,386 and $1,806 in other assets as of March 31, 2021 and December 31, 2020, respectively) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,092 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,512 </td> </tr> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 39,619 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,284 </td> </tr> </table></div>   <div /></div> </div>

11155000

19185000

39130000

33669000

36284000

39619000

-5461000

3335000

<div> <div> 6. Former Agreement with Eli Lilly and Company<a name="a6AgreementwithEliLillyandCompany_802770"></a>  On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the “Lilly Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which the Company agreed to use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly terminated the Lilly Agreement without cause.  The Company recognized revenue under the Lilly Agreement of $22.4 million for the three months ended March 31, 2020. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company.   <div /></div> </div>

<div> <div> 10. Commitments and Contingencies Legal Proceedings On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021 and discovery is stayed pending resolution of that motion.   On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys’ fees and costs, declaratory relief, corporate governance changes, and restitution.  The deadline to respond to the Complaint is May 24, 2021 but we anticipate either stipulating to, or moving for, a stay of proceedings pending resolution of the Ye Zhou action.   The Company intends to vigorously defend the Ye Zhou and Liu actions and believes these cases are without merit. Based on the Company’s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.   <div /></div> </div>

2900000

2589208

0.001

100000000

27568802

27604417

27499260

27516402

27568802

27604417

28000

9190000

-17133000

5000000

130000

209000

792000

2223000

751000

1105000

<div> <div> 7. Stock‑Based Compensation<a name="a11StockBasedCompensation_727125"></a> Employee Equity Plans The NextCure, Inc. 2015 Omnibus Incentive Plan (the “2015 Plan”) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The NextCure, Inc. 2019 Omnibus Incentive Plan (the “2019 Plan”) became effective on May 8, 2019, the date on which the Company’s Registration Statement on Form S-1 filed in connection with the IPO was declared effective (the “Effective Date”). The Company’s board of directors (the “Board”) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and cash bonus awards to the Company’s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan automatically increase each January 1st during the term of the 2019 Plan by 4% of the number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or such lesser number of shares determined by the Board. As of March 31, 2021, 2,589,208 shares were reserved for future grant under the 2019 Plan. Stock options granted under the 2015 Plan and 2019 Plan (together, the “Plans”) to employees generally vest over four years and expire after ten years. A summary of stock option activity for awards under the Plans is presented below:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:39.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding and Exercisable </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value(1) </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of December 31, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,112,376 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 16.95 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.2 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,810 </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,313,150 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.49 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (35,615) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.78 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (49,776) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 29.26 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of March 31, 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,340,135 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15.59 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.6 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,779 </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest as of March 31, 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,340,135 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15.59 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8.6 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,779 </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of March 31, 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,521,940 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10.77 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.4 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,689 </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at March 31, 2021 and December 31, 2020. </td></tr></table></div> The weighted average grant date fair value of stock options granted to employees for the three months ended March 31, 2021 was $8.57. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $0.3 million. As of March 31, 2021, there was $31.1 million of total unrecognized compensation expense related to unvested options under the Plans that will be recognized over a weighted-average period of approximately 2.7 years. The aggregate grant date fair value of stock options and restricted stock vested during the three months ended March 31, 2021 and 2020 was approximately $6.4 million and $30.3 million, respectively. Stock-based compensation expense was classified on the statements of operations as follows for the three months ended March 31, 2021 and 2020:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.08%;"> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 958 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 452 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,550 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 556 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,508 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,008 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>     The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.1 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years  </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.1 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years  </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 79.7 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 69.7 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk free interest rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.8 - 1.4 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.6 - 1.0 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   <div /></div> </div>

0.35

-0.60

0.33

-0.60

<div> <div> 8. Net (Loss) Income Per Share Attributable to Common Stockholders (Loss) Earnings per share The computation of basic (loss) earnings per share ("EPS") is based on the weighted-average number of common shares outstanding, without consideration for dilutive common stock equivalents. The computation of diluted EPS is based on the weighted-average number of common shares outstanding and dilutive potential common shares, which include shares that may be issued under the stock option plan, as determined using the treasury stock method. The computation for basic and diluted EPS were as follows (in thousands, except share and per share data): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (Loss) income (Numerator): </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net (loss) income for basic and diluted EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (16,533) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,733 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Shares (Denominator): </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average number of common shares outstanding </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 27,597,426 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 27,506,927 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Effect of dilutive common stock equivalents </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,841,688 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average shares for diluted EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 27,597,426 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 29,348,615 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Basic EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.60) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.35 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Diluted EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.60) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   For the three months ended March 31, 2020, options to purchase 3,000 shares of the Company's common stock were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive. For the three months ended March 31, 2021, all shares of options to purchase shares of the Company’s common stock were excluded from the computation of diluted net loss per share as the effect would have been anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:24.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding options to purchase common stock </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,340,135 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,000 </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,340,135 </td> <td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,000 </td> </tr> </table></div>   <div /></div> </div>

31100000

P2Y8M12D

<div> <div> The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy as of March 31, 2021 and December 31, 2020:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:45.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets or </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19,185 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19,185 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 250,894 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19,185 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 231,709 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:45.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets or </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,155 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,155 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 243,679 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 243,679 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,997 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,997 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 261,831 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,155 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 250,676 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 5. Fair Value Measurements<a name="a3FairValueofFinancialInstruments_290669"></a> The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. Level 1—Quoted market prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy as of March 31, 2021 and December 31, 2020:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:45.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets or </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19,185 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19,185 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 250,894 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19,185 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 231,709 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:45.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Quoted Prices in </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Other </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Active Markets or </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Observable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Significant </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Identical Assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Inputs </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unobservable </td> </tr> <tr> <td valign="bottom" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 1) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 2) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (Level 3) </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash equivalents: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Money market funds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,155 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,155 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Marketable securities: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 243,679 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 243,679 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,997 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,997 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="top" style="width:43.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 261,831 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,155 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 250,676 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> </table></div>   The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March 31, 2021 and 2020. <div /></div> </div>

3588000

4848000

<div> <div> 9. Income Taxes The Company did not record a provision or benefit for income taxes during the three months ended March 31, 2021 and 2020. The Company continues to maintain a full valuation allowance against its deferred tax assets. The Company has evaluated the positive and negative evidence involving its ability to realize its deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of any commercially ready products. It has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Management reevaluates the positive and negative evidence at each reporting period. Under the provisions of Sections 382 and 383 of the Internal Revenue Code (“IRC”), certain substantial changes in the Company’s ownership may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that can be used to reduce future income taxes. We have not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of credits attributable to periods before the change and could result in a reduction in the total credits available. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act includes various income and payroll tax provisions. The Company has analyzed the tax provisions of the CARES Act and determined they have no significant financial impact to the Company’s condensed financial statements. <a name="_Hlk512945225"></a>On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed financial statements. <div /></div> </div>

402000

-1884000

-812000

-332000

-606000

285000

35000

36000

<div> <div> 4. Marketable Securities Marketable securities consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:48.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Estimated </td> </tr> <tr> <td valign="middle" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gain </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Loss </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 231,530 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 337 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (158) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 231,709 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,530 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 337 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (158) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:48.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Estimated </td> </tr> <tr> <td valign="middle" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gain </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Loss </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 242,900 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 854 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (75) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 243,679 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,997 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,997 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 249,897 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 854 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (75) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 250,676 </td> </tr> </table></div>   The Company uses the specific identification method when calculating realized gains and losses. For the three months ended March 31, 2021 and 2020, respectively, the Company recorded approximately $54,000 and $64,000 in realized gains on available-for-sale securities, which is included in other income, net on the condensed statements of operations.   The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.   The following table summarizes maturities of the Company’s investments available-for-sale as of March 31, 2021:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Maturities: </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Within 1 year </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 115,920 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 116,233 </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Between 1 to 2 years </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 115,610 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 115,476 </td> </tr> <tr> <td valign="bottom" style="width:73.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total investments available for sale </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,530 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> </tr> </table></div>     <a name="_Hlk71011781"></a>The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying condensed balance sheets based on the highly-liquid nature of these investment securities and because these investment securities are considered available for use in current operations. <div /></div> </div>

12923000

11800000

306644000

290959000

10325000

8188000

1667000

1806000

1389000

-240000

-354000

5373000

17600000

-10594000

-13911000

9733000

-16533000

14166000

17234000

8212000

-17234000

<div> <div> 1. Nature of the Business<a name="a1NatureoftheBusinessandBasisofPresentat"></a> Organization NextCure, Inc. (“NextCure” or the “Company”) was incorporated in Delaware in September 2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first‑in‑class immunomedicines to treat cancer and other immune‑related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno‑Oncology (“FIND‑IO”) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company’s product candidates, building and optimizing the Company’s manufacturing capabilities and conducting discovery, research and development activities for the Company’s product candidates, discovery programs and its FIND‑IO platform. Liquidity The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through March 31, 2021, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company’s former agreement with Eli Lilly and Company, which was terminated in March 2020 (see Note 6). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.  Risks and Uncertainties COVID-19 In March 2020, the World Health Organization declared the novel coronavirus disease 2019 (“COVID-19”), outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities, including clinical trial sites. However, the Company’s laboratories have continued operations throughout the pandemic mostly without interruption. The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company’s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of “lockdown,” “social distancing” and “shelter in place” directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic initially placed significant strain on the Company’s clinical trial sites, have raised concerns around monitoring patient safety, and caused enrollment to slow in the Phase 2 portion of the ongoing Phase 1/2 monotherapy clinical trial of the Company’s lead product candidate, NC318. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company’s planned activities. <div /></div> </div>

2857000

2438000

-543000

-600000

1521000

701000

23531000

38420000

1445000

766000

0.001

10000000

2824000

3109000

37000

63000

30349000

56786000

9733000

-16533000

15809000

15470000

277000

417000

10578000

12386000

1706000

-117637000

-134170000

22378000

22400000

<div> <div> Marketable securities consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:48.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31, 2021 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Estimated </td> </tr> <tr> <td valign="middle" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gain </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Loss </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 231,530 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 337 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (158) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 231,709 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,530 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 337 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (158) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 231,709 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:48.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, 2020 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gross </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amortized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Unrealized </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Estimated </td> </tr> <tr> <td valign="middle" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Cost </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Gain </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Loss </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Corporate bonds </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 242,900 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 854 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (75) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 243,679 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Commercial paper </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,997 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6,997 </td> </tr> <tr> <td valign="bottom" style="width:49.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 249,897 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 854 </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (75) </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 250,676 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the condensed statement of cash flows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="middle" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="middle" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="middle" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash and cash equivalents </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,527 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 32,772 </td> </tr> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash (including $1,386 and $1,806 in other assets as of March 31, 2021 and December 31, 2020, respectively) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,092 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,512 </td> </tr> <tr> <td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 39,619 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36,284 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The computation for basic and diluted EPS were as follows (in thousands, except share and per share data): <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months ended </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (Loss) income (Numerator): </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net (loss) income for basic and diluted EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (16,533) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 9,733 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Shares (Denominator): </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average number of common shares outstanding </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 27,597,426 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 27,506,927 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Effect of dilutive common stock equivalents </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,841,688 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted-average shares for diluted EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 27,597,426 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 29,348,615 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Basic EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.60) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.35 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Diluted EPS </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (0.60) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.33 </td> <td valign="bottom" style="width:00.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div>     <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.08%;"> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="middle" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 958 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 452 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,550 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 556 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:73.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total stock-based compensation expense </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,508 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,008 </td> <td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:39.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Outstanding and Exercisable </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value(1) </td> </tr> <tr> <td valign="bottom" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Life (Years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of December 31, 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,112,376 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 16.95 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.2 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10,810 </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,313,150 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12.49 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (35,615) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.78 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (49,776) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 29.26 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding as of March 31, 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4,340,135 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15.59 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.6 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,779 </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested and expected to vest as of March 31, 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,340,135 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15.59 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8.6 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 8,779 </td> </tr> <tr> <td valign="top" style="width:58.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercisable as of March 31, 2021 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,521,940 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 10.77 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.4 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6,689 </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></hr></div> The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at March 31, 2021 and December 31, 2020. <div /></div> </div>

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:25.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.1 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years  </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.1 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years  </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 79.7 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 69.7 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk free interest rate </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.8 - 1.4 </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.6 - 1.0 </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:66.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   <div /></div> </div>

1008000

2508000

P4Y

0.00

P6Y1M6D

0.010

0.006

0.014

0.008

0.697

0.797

300000

49776

1313150

8.57

10810000

8779000

3112376

4340135

16.95

15.59

P8Y2M12D

P8Y7M6D

6689000

1521940

10.77

P8Y4M24D

8779000

4340135

15.59

P8Y7M6D

30300000

6400000

1.78

29.26

12.49

<div> <div> 2. Summary of Significant Accounting Policies<a name="a2SummaryofSignificantAccountingPolicies"></a> There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Basis of Presentation The unaudited condensed financial statements include the accounts of NextCure and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”). Unaudited Financial Information In the opinion of management, the information furnished reflects certain adjustments, all of which are of a normal and recurring nature and are necessary for a fair presentation of the Company’s financial position as of the reported balance sheet date and of the Company’s results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. Recently Issued Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies.   In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 (Topic 842), Leases (“ASC 842”). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year.  As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022.  Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. The Company is currently evaluating the impact of adopting this guidance on the Company’s financial statements. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the total assets and total liabilities that it reports relative to such amounts presented prior to adoption.       In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s financial statements. The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company’s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations. <div /></div> </div>

321484000

-38000

402529000

27000

-81034000

331757000

-543000

403573000

28000

-71301000

293721000

779000

410551000

28000

-117637000

279159000

179000

413122000

28000

-134170000

17142

35615

37000

36000

1000

63000

nxtc:RelatedPartyMember

1841688

29348615

27597426

27506927

27597426

EX-101.SCH 6 nxtc-20210331.xsd EX-101.SCH 00100 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Marketable Securities - (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Fair Value Measurements - (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders - Other (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Term Loan - Maturities (Details)_Calc2 link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED BALANCE SHEETS - (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Former Agreement with Eli Lilly and Company (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Stock-Based Compensation - Stock options (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Stock-Based Compensation - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders - Anti-dilutive effect (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Income Taxes - (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of the Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Restricted Cash link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Former Agreement with Eli Lilly and Company link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Restricted Cash (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nxtc-20210331_cal.xml EX-101.CAL EX-101.DEF 8 nxtc-20210331_def.xml EX-101.DEF EX-101.LAB 9 nxtc-20210331_lab.xml EX-101.LAB Cover Abstract Statement [Table] Statement [Line Items] Document Type Document Period End Date Entity Registrant Name Entity Central Index Key Title of 12(b) Security Trading Symbol Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED BALANCE SHEETS Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Debt Securities, Available-for-sale, Current Marketable securities Restricted Cash, Current Restricted cash Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Deferred Rent Credit, Current Deferred rent, current portion Long-term Debt, Current Maturities Term loan, current portion Liabilities, Current Total current liabilities Deferred Rent Credit, Noncurrent Deferred rent, net of current portion Long-term Debt, Excluding Current Maturities Term loan, net of current portion Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders’ equity Preferred Stock, Value, Issued Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at March 31, 2021 and December 31, 2020, no shares issued and outstanding at March 31, 2021 and December 31, 2020 Common Stock, Value, Issued Common stock, par value of $0.001 per share; 100,000,000 shares authorized at March 31, 2021 and December 31, 2020; 27,604,417 and 27,568,802 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance at the end Balance at the beginning Total stockholders’ equity Liabilities and Equity Total liabilities and stockholders’ equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value per share Preferred Stock, Shares Authorized Preferred stock, number of shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value per share Common Stock, Shares Authorized Common stock, number of shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Balance at the end (in shares) Balance at the beginning (in shares) Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Revenue from Contract with Customer [Abstract] Revenue: Revenue from Contract with Customer, Excluding Assessed Tax Revenue from former research and development arrangement Revenue, Product and Service [Extensible List] Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) (Loss) income from operations Other Nonoperating Income (Expense) Other income, net Net Income (Loss) Attributable to Parent Net (loss) income Net (loss) income Net (loss) income for basic and diluted EPS Earnings Per Share, Basic and Diluted [Abstract] (Loss) earnings per share Earnings Per Share, Basic Basic EPS (in dollars per share) Basic (in dollars per share) Earnings Per Share, Diluted Diluted EPS (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Shares used in the calculation of (loss) earnings per share Weighted Average Number of Shares Outstanding, Basic Weighted-average number of common shares outstanding (in shares) Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares for diluted EPS (in shares) Diluted (in shares) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Comprehensive (loss) income: Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Unrealized loss on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive (loss) income CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income (Loss) Retained Earnings [Member] Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Deficit Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock based compensation Stock Issued During Period, Value, New Issues Issuance of common stock Stock Issued During Period, Shares, New Issues Issuance of common stock (in shares) Adjusted amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities. Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted Unrealized loss on marketable securities, net of tax $0 Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Unrealized loss on marketable securities, tax CONDENSED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) income Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Share-based Compensation Stock-based compensation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued liabilities Amount of increase (decrease) of consideration of unpaid rent that provides economic benefits in future periods. Increase Decrease In Deferred Rent Deferred rent Amount of increase (decrease) in deferred income from related party and obligation to transfer product and service to customer for which consideration has been received or is receivable. Increase (Decrease) in Deferred Revenue From Related Party Deferred revenue Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Proceeds from Sale and Maturity of Marketable Securities Maturities of marketable securities Payments to Acquire Marketable Securities Purchase of marketable securities Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuances of common stock Repayments of Debt Payments of the term loan Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash—beginning of period Total Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Noncash Investing and Financing Items [Abstract] Supplemental disclosures of noncash investing and financing activities: Capital Expenditures Incurred but Not yet Paid Purchase of property and equipment included in accrued liabilities Nature of the Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of the Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Restricted Cash. Cash and Cash Equivalents Disclosure [Text Block] Restricted Cash Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Securities Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements N/A Former Agreement with Eli Lilly and Company Collaborative Arrangement Disclosure [Text Block] Former Agreement with Eli Lilly and Company Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Net (Loss) Income Per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Net (Loss) Income Per Share Attributable to Common Stockholders Income Taxes Income Tax Disclosure [Text Block] Income Taxes Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Basis of Accounting, Policy [Policy Text Block] Basis of Presentation and Unaudited Financial Information Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy pertaining to new accounting pronouncement that has been issued but not yet adopted. Description of New Accounting Pronouncements Not yet Adopted [Policy Text Block] Recently Issued Accounting Pronouncements Cash, Cash Equivalents and Investments [Table Text Block] Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of marketable securities Tabular disclosure of the maturities of available-for-sale securities from cost basis to fair value. Schedule Of Available For Sale Securities Maturities Table Text Block Schedule of available-for-sale maturities Fair Value, by Balance Sheet Grouping [Table Text Block] Summary of fair value of the Company’s financial assets Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of stock based compensation expense recorded Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of assumptions used in the Black Scholes option pricing model for stock options granted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of computation of basic and diluted net loss per share attributable to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of shares excluded from the computation of diluted net loss per share Restricted Cash Debt Instrument, Face Amount Face amount Amount of required reserve of restricted cash. Required Reserve Restricted Cash Current Restricted cash required reserve Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Reconciliation of cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows Represents restricted cash and other assets current. Restricted Cash And Other Assets Current Restricted cash (including $1,386 and $1,806 in other assets as of March 31, 2021 and December 31, 2020, respectively) Represents other assets non-current from restricted cash. Restricted Cash Other Assets Non Current Other assets, restricted cash Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Financial Instruments [Domain] Corporate Debt Securities [Member] Corporate bonds Debt Securities, Available-for-sale [Line Items] Investments Debt Securities, Available-for-sale, Amortized Cost Amortized Cost Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Loss Debt Securities, Available-for-sale Marketable securities Estimated Fair Value Available-for-sale Securities, Gross Realized Gains Gross realized gains Available-for-sale Securities, Debt Maturities [Abstract] Cost Maturities: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost Within 1 year Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year to year two. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost Between 1 to 2 years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost Total investments available for sale Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Fair Value Maturities: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Within 1 year Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Available For Sale Securities Debt Maturities After One Through Two Years Fair Value Between 1 to 2 years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value Total investments available for sale Fair Value, by Balance Sheet Grouping [Table] Cash and Cash Equivalents [Axis] Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money market funds (cash equivalents) Measurement Basis [Axis] Portion At Fair Value Fair Value Disclosure [Member] Portion at Fair Value Measurement [Member] Carrying Reported Amount Fair Value Disclosure [Member] Carrying Amount Estimate Of Fair Value Fair Value Disclosure [Member] Fair Value Fair Value Hierarchy and NAV [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Inputs Level1 [Member] Quoted Prices in Active Markets (Level 1) Fair Value Inputs Level2 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Fair value of the Company’s financial assets Cash and Cash Equivalents, Fair Value Disclosure Money market funds (cash equivalents) 1 Marketable Securities And Cash Equivalents Total financial assets Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Assets transferred from level 1 to level 2 Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Assets transferred from level 2 to level 1 Collaborative Arrangement and Arrangement Other than Collaborative [Table] EX-101.PRE 10 nxtc-20210331_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 05, 2021
Cover Abstract
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Entity Registrant Name	NextCure, Inc.
Entity Central Index Key	0001661059
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	NXTC
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,609,863
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 36,527	$ 32,772
Marketable securities	231,709	250,676
Restricted cash	1,706	1,706
Prepaid expenses and other current assets	3,109	2,824
Total current assets	273,051	287,978
Property and equipment, net	15,470	15,809
Other assets	2,438	2,857
Total assets	290,959	306,644
Current liabilities:
Accounts payable	2,017	3,901
Accrued liabilities	4,295	4,627
Deferred rent, current portion	209	130
Term loan, current portion	1,667	1,667
Total current liabilities	8,188	10,325
Deferred rent, net of current portion	2,223	792
Term loan, net of current portion	1,389	1,806
Total liabilities	11,800	12,923
Stockholders’ equity
Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at March 31, 2021 and December 31, 2020, no shares issued and outstanding at March 31, 2021 and December 31, 2020
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at March 31, 2021 and December 31, 2020; 27,604,417 and 27,568,802 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	28	28
Additional paid-in capital	413,122	410,551
Accumulated other comprehensive income	179	779
Accumulated deficit	(134,170)	(117,637)
Total stockholders’ equity	279,159	293,721
Total liabilities and stockholders’ equity	$ 290,959	$ 306,644

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
CONDENSED BALANCE SHEETS
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, number of shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, number of shares authorized	100,000,000	100,000,000
Common stock, shares issued	27,604,417	27,568,802
Common stock, shares outstanding	27,604,417	27,568,802

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Revenue from former research and development arrangement		$ 22,378
Revenue, Product and Service [Extensible List]	nxtc:RelatedPartyMember
Operating expenses:
Research and development	$ 12,386	10,578
General and administrative	4,848	3,588
Total operating expenses	17,234	14,166
(Loss) income from operations	(17,234)	8,212
Other income, net	701	1,521
Net (loss) income	$ (16,533)	$ 9,733
(Loss) earnings per share
Basic (in dollars per share)	$ (0.60)	$ 0.35
Diluted (in dollars per share)	$ (0.60)	$ 0.33
Shares used in the calculation of (loss) earnings per share
Basic (in shares)	27,597,426	27,506,927
Diluted (in shares)	27,597,426	29,348,615
Comprehensive (loss) income:
Net (loss) income	$ (16,533)	$ 9,733
Unrealized loss on marketable securities	(600)	(543)
Total comprehensive (loss) income	$ (17,133)	$ 9,190

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2019	$ 27	$ 402,529	$ (38)	$ (81,034)	$ 321,484
Balance at the beginning (in shares) at Dec. 31, 2019	27,499,260
Increase (Decrease) in Stockholders' Deficit
Stock based compensation		1,008			1,008
Issuance of common stock	$ 1	36			37
Issuance of common stock (in shares)	17,142
Unrealized loss on marketable securities, net of tax $0			(505)		(505)
Net (loss) income				9,733	9,733
Balance at the end at Mar. 31, 2020	$ 28	403,573	(543)	(71,301)	331,757
Balance at the end (in shares) at Mar. 31, 2020	27,516,402
Balance at the beginning at Dec. 31, 2020	$ 28	410,551	779	(117,637)	$ 293,721
Balance at the beginning (in shares) at Dec. 31, 2020	27,568,802				27,568,802
Increase (Decrease) in Stockholders' Deficit
Stock based compensation		2,508			$ 2,508
Issuance of common stock		63			63
Issuance of common stock (in shares)	35,615
Unrealized loss on marketable securities, net of tax $0			(600)		(600)
Net (loss) income				(16,533)	(16,533)
Balance at the end at Mar. 31, 2021	$ 28	$ 413,122	$ 179	$ (134,170)	$ 279,159
Balance at the end (in shares) at Mar. 31, 2021	27,604,417				27,604,417

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
Unrealized loss on marketable securities, tax	$ 0	$ 0

XML 17 R7.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net (loss) income	$ (16,533)	$ 9,733
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization	1,105	751
Stock-based compensation	2,508	1,008
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(285)	606
Accounts payable	(1,884)	402
Accrued liabilities	(332)	(812)
Deferred rent	1,510	96
Deferred revenue		(22,378)
Net cash used in operating activities	(13,911)	(10,594)
Cash flows from investing activities:
Maturities of marketable securities	56,786	30,349
Purchase of marketable securities	(38,420)	(23,531)
Purchase of property and equipment	(766)	(1,445)
Net cash provided by investing activities	17,600	5,373
Cash flows from financing activities:
Proceeds from issuances of common stock	63	37
Payments of the term loan	(417)	(277)
Net cash used in financing activities	(354)	(240)
Net increase (decrease) in cash, cash equivalents and restricted cash	3,335	(5,461)
Cash, cash equivalents and restricted cash—beginning of period	36,284	39,130
Cash, cash equivalents and restricted cash—end of period	39,619	33,669
Supplemental disclosures of cash flow information:
Cash paid for interest	$ 36	35
Supplemental disclosures of noncash investing and financing activities:
Purchase of property and equipment included in accrued liabilities		$ 156

XML 18 R8.htm IDEA: XBRL DOCUMENT

Nature of the Business	3 Months Ended
Nature of the Business	Mar. 31, 2021
Nature of the Business
Nature of the Business	1. Nature of the Business Organization NextCure, Inc. (“NextCure” or the “Company”) was incorporated in Delaware in September 2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first‑in‑class immunomedicines to treat cancer and other immune‑related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno‑Oncology (“FIND‑IO”) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company’s product candidates, building and optimizing the Company’s manufacturing capabilities and conducting discovery, research and development activities for the Company’s product candidates, discovery programs and its FIND‑IO platform. Liquidity The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through March 31, 2021, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company’s former agreement with Eli Lilly and Company, which was terminated in March 2020 (see Note 6). The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future. Risks and Uncertainties COVID-19 In March 2020, the World Health Organization declared the novel coronavirus disease 2019 (“COVID-19”), outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities, including clinical trial sites. However, the Company’s laboratories have continued operations throughout the pandemic mostly without interruption. The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company’s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of “lockdown,” “social distancing” and “shelter in place” directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic initially placed significant strain on the Company’s clinical trial sites, have raised concerns around monitoring patient safety, and caused enrollment to slow in the Phase 2 portion of the ongoing Phase 1/2 monotherapy clinical trial of the Company’s lead product candidate, NC318. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company’s planned activities.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Basis of Presentation The unaudited condensed financial statements include the accounts of NextCure and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”). Unaudited Financial Information In the opinion of management, the information furnished reflects certain adjustments, all of which are of a normal and recurring nature and are necessary for a fair presentation of the Company’s financial position as of the reported balance sheet date and of the Company’s results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. Recently Issued Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 (Topic 842), Leases (“ASC 842”). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. The Company is currently evaluating the impact of adopting this guidance on the Company’s financial statements. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the total assets and total liabilities that it reports relative to such amounts presented prior to adoption. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s financial statements. The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company’s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Restricted Cash

3 Months Ended

Mar. 31, 2021

Restricted Cash.

Restricted Cash

3. Restricted Cash

The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the condensed statement of cash flows:


	March 31,		December 31,
(in thousands)	2021		2020
Cash and cash equivalents	$	36,527	$	32,772
Restricted cash (including $1,386 and $1,806 in other assets as of March 31, 2021 and December 31, 2020, respectively)		3,092		3,512
Total	$	39,619	$	36,284

XML 21 R11.htm IDEA: XBRL DOCUMENT

Marketable Securities

3 Months Ended

Mar. 31, 2021

Marketable Securities

Marketable Securities

4. Marketable Securities

Marketable securities consist of the following:


	March 31, 2021
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
(in thousands)	Cost		Gain		Loss		Fair Value
Corporate bonds	$	231,530	$	337	$	(158)	$	231,709
Total	$	231,530	$	337	$	(158)	$	231,709


	December 31, 2020
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
(in thousands)	Cost		Gain		Loss		Fair Value
Corporate bonds	$	242,900	$	854	$	(75)	$	243,679
Commercial paper		6,997		—		—		6,997
Total	$	249,897	$	854	$	(75)	$	250,676

The following table summarizes maturities of the Company’s investments available-for-sale as of March 31, 2021:


	March 31, 2021
			Fair
(in thousands)	Cost		Value
Maturities:
Within 1 year	$	115,920	$	116,233
Between 1 to 2 years		115,610		115,476
Total investments available for sale	$	231,530	$	231,709

XML 22 R12.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2021

Fair Value Measurements

Fair Value Measurements

5. Fair Value Measurements

Level 1—Quoted market prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3—Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.

To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy as of March 31, 2021 and December 31, 2020:


	March 31, 2021
					Significant
			Quoted Prices in		Other
			Active Markets or		Observable		Significant
			Identical Assets		Inputs		Unobservable
(in thousands)	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	19,185	$	19,185	$	—	$	—
Marketable securities:
Corporate bonds		231,709		—		231,709		—
Total	$	250,894	$	19,185	$	231,709	$	—


	December 31, 2020
					Significant
			Quoted Prices in		Other
			Active Markets or		Observable		Significant
			Identical Assets		Inputs		Unobservable
(in thousands)	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	11,155	$	11,155	$	—	$	—
Marketable securities:
Corporate bonds		243,679		—		243,679		—
Commercial paper		6,997		—		6,997		—
Total	$	261,831	$	11,155	$	250,676	$	—

The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March 31, 2021 and 2020.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Former Agreement with Eli Lilly and Company	3 Months Ended
Former Agreement with Eli Lilly and Company	Mar. 31, 2021
Former Agreement with Eli Lilly and Company
Former Agreement with Eli Lilly and Company	6. Former Agreement with Eli Lilly and Company On November 2, 2018, the Company entered into a multi-year research and development collaboration agreement (the “Lilly Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which the Company agreed to use its proprietary FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by the Company and Lilly. Effective March 3, 2020, Lilly terminated the Lilly Agreement without cause. The Company recognized revenue under the Lilly Agreement of $22.4 million for the three months ended March 31, 2020. Effective with the termination of the agreement, no further quarterly research and development support payments are payable to the Company.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2021

Stock-Based Compensation

Stock-Based Compensation

7. Stock‑Based Compensation

Employee Equity Plans

As of March 31, 2021, 2,589,208 shares were reserved for future grant under the 2019 Plan.

Stock options granted under the 2015 Plan and 2019 Plan (together, the “Plans”) to employees generally vest over four years and expire after ten years.

A summary of stock option activity for awards under the Plans is presented below:


	Options Outstanding and Exercisable
				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value(1)
	Shares	Price		Life (Years)	(in thousands)
Outstanding as of December 31, 2020	3,112,376	$	16.95	8.2	$	10,810
Granted	1,313,150	$	12.49
Exercised	(35,615)	$	1.78
Forfeited	(49,776)	$	29.26
Outstanding as of March 31, 2021	4,340,135	$	15.59	8.6	$	8,779
Vested and expected to vest as of March 31, 2021	4,340,135	$	15.59	8.6	$	8,779
Exercisable as of March 31, 2021	1,521,940	$	10.77	8.4	$	6,689

(1)

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at March 31, 2021 and December 31, 2020.

The aggregate grant date fair value of stock options and restricted stock vested during the three months ended March 31, 2021 and 2020 was approximately $6.4 million and $30.3 million, respectively.

Stock-based compensation expense was classified on the statements of operations as follows for the three months ended March 31, 2021 and 2020:


	Three Months Ended
	March 31,
(in thousands)	2021		2020
Research and development	$	958	$	452
General and administrative		1,550		556
Total stock-based compensation expense	$	2,508	$	1,008


	Three Months Ended
	March 31,
	2021		2020
Expected term	6.1	years	6.1	years
Expected volatility	79.7	%	69.7	%
Risk free interest rate	0.8 - 1.4	%	0.6 - 1.0	%
Expected dividend yield	—	%	—	%

XML 25 R15.htm IDEA: XBRL DOCUMENT

Net (Loss) Income Per Share Attributable to Common Stockholders

3 Months Ended

Mar. 31, 2021

Net (Loss) Income Per Share Attributable to Common Stockholders

Net (Loss) Income Per Share Attributable to Common Stockholders

8. Net (Loss) Income Per Share Attributable to Common Stockholders

(Loss) Earnings per share

The computation for basic and diluted EPS were as follows (in thousands, except share and per share data):


	Three months ended
	March 31,
	2021		2020
(Loss) income (Numerator):
Net (loss) income for basic and diluted EPS	$	(16,533)	$	9,733
Shares (Denominator):
Weighted-average number of common shares outstanding		27,597,426		27,506,927
Effect of dilutive common stock equivalents		—		1,841,688
Weighted-average shares for diluted EPS		27,597,426		29,348,615

Basic EPS	$	(0.60)	$	0.35
Diluted EPS	$	(0.60)	$	0.33

For the three months ended March 31, 2021, all shares of options to purchase shares of the Company’s common stock were excluded from the computation of diluted net loss per share as the effect would have been anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:


	March 31,
	2021		2020
Outstanding options to purchase common stock		4,340,135	3,000
Total		4,340,135	3,000

XML 26 R16.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2021
Income Taxes
Income Taxes	9. Income Taxes The Company did not record a provision or benefit for income taxes during the three months ended March 31, 2021 and 2020. The Company continues to maintain a full valuation allowance against its deferred tax assets. The Company has evaluated the positive and negative evidence involving its ability to realize its deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of any commercially ready products. It has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Management reevaluates the positive and negative evidence at each reporting period. Under the provisions of Sections 382 and 383 of the Internal Revenue Code (“IRC”), certain substantial changes in the Company’s ownership may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that can be used to reduce future income taxes. We have not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of credits attributable to periods before the change and could result in a reduction in the total credits available. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act includes various income and payroll tax provisions. The Company has analyzed the tax provisions of the CARES Act and determined they have no significant financial impact to the Company’s condensed financial statements. On March 11, 2021, the American Rescue Plan Act of 2021 (“ARPA 2021”) was signed into law. ARPA 2021 included various income and payroll tax provisions. The Company has analyzed the tax provisions of ARPA 2021 and determined they have no significant financial impact to the Company’s condensed financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	10. Commitments and Contingencies Legal Proceedings On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Securities Act of 1933, as amended, with respect to statements made regarding our lead product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021 and discovery is stayed pending resolution of that motion. On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys’ fees and costs, declaratory relief, corporate governance changes, and restitution. The deadline to respond to the Complaint is May 24, 2021 but we anticipate either stipulating to, or moving for, a stay of proceedings pending resolution of the Ye Zhou action. The Company intends to vigorously defend the Ye Zhou and Liu actions and believes these cases are without merit. Based on the Company’s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2021
Summary of Significant Accounting Policies
Basis of Presentation and Unaudited Financial Information	There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Basis of Presentation The unaudited condensed financial statements include the accounts of NextCure and have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”). Unaudited Financial Information In the opinion of management, the information furnished reflects certain adjustments, all of which are of a normal and recurring nature and are necessary for a fair presentation of the Company’s financial position as of the reported balance sheet date and of the Company’s results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company qualifies as an emerging growth company (“EGC”) as defined under the Jumpstart Our Business Startups Act (the “JOBS Act”). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 (Topic 842), Leases (“ASC 842”). ASC 842 supersedes the lease recognition requirements in ASC 840, Leases. ASC 842 clarifies the definition of a lease and requires lessees to recognize right-of-use assets and lease liabilities for all leases, including those classified as operating leases under previous lease accounting guidance. For public entities, ASC 842 was effective for fiscal years beginning after December 15, 2018, including interim periods within that year. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, ASC 842 will be effective for the Company on January 1, 2022. Originally, entities were required to adopt ASC 842 using a modified retrospective transition method. However, in July 2018, the FASB issued ASU 2018-11 (Topic 842), Leases: Targeted Improvements, which provides entities with an additional transition method. Under ASU 2018-11, entities have the option of initially applying ASC 842 at the adoption date, rather than at the beginning of the earliest period presented, and recognizing the cumulative effect of applying the new standard as an adjustment to beginning retained earnings in the year of adoption while continuing to present all prior periods under previous lease accounting guidance. The Company is currently evaluating the impact of adopting this guidance on the Company’s financial statements. The Company currently expects that its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and operating lease liabilities upon adoption of this standard, which will increase the total assets and total liabilities that it reports relative to such amounts presented prior to adoption. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 will require credit losses to be reported using an expected losses model rather than the incurred losses model that is currently used and will require additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard will require allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for non-EGCs for fiscal years beginning December 15, 2019 and interim periods within those fiscal years, and will be effective for the Company for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, assuming the Company remains an EGC. The Company adopted this standard early, effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s financial statements. The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company’s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company’s financial position or results of operations.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Restricted Cash (Tables)

3 Months Ended

Mar. 31, 2021

Restricted Cash.

Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows

The following table reconciles cash and cash equivalents and restricted cash per the balance sheet to the condensed statement of cash flows:


	March 31,		December 31,
(in thousands)	2021		2020
Cash and cash equivalents	$	36,527	$	32,772
Restricted cash (including $1,386 and $1,806 in other assets as of March 31, 2021 and December 31, 2020, respectively)		3,092		3,512
Total	$	39,619	$	36,284

XML 30 R20.htm IDEA: XBRL DOCUMENT

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2021

Marketable Securities

Schedule of marketable securities

Marketable securities consist of the following:


	March 31, 2021
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
(in thousands)	Cost		Gain		Loss		Fair Value
Corporate bonds	$	231,530	$	337	$	(158)	$	231,709
Total	$	231,530	$	337	$	(158)	$	231,709


	December 31, 2020
			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
(in thousands)	Cost		Gain		Loss		Fair Value
Corporate bonds	$	242,900	$	854	$	(75)	$	243,679
Commercial paper		6,997		—		—		6,997
Total	$	249,897	$	854	$	(75)	$	250,676

Schedule of available-for-sale maturities


	March 31, 2021
			Fair
(in thousands)	Cost		Value
Maturities:
Within 1 year	$	115,920	$	116,233
Between 1 to 2 years		115,610		115,476
Total investments available for sale	$	231,530	$	231,709

XML 31 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2021

Fair Value Measurements

Summary of fair value of the Company’s financial assets

The following tables set forth the fair value of the Company’s financial assets by level within the fair value hierarchy as of March 31, 2021 and December 31, 2020:


	March 31, 2021
					Significant
			Quoted Prices in		Other
			Active Markets or		Observable		Significant
			Identical Assets		Inputs		Unobservable
(in thousands)	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	19,185	$	19,185	$	—	$	—
Marketable securities:
Corporate bonds		231,709		—		231,709		—
Total	$	250,894	$	19,185	$	231,709	$	—


	December 31, 2020
					Significant
			Quoted Prices in		Other
			Active Markets or		Observable		Significant
			Identical Assets		Inputs		Unobservable
(in thousands)	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents:
Money market funds	$	11,155	$	11,155	$	—	$	—
Marketable securities:
Corporate bonds		243,679		—		243,679		—
Commercial paper		6,997		—		6,997		—
Total	$	261,831	$	11,155	$	250,676	$	—

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2021

Stock-Based Compensation

Summary of stock option activity


	Options Outstanding and Exercisable
				Weighted
		Weighted		Average	Aggregate
		Average		Remaining	Intrinsic
	Number of	Exercise		Contractual	Value(1)
	Shares	Price		Life (Years)	(in thousands)
Outstanding as of December 31, 2020	3,112,376	$	16.95	8.2	$	10,810
Granted	1,313,150	$	12.49
Exercised	(35,615)	$	1.78
Forfeited	(49,776)	$	29.26
Outstanding as of March 31, 2021	4,340,135	$	15.59	8.6	$	8,779
Vested and expected to vest as of March 31, 2021	4,340,135	$	15.59	8.6	$	8,779
Exercisable as of March 31, 2021	1,521,940	$	10.77	8.4	$	6,689

Summary of stock based compensation expense recorded


	Three Months Ended
	March 31,
(in thousands)	2021		2020
Research and development	$	958	$	452
General and administrative		1,550		556
Total stock-based compensation expense	$	2,508	$	1,008

Summary of assumptions used in the Black Scholes option pricing model for stock options granted


	Three Months Ended
	March 31,
	2021		2020
Expected term	6.1	years	6.1	years
Expected volatility	79.7	%	69.7	%
Risk free interest rate	0.8 - 1.4	%	0.6 - 1.0	%
Expected dividend yield	—	%	—	%

XML 33 R23.htm IDEA: XBRL DOCUMENT

Net (Loss) Income Per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2021

Net (Loss) Income Per Share Attributable to Common Stockholders

Summary of computation of basic and diluted net loss per share attributable to common stockholders

The computation for basic and diluted EPS were as follows (in thousands, except share and per share data):


	Three months ended
	March 31,
	2021		2020
(Loss) income (Numerator):
Net (loss) income for basic and diluted EPS	$	(16,533)	$	9,733
Shares (Denominator):
Weighted-average number of common shares outstanding		27,597,426		27,506,927
Effect of dilutive common stock equivalents		—		1,841,688
Weighted-average shares for diluted EPS		27,597,426		29,348,615

Basic EPS	$	(0.60)	$	0.35
Diluted EPS	$	(0.60)	$	0.33

Summary of shares excluded from the computation of diluted net loss per share


	March 31,
	2021		2020
Outstanding options to purchase common stock		4,340,135	3,000
Total		4,340,135	3,000

XML 34 R24.htm IDEA: XBRL DOCUMENT

Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Restricted Cash
Face amount	$ 5,000
Restricted cash required reserve	3,100	$ 3,500
Reconciliation of cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows
Cash and cash equivalents	36,527	32,772
Restricted cash (including $1,386 and $1,806 in other assets as of March 31, 2021 and December 31, 2020, respectively)	3,092	3,512
Total	39,619	36,284	$ 33,669	$ 39,130
Other assets, restricted cash	$ 1,386	$ 1,806

XML 35 R25.htm IDEA: XBRL DOCUMENT

Marketable Securities - (Details) - USD ($)	3 Months Ended
Marketable Securities - (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Investments
Amortized Cost	$ 231,530,000		$ 249,897,000
Gross Unrealized Gain	337,000		854,000
Gross Unrealized Loss	(158,000)		(75,000)
Estimated Fair Value	231,709,000		250,676,000
Gross realized gains	54,000	$ 64,000
Cost Maturities:
Within 1 year	115,920,000
Between 1 to 2 years	115,610,000
Total investments available for sale	231,530,000
Fair Value Maturities:
Within 1 year	116,233,000
Between 1 to 2 years	115,476,000
Total investments available for sale	231,709,000
Corporate bonds
Investments
Amortized Cost	231,530,000		242,900,000
Gross Unrealized Gain	337,000		854,000
Gross Unrealized Loss	(158,000)		(75,000)
Estimated Fair Value	$ 231,709,000		243,679,000
Commercial Paper
Investments
Amortized Cost			6,997,000
Estimated Fair Value			$ 6,997,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Fair value of the Company’s financial assets
Marketable securities	$ 231,709	$ 250,676
Assets transferred from level 1 to level 2	0		$ 0
Assets transferred from level 2 to level 1	0		$ 0
Carrying Amount
Fair value of the Company’s financial assets
Total financial assets	250,894	261,831
Fair Value \| Quoted Prices in Active Markets (Level 1)
Fair value of the Company’s financial assets
Total financial assets	19,185	11,155
Fair Value \| Significant Other Observable Inputs (Level 2)
Fair value of the Company’s financial assets
Total financial assets	231,709	250,676
Money market funds (cash equivalents) \| Carrying Amount
Fair value of the Company’s financial assets
Money market funds (cash equivalents)	19,185	11,155
Money market funds (cash equivalents) \| Fair Value \| Quoted Prices in Active Markets (Level 1)
Fair value of the Company’s financial assets
Money market funds (cash equivalents)	19,185	11,155
Corporate bonds \| Carrying Amount
Fair value of the Company’s financial assets
Marketable securities	231,709	243,679
Corporate bonds \| Fair Value \| Significant Other Observable Inputs (Level 2)
Fair value of the Company’s financial assets
Marketable securities	$ 231,709	243,679
Commercial Paper \| Carrying Amount
Fair value of the Company’s financial assets
Marketable securities		6,997
Commercial Paper \| Fair Value \| Significant Other Observable Inputs (Level 2)
Fair value of the Company’s financial assets
Marketable securities		$ 6,997

XML 37 R27.htm IDEA: XBRL DOCUMENT

Former Agreement with Eli Lilly and Company (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Collaborative Arrangements
Revenue from former research and development arrangement	$ 22,378
Lilly Agreement
Collaborative Arrangements
Revenue from former research and development arrangement	$ 22,400

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock options (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
	May 03, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
2015 Plan
Number of Shares
Outstanding at the beginning (in shares)		3,112,376
Granted (in shares)		1,313,150
Exercised (in shares)		(35,615)
Forfeitures (in shares)		(49,776)
Outstanding at the end (in shares)		4,340,135		3,112,376
Vested and expected to vest at the end (in shares)		4,340,135
Exercisable at the end (in shares)		1,521,940
Weighted Average Exercise Price
Outstanding at the beginning (in dollars per share)		$ 16.95
Granted (in dollars per share)		12.49
Exercised (in dollars per share)		1.78
Forfeited (in dollars per share)		29.26
Outstanding at the end (in dollars per share)		15.59		$ 16.95
Vested and expected to vest at the end (in dollars per share)		15.59
Exercisable at the end (in dollars per share)		$ 10.77
Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value
Outstanding (in years)		8 years 7 months 6 days		8 years 2 months 12 days
Vested and expected to vest at the end (in years)		8 years 7 months 6 days
Exercisable at the end (in years)		8 years 4 months 24 days
Outstanding at the beginning (in dollars)		$ 10,810
Outstanding at the end (in dollars)		8,779		$ 10,810
Vested and expected to vest at the end (in dollars)		8,779
Exercisable at the end (in dollars)		$ 6,689
Weighted average grant date fair value per share of stock options granted		$ 8.57
Aggregate intrinsic value of stock options exercised		$ 300
Aggregate grant date fair value		6,400	$ 30,300
Share Based Compensation Expense Not Recognized
Unrecognized compensation cost		$ 31,100
Compensation expense recognition period		2 years 8 months 12 days
Omnibus Incentive Plan
Stock Based Compensation
Number of shares reserved for issuance under the plan	2,900,000
Annual increase in number of share reserved for issuance (as percent)	4.00%
2015 Plan and 2019 Employee Stock Purchase Plan
Stock Based Compensation
Vesting period		4 years
Expiration period		10 years
2019 Employee Stock Purchase Plan
Stock Based Compensation
Number of shares reserved for issuance under the plan		2,589,208

XML 39 R29.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock based compensation expense
Total stock-based compensation expense	$ 2,508	$ 1,008
Research and development
Stock based compensation expense
Total stock-based compensation expense	958	452
General and administrative
Stock based compensation expense
Total stock-based compensation expense	$ 1,550	$ 556

XML 40 R30.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Assumptions (Details)	3 Months Ended
Stock-Based Compensation - Assumptions (Details)	Mar. 31, 2021	Mar. 31, 2020
Fair value assumptions
Expected term	6 years 1 month 6 days	6 years 1 month 6 days
Expected volatility	79.70%	69.70%
Expected dividend yield	0.00%	0.00%
Minimum
Fair value assumptions
Risk free interest rate	0.80%	0.60%
Maximum
Fair value assumptions
Risk free interest rate	1.40%	1.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Net (Loss) Income Per Share Attributable to Common Stockholders - Other (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income (loss) (Numerator):
Net (loss) income for basic and diluted EPS	$ (16,533)	$ 9,733
Shares (Denominator):
Weighted-average number of common shares outstanding (in shares)	27,597,426	27,506,927
Effect of dilutive common stock equivalents (in shares)		1,841,688
Weighted-average shares for diluted EPS (in shares)	27,597,426	29,348,615
Basic EPS (in dollars per share)	$ (0.60)	$ 0.35
Diluted EPS (in dollars per share)	$ (0.60)	$ 0.33

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 42 R32.htm IDEA: XBRL DOCUMENT

Net (Loss) Income Per Share Attributable to Common Stockholders - Anti-dilutive effect (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities
Antidilutive securities excluded from computation of diluted net loss per share	4,340,135	3,000
Option to purchase common stock
Antidilutive Securities
Antidilutive securities excluded from computation of diluted net loss per share	4,340,135	3,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Income Taxes - (Details) - USD ($)	3 Months Ended
Income Taxes - (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Income Taxes
Provision or benefit from income taxes	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 70 245 1 false 23 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.nextcure.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.nextcure.com/role/StatementCondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED BALANCE SHEETS - (Parenthetical) Sheet http://www.nextcure.com/role/StatementCondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS - (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.nextcure.com/role/StatementCondensedStatementsOfOperationsAndComprehensiveLoss CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.nextcure.com/role/StatementCondensedStatementsOfStockholdersEquity CONDENSED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 5 false false R6.htm 00305 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical) Sheet http://www.nextcure.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical CONDENSED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.nextcure.com/role/StatementCondensedStatementsOfCashFlows CONDENSED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 10101 - Disclosure - Nature of the Business Sheet http://www.nextcure.com/role/DisclosureNatureOfBusiness Nature of the Business Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Restricted Cash Sheet http://www.nextcure.com/role/DisclosureRestrictedCash Restricted Cash Notes 10 false false R11.htm 10401 - Disclosure - Marketable Securities Sheet http://www.nextcure.com/role/DisclosureMarketableSecurities Marketable Securities Notes 11 false false R12.htm 10501 - Disclosure - Fair Value Measurements Sheet http://www.nextcure.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 10601 - Disclosure - Former Agreement with Eli Lilly and Company Sheet http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany Former Agreement with Eli Lilly and Company Notes 13 false false R14.htm 10701 - Disclosure - Stock-Based Compensation Sheet http://www.nextcure.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 10801 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders Sheet http://www.nextcure.com/role/DisclosureNetLossIncomePerShareAttributableToCommonStockholders Net (Loss) Income Per Share Attributable to Common Stockholders Notes 15 false false R16.htm 10901 - Disclosure - Income Taxes Sheet http://www.nextcure.com/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 11001 - Disclosure - Commitments and Contingencies Sheet http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30303 - Disclosure - Restricted Cash (Tables) Sheet http://www.nextcure.com/role/DisclosureRestrictedCashTables Restricted Cash (Tables) Tables http://www.nextcure.com/role/DisclosureRestrictedCash 19 false false R20.htm 30403 - Disclosure - Marketable Securities (Tables) Sheet http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.nextcure.com/role/DisclosureMarketableSecurities 20 false false R21.htm 30503 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.nextcure.com/role/DisclosureFairValueMeasurements 21 false false R22.htm 30703 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.nextcure.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.nextcure.com/role/DisclosureStockBasedCompensation 22 false false R23.htm 30803 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders (Tables) Sheet http://www.nextcure.com/role/DisclosureNetLossIncomePerShareAttributableToCommonStockholdersTables Net (Loss) Income Per Share Attributable to Common Stockholders (Tables) Tables http://www.nextcure.com/role/DisclosureNetLossIncomePerShareAttributableToCommonStockholders 23 false false R24.htm 40301 - Disclosure - Restricted Cash (Details) Sheet http://www.nextcure.com/role/DisclosureRestrictedCashDetails Restricted Cash (Details) Details http://www.nextcure.com/role/DisclosureRestrictedCashTables 24 false false R25.htm 40401 - Disclosure - Marketable Securities - (Details) Sheet http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails Marketable Securities - (Details) Details http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables 25 false false R26.htm 40501 - Disclosure - Fair Value Measurements - (Details) Sheet http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements - (Details) Details http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables 26 false false R27.htm 40601 - Disclosure - Former Agreement with Eli Lilly and Company (Details) Sheet http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompanyDetails Former Agreement with Eli Lilly and Company (Details) Details http://www.nextcure.com/role/DisclosureFormerAgreementWithEliLillyAndCompany 27 false false R28.htm 40701 - Disclosure - Stock-Based Compensation - Stock options (Details) Sheet http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock-Based Compensation - Stock options (Details) Details 28 false false R29.htm 40702 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details) Sheet http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock based compensation expense (Details) Details 29 false false R30.htm 40703 - Disclosure - Stock-Based Compensation - Assumptions (Details) Sheet http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails Stock-Based Compensation - Assumptions (Details) Details 30 false false R31.htm 40801 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders - Other (Details) Sheet http://www.nextcure.com/role/DisclosureNetLossIncomePerShareAttributableToCommonStockholdersOtherDetails Net (Loss) Income Per Share Attributable to Common Stockholders - Other (Details) Details http://www.nextcure.com/role/DisclosureNetLossIncomePerShareAttributableToCommonStockholdersTables 31 false false R32.htm 40802 - Disclosure - Net (Loss) Income Per Share Attributable to Common Stockholders - Anti-dilutive effect (Details) Sheet http://www.nextcure.com/role/DisclosureNetLossIncomePerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails Net (Loss) Income Per Share Attributable to Common Stockholders - Anti-dilutive effect (Details) Details http://www.nextcure.com/role/DisclosureNetLossIncomePerShareAttributableToCommonStockholdersTables 32 false false R33.htm 40901 - Disclosure - Income Taxes - (Details) Sheet http://www.nextcure.com/role/DisclosureIncomeTaxesDetails Income Taxes - (Details) Details http://www.nextcure.com/role/DisclosureIncomeTaxes 33 false false All Reports Book All Reports nxtc-20210331.xml nxtc-20210331.xsd nxtc-20210331_cal.xml nxtc-20210331_def.xml nxtc-20210331_lab.xml nxtc-20210331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 49 0001558370-21-006266-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-006266-xbrl.zip M4$L#!!0 ( -V$IE*-BOQHJJ, (S[#@ 1 ;GAT8RTR,#(Q,#,S,2YX M;6SLO6MWXDBR+OSYS%K[/^3Q=.^W:BU,(3 87-UUELME]WAVW:;LWOOT^5(K M+25&TT)BE!(NYM>_$:D+ F.;FY"4BIGI:0-27IZ(>"(R\O;+__DQ=MA4^-+V MW%^/C&;KB G7]"S;O?_U*)3'7)JV??1_WOW'7W[YW\?'__?]MX_,\LQP+-R MF;[@@;#8@QV,V*TWF7"7?1*^;SL.>^_;UKU@;- T6LU6TSCIL>/CN)3W7,); MGLM4<>VFD?YR$9?HN6>L^Z;WIMUJ&ZQSUNF==0SV]5/TW(\[WV'0;%?^>C0* M@LG9FS%V;SWIF_@!^QKZ[AE''>, M;,GV!GUT?P3FPN.N@&]"7S1-;ZRP;'7FI=O2.VD;I\^5'SV1O #:<,_Y)'UA MR.6=>CC^854/I+T*1"C=>/-_/WV\,4=BS(^7^R']X'$E\&6V E $QGY!.9Q) M5.)@D>J[D2^&OQXA0,<)#LT?TCIB;Z*"4/<\-P"\ MV(TP S &I6OPBQE_;5N_'GT(?8Z_?3?@OUC.]UOO>^=[)_X0X_#])@ E1@NY M_%=H![,+;SSQ7/@HSW_8,GT*OAY[[DW@F7]^$N,[X4=]@BKA47@M_@2?;0N_ M&=K"9ZJO8@'31(B1\3 MQS;M(&H+LVQX+B*%N,%GSW;KZ%WRV*-^_?)F917S1KU9;-4O;Q8 ^&4B?-NS M,GT(N!]\@+:\0]11'UH&E)%^FSXH7"OS6 ?4!HNV,@_]\B93^"]O8EF_+/A6 M5O M$GP!@F^M)_C6;H(_E]^_#+692,#<._91>XT=[2_Q(K[U.6K6.C79PLB9:UE2SQ\L%Y>2\2 MWW981+2\7U'N,:8B5BX3*Q/CID^W:XW!<;DE!0\_29A^]PX\+[=9P\ NB&_!^![+;CD^J[S8GN]0KN;6 MZH+0]N3Q^.%=0HJ[EQ9$77&)J$_^%_F#*G4<>[A.XA]DG[O\I@JO0M>+\ M1OKS%;?]_^9.*-[/TC__!EW$I.GL(Z9,%TI+G[EV)V$@U0/&TT5^$ER&OO)7 M[[FT%UMV*0-[#-[LRS!](_WC@RU-Q\-WJT$03PMB[I-72^(EIMBD%>L)<]ZB M9Z294[-6*<2\/9MH1-E]8L[&^JQE77#?G]GN_3D-\CMD&60VREE*BMO:R6_0W[GL$G9C0*H"\^?X+H.\4'+N+)=[J(\KJ%UN#F57UR=Z?@A=+5H/'J>>7E:# M9YR5!I+>P167,.%"TBQ"FOF>S)'([AR:8]E.B,LIYYV[_!$QTY7OC7&Y+S5!2R.B;.K;;],L*1JZ$:.X&3&?D^AH\$6N36WQ)(2 MUE,)2[4I-SH!+]WK\=$SU5M+N[)7'6UP^6,"0JO(L.J9;F8W:+_83PW9:0?% M^$VXPN<.X'5NC6W7AE!"'72AGVJLU5,-E>,)UT6L41[6*-5Q0,0:Y6*-4L4: M=/1T&MT>\NCI\KH14HCB%>+ #)%NX 6%H,V\>6_FS4IZOIWW64G/'SOP85 K MD.GB4^ ]]=R.OUN'-? 2RZGW$FVC/E >FJYL*-65#96/E$A1"E"48J^7IE6? M>]$X6DM9GLGX7)2<-G'3]NG**'F=5CQ67A>;(E^>W6I:<>5FT MG)SY(;24WV+&9S")WB!+^:)RD:%CV%'HRKQR?^QR.P04'WH+S'$=, M^,Z6WDG;.#W[_>;#+V^2+^<,MOI]5>P'X7ICVWVJ8.1&^TSBRE?Y5,F/B_CE M3:8'T4.K.MQ).[Q8W03^7*SLZ3+:C\IX$HNG"WFB':NZG2T$I'H;3ARQ+%;X M_M)1[FGY%TO89^?P@X4_7CG\GL5J\DT,7[:5(7[*TIRK$-FU> M'?[_J@K3TAY7%[5E&T"SG/%DB8\KQ$OA-JK':!W_8[$&+&)>\*6BP@OXWL?] M.9;X\5]BME$-6:Y]LL1'%J>M1NR+5CN)$^!WGAC94HS^0'EXJ<;G> M2R#B>_CU-]]["$8XM<3=S<00^*'(UKNRQ$?5_KCU.0356'"D>=N2SU/E+==X M93O"OP#=OO?\S3KX&2B3FZ9PT&4)BZF2LI4O%+U<[S54Y',3ESZ 9?%8*KL( M=G6)R_5^$_=J):8;X(*,S3H,#T*IHL&N7;.9K7JQT.4J;T;"<;91H4?BS);T MJ!:P.N=]*&U7R,T,9%E3%TJ:5Q/OHYD9[;M;.W VPRZR>::,OL%^:C6!I-B$ M^VR*XSTVP1@2N2!JQW)5\T: .B--W,S&=YZSF?3^[^U%5/I"&5'1T05?4VX[ M_,X15YY_PYW,QB'1C0$1?OBBMN1[X7WH]L'#SV2A#$L$,J_A77A MR6 %9\[;LD2:[2QK'D/ 91A=X&_XSR]O]MZP_?4W':WOVM<3\!'[ZFO:J$P_ M/PAI^O8DVBOV63R"W^:*@Z4G[W@#Q&<6]X$Z.RKY]CF[!:Z M]=X!G=U(U?[3"=Y"Y0T0K4"?TT:8MERXO#9F>TZ8/1K5Z *_"9P!9LS M8]=2AN &YNBR17BQTC=8=!:+-Y.UD4'XCVT71X]GG5[R!2!R[Y[],Y0PI)Q% M7\4?H#>@(LYT_B;<*8BL$W>D. ECP\$V[R">?FW(\$2 M%_&O$#H%XV/)./S/92*.'-B]"AU %:/G7OTG'T_>_O5'NV5X@:_"B<2A!>P5_A@MNB_?WE_ M@[\LE-]DOTMLD_@AQLJT))OX'@XH%^J+7YW_%G@,FBH;ZN>DQR-H+,019A ] M .V&][&;CLU!?=B##=UV 4S/9[Z8VA*>&R:;V!F?:YP*([EO289?. P'D!)> M^5=H^U'9JM195*(,S='\E09[&-GP!;QP'VW=<)2[EN#:,311KZ1%<:0)Z#:S M(,"1S!M"%^UI-.K 3H'XFA&*[IVA\4_\YVE*=C0]!Z4,;H%U!36YVA@J &(P^>A?9(B0VRT.B]"<;C^&OT M?&R-$[0;+Y1)^^:2N0]M"ZVLR<#ELDEX!SZ&J8R\RB9)Q4I@6(!R,> MJ.*:&<-)_SH'? _&3H!(KW('U/%10F%P$]@.,)5A),.@.+J5-LC&L"75G'+ M2D:9A+X,(<1',<8I(["MTU=WKY/F)&R7 "R38="_LY=94$& M5N MK^S\%U 7,"N@I$8J&_8@?+% ;HJ4TLI#1="-^5WJO)49ORZ3=I,O3]0F65$'';PB/S0S,=V$%%Z8HLR MO/LGB@) >2R!C! C.GV*II=KRA)V./'$,5S.I3MQ?@6$#;/GI2 M15L1UW?:O==G+#/!CRJ^^"2H_&_,"?!,_!QY0. L$KVC*54RR]%1D85EV"U5( .:XT)*,L[+2Y0JQ M0<9#C:BMOBW_E%%PQ9/DQC&$ <>2.Q@^WH'4TR1'Y M#%TC!4104M:VQ2"%+ M+7$<[P%Y=0Z(Z?D8^^!TL. 6R@?:$IH)0?,D(P0$*=-HRG:G(G(\BP*PEP,_ MUW./<1#W7!2X'/\-%()/!GX8QV9+:LP!?S9\VC0.;;^)1 FE)8A@Y8.R6]F0QZC.B,IYT&J!C%N >1)$.Q'0<.P"M3'SM MIAZUU-R^X.UQ! X12C3:PN#)-B-_.(M$.0\V0%E ;V5"=7>SE/U H>%'3]E_ M]A&(!21841QKX=-#*'D>[ZW$\]P%R3DLFD&*@G#TV3*A"0M"7W^L0K7('H6M M*@8QQ*T'NU=F%,R9"I[<2;03+PZ7U3 &!TDJ*1&'*8#AU^P/0/\-6WER:$EA9;O91J'F32S,_7NI_F M+:6%7\R$=[,Y_[TT<"K<4.!Q:=\BK_25^\'S4U ;0GK<;G=.^^NU>F5C,AV) M;C=#X\B-@5DPT'7'_Y$A[MGM'O&',\UNM3_B"4>JGURU-$1K>K#Z8' MV:3QHJ)V6[WLM-OA0#W($#/#4<.FS"+X,;_F/IS\5 M\*_ MW'@CK2[:O'BH^.-GNU:]^A=IYOMVCKU[=Z\-;4>6V?LU+KL[^"KE.#. MU3S'[MAU$#NCG6W=B]7MW+CU^:+3&NRI;9E'/WON7H S^JW>4XU;6=W.C=L@ M']+I;]VV&W,DK-"! .SI]83SM82W^'LN2_TPJ1;G.1]L*QB=@1G]',]?P<\J MBF.F<)P)3B>X][\>@!N5S*#H9EIZ MFFH-_/1C]-G");?VO8L%!H$W/EILX&FGV6O__#:N+/ F9\8DP(R_8'_],,#_ MLN1'1PR#IW^-2G_Z=S6QNN+G4;3VT8"^3(*W,2YGBSGDYR?U (;N!JGJQ0J] MJ?"'CO=P-K(M2[B91/9R$]::M(N6^25O/C%GN9AZCQ.S@;69X%KM9N>$!+>6 MX!;%L#/R1K-+)E,(\H-FNT?(%X$\L$V?D">VJ1/R@V:'V&;/R$>?_6K'K'?< M_//>]T+7PO#<\\_87WD8>+N(*"KGKVK4W=IFV45_ZW U?5/K<#4'F676#>*> M*.'O+D5C#Z0&C8#A) BB>_2\3-HGS=:^92(]Q[98C( F0MG*M-:M(KOW;T5+ M%RWT$TYFS36B8S3F'S!!L9'=$A43%>LBLY)2<;DC>Y)#.;(*)(=RY!CJ(X=>!5M=0DE=RWYF@)*S4CB1?EOM?\S M#U=RNF]70MF&/'D#SX_*ARTHI""V.'S@26R1)UNHU>X4>H*:7%Q<7EY=%1I\ MKA@DYD$?<5(Z65AW5H_8LISRU3\Y60O<2YB,K 7N)8Q*:X$[\4Q1/%/LXB;] M<-"S&9Q5!W5$BDSC&YCT&YIF-@MF542YQ'GE238)L[K-=J=#F6G2SO*RDWV M[T7P( 1&^H''VM$IGQK&^Y41=/F]XL[3A.4$/C<+RW6M>@ZCA:+DJY]3[39Z MAHX#B43+SE=IAM^-WR0E2)=1FU9/A6+"NWU['% :2GF]=K=XQ&MZ/C$*)D=DF\ M1[R7US" >&\KWCMM#7:)]J./&#ZF+[]\[_@>@'D!E><&L6FS-[^$:)<#7K/G MQ(ZX+]YS*2P\1EJX4AWV>N[[W+V/SO:?S1_YRF?XU?D#]RWU?Y<_)G9T/&QT M?O0V)VA_=;C[F8^%.C ;V_3]R]BU[T)Y[>*6$'LJVBVCBT^=N];E>.)X,R%N M NC&U] W1] NO H*?X^/T'[WU6C]D:"TU^YM@EMR$="UJQZ5(!R\'QYOJ3N7 M4!SVC=^#^#Z'V.HO0RAG[+FJ8U_"0%U[AO=PK42T"SABKQ'1].^- ,T"MG0. M<2=[#O'UYZNC=T S)^L"NJ=^1U#'73J+;]B2("%4Y/TM:_>"3VS,[NRFC4:KVUVRT=7U M;-N8#731Z!CM]C9M2>ZREK?>$V\HHKQ;YE1UQ8"T _#G_M0V1>2"OD5W,^,# M:GOA/J^> :C[2SW,M_&EA6K3ZSU6-W;=&Z-J#/N&5\_@A64$U387T.RDH47# M[L"@!?W2ZN 3HG3X,VBKC:-27?[?8JC@/>T(-GA (0'_!&.V^BC&4C%$ZZ[3*@L#-9EJ'9 M!2AQ='EJI8'8AQ8/NGM0!S>P+=L)40CS/-/E#],)+6'AW<981!CPZ'+L2^[C M3?0X[E>51!>6[L#4V3ZU\&JIA0[MHW'%]G?NL'>K^/UL=0&+EW1FDVE?U'WF MJU6)4"?4]X'Z\PYLJ;\GG9.6T>EJU>5**-I!@%B$K'M_NG@M+^BQM4)S[W=U=@^[;264V[/U+LT\_1!W 49 M99PG%'_S/2GGEY+B;:3OQ=#SQ<[IUWYW20/VT:1#]W)^O;;MTN7/M0J@; MJMFHA0O@/7_B <$LM6'- +#"6&UPVVCGM/*=/) ^E!@JG&G8$T.<=O?2R846 M';J3!U*(ZD*UP;37\BBX@IT\D#H4#]78\P,L <_=?<^EO6/$V#X9] <;<=ZC M!N38_ VD.AX+'Q_XRB?"_^SAH@L5B^,9/O&UVO@OG!*80K/<8%V1]P9:X+.+ MUK=/VH-6JUP@;!# =XQNIZRM/Y0$\\9@_B:6,U]E=P/#7D?$GV!IV8?\JAN96(",J)QVX10*>W MO#BN!)U>+<8]Z<$J"] MI1PO90!2",278?H&F<:+IE%I*97!U'(<6^39VL.-"TO8Y^K[F-K 6FU^.K28 M]C,1OOV ;*TIZ\T;?Q".W;#M*N'^+3,=MV@C.ZR&;D'X\?RL\7.MR*G]&RR$ MA?:_,.N]?ON5@7X9QOOS@$&_>HYMSJ+_3S?7;M+R=_&6WW23[\L;EM6^?:.= M[/BV70OTY*S36]P"CLOS[>$L^BK^<&;C!6O'MB6\>Y]/1LD^[+;1[K8'^6^$ MWN6HH)'P!1OQJ6!W>'2IZS'D1=_&75TCW'HJ\3#38"28A.[;0]ODT Z>2HI- M4$CH.R:^F-I>*)T9LR(*%193U\$*ALN8N#M3F[7_^@-WR;Z5[-QU0Z@F\I;, M +UTK8R6@ZA/N0V%WLZQZ MH[9#1:"\8SN8L0<83B]8B@_5V!,'VGT?+;\'4X'?Q2286PH2+7Q2B]95$\YA ML Y&QU[-C>?B[6_GYU_GGS^\?:T:. E]W \>)!;KAU@7_N*+>YQ !BU19>*/ MF:@/G[C\$9D[]F5L2PF/+E9Y[P2U":[$'X 9 ]/(22J>E77 MT/,"UPM$PA, L 3F@4<0D5@6"I&5PDK1AP<07M_"/? 1W A,1E!SL4-C/9 * M8IN%28;F:#5.37:NRL:YD%D#(8LV(3RG1G+DA0YH!4 ON!6KPS]#UU1=5PU\ MD@T335U9,+8-WT34)/[E"VC\CN0Z!/3AD14J[K1,@+:%U'VNI-;!>M 6@('N/1V1;*OA9X8ACZKBU' FURZ @3 M%QK'=,+G>R0;#"@#BWH8V6#(P KX@<=D$ILT\)R/_.OBM%A$Y?B@"\HN)?=G MRB X&$ $+DE=:@)4ZZTK[F93CQI1]26(NI[@A2@Z0$H ML7O+NJ48JDC<7I"*W%9NQK+-J'%00%(6M ?86_R8@,8A&2=4&3HQ4:*J -X> MJUB\HOK/=A\-D+_A !;B3>ZW[> MI6VLZ[9AN>4K4TI!DE![:@Y]DST-[=/3]E)3UZBT7NW<8#%XK[MTH$W=FCE/ M$QX^05&:2"FJ,O*VT:N=)L2&,H A"_(G8D9AT*-Q:3I>E(F?LQH8/G UP+"3 MX,,&A_13M]EB4+*#WT&_QLSQN/LX+K_%GS["3PLQ>0,=VAB\KO*$D@#:G!P M*3&,/G%48 D5OJBA%)/B'@9 N,Z8C3U7H$?V_X3 X(Z[?R8#60;MA5?C$68\ MI%51D)^-F=+FJ'Y9 EL.4%E8)V=0!(0T/GCA._1SD3M7M8SY#'VQTA\U8+)\ M_@#FG,8S0XP08-B-XSD7?/6(.\.E>"H*(![44&QJ>]A;^&J.-08Q2001@3]O M+E8N?!6P@!W!+S]UFD:*/\9N\$5W_H6*/C[AC$4R9C+44X]&4@TL&:,*"#B< MF:H>QI-\'*4:,$")0\]H7 L#W !+]^>VI*2'96=^CL(0'FW$\]PT?Z%PB ^Y MBP>L"[&>W'*P5@%C3(UL"(KN/2 (ZNA*' AXH*PXU$^A5'^(.:G'(X9%S";2*9R=2G"5_O(TJ M@JZUFFEE.UVF4.@]?Z,H_#"@+R"J#4_975LE%FOQIL)'53X;V1:H8T9AMCI1 M5[UI)&_F>AU*T6>$EUU:Y3XTG. N]SW+-8.;R(3(1%^XB4SV!/?2*?XOA9EC MJ-H190LS5USCQL/ VU@N6R[AV?Z2A_[6$6GZYIXBTI6"+=R)[$NPI;C"!AH! M T/ NGWT/+L9K>:I%K!G["D:_Q9D,>M6D*I=2#U< 7;B9@E__3*,N0O]_1-36TKG]NDBYT:VI\-Q;=,ZW'%=*?7 MZ+9/B3/+GAHEGBRA]1!/UHCT>GW MHET#1J/?ZN'2_84E^]ON']@M:5U.9TO#D'P3/F6PPO(O%L4AA:N8P!XV>,2#>K';025Q)7%E&86K&E;U&NW^RR^@B^HBG2*0O MOWS TRIQ7*G_''ZUMK$ ]SI8KW6:0HK-5J?BK7T2USH'>*TX\']O%[1\ BN; M?5*G)UV!-,MRH81A&-W%FXC7AJ8ZB&Y[EX11AKLD2B&AK>[\**O*#XR^[H!6 M6^/W*:"E=^9SLW&9BU]DGGR&IXS!R\=,#HREJU9W:DR^_5K_<-=.I]<;5*5; MFYRQVH/HCOI5#C5G[OB^C\3W7ER*5CLX^VNFS&M=)+!Z ^ MSEP^AKIX+WT#7X#GU>/P=/SP]WZK?7K:2H_'?,/7'N*O)8KRGS"Z$?Y?7/;9 MFT;K]]JX?,_H-Q8.*%;[Y*(K'3S&V3AT OM872^ 9P"KU8 H*@N#=&\RCJ[+ M2RT(SQU.)?SH(.A(TJE %^_L>5H?%B_[43\OG22=O38GNFXCVR75(G4?1"B% M.KEZXGL3WQ8!WK!Q=?WYP_'U%P:0!GC'Q\*]#RY@A8=18\[J?L;@A7L17X"1 MN?W!S%+($DY^>*]NA\!CM&;+ES+A$ZH_3191$[X?+[E,UE9&<$2'5*OSK[& M)205>%X(HN#0Q>:NVE\!I7]T7CD>H7SOXB5^\.=4N"%>L67%QR,OP^4-V4_M M=O,D/2P[N4PC&,$C>,)X,)+QQ4,+*V!;64&EER8EPLD<,IY:00-T"&^,44MK MYX>+/VE,,IRH:Y$F?#:_T00^J%-_XX.=XSXW697$6\JD[?J^?SEH&(_MZ)X? M3 =XZAX4X>)E@X7'#;G[FFQ@HMXTP"PRB,31F$/AW'#U947:MVC\KL0CRJ' M@%<8J">CRQQPNX2/XVWX;@S=O\<[9 ,(-1KIM5)X"U3HP[^&MHEW1*!]C!6H M,OGMSN.^NGS+LL&3!9Z/]X?%-^LI/_;@V^H&*BP.GO_$9QB\#> S1"%XR45X M!UJ*=0AUHQB^/(_T\,FTF$"X3.*- Q8"L?1B=/O$O(_<<82Z:17[BJVQQ!!P MX&CG\0T65G3/EGSB"L?T^L;S2*[&H',272D2 3IG]D?= MO!/! UX@B2K0;T2RQ4;]/82XPCA)XI0/O2" MMD.SSR%J=EC[-+,;:![;VA*!G:$ZX 5;@"9 [CGA/"P"#8J:H/D5'S6(OS<= M=$91=/LD(=VLVLL1Q+BQ#X%_[&GD6AS^($,[V,R39!T(U#ES0$<;6?\2\50C M<2K_CT.S/MK*JWR#@2.T?]&;G+4-Y4M:I]V31L2&J-IWOH WHVMPAS90A8U< M:H6!&N-EF?X-M"Q#ZJ&+,H.QA8^UJ0$"O\-Q*=Z' J#ZGM-@]W@I.0Q.9/8: M2L AB!]#Y-2%C6JK7L1)$1EG.7B!>)_GR_F-C2^0%]050$=<,9/9NR'94,37 MU)J>Q!99 L@,VNCY.-9Q;#%L9-I]CXSAJAMKXIN\&^GU-G801A2QXN"C6^5_ MN(4JB$2.G.ZY5G9<%+4?N$AYR%C?U-61#WC!96#CG5#0!&&K$1G4-U'7ZN)= M/%X#[VX:@R^#3Z!1J*9(:8J2YS'?D_PFTA@E"H+V1G/;F',[#W/.#,S:&XW, MJLUVC[(-V +74G=R3NU[SX_OEE?@_=I 1N^YC*XG>_J&9B "*9/"MHNY#3!CL(1[$1>?M'8Q=PC!$EYEFMRB&M\1RZ7G M\CN 9P*D9F,:PT%V TM3XVU5M2?C"#.^9"UT@-)];QS7%:/79#EE 389S#]. M!'CN#8Z"XOM%;]";X?0%WM5F77G^58AWC5Y+S%":JY9@=&'XCW),%S' 0,3] M# &86MG@_@C,[U_&K@U> D8[F)B<"GPKH77O06EH#L&FS M]]_KQPM/'G?[$OC_V!^U6/X^>?^7^%_\&AQ*66OSQ M5?BJJ(TFRD\>R0IOX#)6MO>I"O?1PBU2Z.>1"O?-EU'%UOO!%+[M-OK]UOM9]H35;-M6];'IGW::YV<&*>[ M-N5+&(!OBD*RY]9*I41SDXS_<18YF*'[\MQ'B]PR]:Q'-:4WF]8,@X"1<"6$G1!_>F/Q601?AK?\QSZ75@W4>K/%5CU5 M[WX:N.&:I6/CU.ATMFOB!W$77+LR\$/4YRMNBFCI^/92[!Z]ZR['%4_5LMR6 MH?!]87V#9R[@WS9.I/AB96,VT.;E1<9/5K-]:S90\-9@/XWY[+GF/M YA3'( M\PV:U[13FS; J-WN;-TF4'O35M8$?SL"_X"1,ZB;']C_CM9![)$;( A9:NG+ M]>^YQ1N2A6&TNKLV.^"37E=H%I5N6O5'+H:[Q:I Y+%3>: M>CAM,N79HG19'YCA;91-RV*ZL.#0,-0+ZJGL0]]/VZ=&N[N\T'"/RPN7=J?B MQMHRS/*LL2PBR=.P*%;#F71WYT4?%4H++ZY'F".8IU63[Y:0Z1P8]#[* _,'[EMJ.D@MTV!0 M"*91U7F-R<&0T2_1DS@[]<1/Z?3,PF](@RH)+F(%P$4/4$/H!#Q9")3.?269 MZ63U6FWU(YJRWT M!BO4XDZ8P%=,I*L1O845 5%B'J?R\8=':V(79P^^B7N< M-HW<8#KNPA=Q.3B[.3;F$[ @7E?$2WR2]8_77[\H-8TF_>"Y>:L>+^E(?_H M]2ST:3X)^:B%CY?'/"[Y/3ZS")(EHJ69T"22]J/IR^4PMG)K,N"6L>J:4O6;L#XJ(&'<$R<,%K[LZJ"I.1HC1=N M!XAU-Y/)664X:B)/AG<2- BPS:Y>Q\41XL?$CKD&V@KM'0H[4.1H8J,=)_U- MZ<*#+><3HEA1VCML8@B\%K4X,L%'_5@?&+QB: QUFQP7B]OQ?B*&ZSS8W[FK M5@T:,F!6Z">D@/UZQ 78QY.?DZ]7 ?NDL2R(- NSYV:/79;I+"^2A8A, TW8 MXCY3>S6@KPH:1^#JQ,>-R!!CO"5!L6==?/+YBK.MX?\;W?Z@T6[U$Y0>A"\6 M%6BHI@9C-E^A1'4!\";KNR(X *%59("-5X%W+]"JH_@DZ[ZC,<."^\X& MENP>/*^O3',JT "F LDCC!0^\AV*6<"]#P-LAG"CGZJU36(+9093'X^1G9:" M"K5L8HKC,;5?:3G248"C.YB@BBL!W@F(>,XTQVNC]4JXCF3I=KS6SV_3)( Z M1HFATXH/I<))!O593KB9?(Y/VHKNH$M/VHK/OU*;QR92G"5_O(TJ@J[A3/O/ M2[W;]%C8;K]Y4N@9>*,H?6! 7T!46YT7VFQU-U@$A\PP5'H\LBU0QHRZ;'50 MUUK[D/9SZIK1[)V0K)Z2U=X/R2;#.!C8I-D'!;M%8!\*[&ZS3S1"-*(AV/V" M;]VK%=BDV0<%^X0T^W TTB.P=P<[^KS;'3&%)P-6G"*-:?==I++S<=+]K9," MZ9M:)P7**+-]W&8 C9 3#K /CIZ70&>P_Q!_L^NTQ8:)EHF62V0%O-M3.4G)@ MXD-<]D/:7P3JQ29VZXEZT1E>XASBG.)0+SH+7 WM+\_8YW_4P\*BD%<3 RPZ M65U/U(O.6E>#]G:1 V5.*'-",J/,B3:$1MI?BNF<]@O3.:U>;S8N2_57"&1HM_:84]+;%^WN\KB*@50JE,%8::U=/9C36 M+@>ITEB[JMI/8VUMPPL*]2MFBS34ULG^OHDQMUU7BJZLY08@1AA:T8H-*=#[) G.WSU;9,R.D0.>84+.>28B!#R M)(2/]E#,->+5'WA!SF9#1"*(LFE!1:*'/!)@1!9YDL4KVYTK!U[ )[EK;4@7 M&V:40"TJD$ZZN+B\O+HJ6^XZ#S:)CE/-W$3(U=5YR66$<_7H&(WY![S6O1Y. MI6::4+7<4T'B[32[J8!1UEDWH6JOEM19IV$8[4;GM$=&79Q1ZW^6:#EQS\VL M?LK!FDIX5BEQJ.)0H]<<=(D_-;3CJF78R*#W8M#]9IO,6:-PJ'2GK)83]TJ% M0R4\Q978,PJ'6HV^L5F2J/JIQ.U-F?6J9LZ_^=S5\]"^DA&R9MOI:D^,C8[1 M:1A='1/H>EM.T1FUDJ%;J4"QZ+Q9[5FOW3P9$.-5C/&*3D[M9^%&?O:BV7%V M>BMST1D@O=$M.A.C#554/PN21ZJS>OF1Y+P%'3,DE4EF:Y8[R07WBH\L7G6Z MC9[1K=HG^M2&/HO.VE0W2M$LGU-7 R@Z MTU-7W(O. =6 >*J?':I3#NC*\X?"IE4RU:.RPL])*CMCY9C0.1DT3D][.B9T M]+:9HM,V)4.7DC.T/F9MTFL/FFT==]^6S"8UR[24/4C0+)^BMS(7G371&]VB M.V.6< M.)H)5L.0DT;GI-4P.G20A3[V5G1:IC*X4\*&5M/L8S5-M]G5<:M39>Q8LR0/ M6=K3)_3HF#*MJYT5G7^J#.Z5BE.*SGL1>S[)GHW3T\WBE.JGWNIBR?\M9" L MQEV+B1\38>*'P&-3^+J^";>Z"/_PAWBO7MJ45_JN[L2MOV=THC11TQ(I2];]C3[:_P1_QSY21=B@<7Z\3;Z=[O[\]N12&08M_?. >$] MEF#T]1&+]0[UYBAMP10L_>YY/1UNJ\Q(M&>U'%EQ5\U>/K5KU5EU1354N3 M(Z",UPM6,5?]R:+F6]L*?&O1+T@[JP=E%O$+%+:"FFY'@O'[>U_<\T P:*5O MN](VL<S@4OG!-P>Y$\""$J[X6\3T(;.+;\),W M5-\"E0C?F>$&<&\2V)XKU6)5]0(@,U8%#[GMQS7&KYG>>.RYT W/_),-/5]] MF100C'C 'J )T%[U SPJ9@R^5&EZUC$:#)/RJJ8/PA3C.^$O)._QYU;SQ:', MDE:\F?/.\US\5*"B)+@H!*4D-H#D!F>=WJ*GRU61UE::=2M(U>E!^1;4EZGP M^;U@]WB#*+-0P18E'8DW$>M]=-$HKE\6XXGCS034E<@^&/E""3H8228 +VM9 MV ^@GC_! /*TR9Y7ZD<5)YIK,2OT45,WJ+#5[#" QH&"FNR1&FUFB^?SJ::T ME@8V!C1=5=8QFD92F[(4+^ .F)@O3._>!=E::#@3X4J./5-+PEVP2%]$!@S( MANXT6C*>=%X9J.KQ5X>GQ@5U@'&S3,$>")/Q5+C'B7 G('S/PM;PR<3W?BB3 M=F:LW3QE,\%]N01+RNF3M2U&0QN9:^>:QH%4YH/D@%M1>M&/L2@WTEHL"-E/ M:=2BR'[J-4]2]<+G?NIDU+N!]>,6 WL*#S>W$ZINLKQ!.1S?(]&Q+2ZN 4)Y+/:[NY\HA MR-NE,<@+XXTD"#0%]O=H:50%#.[PB11GR1]QL,GZ[6:K__-2YS9: W+::9[T MBAS*)^/#:%BSX?!];758K 4]S!!4_VQD6Z"*JP+V38;JT6 C#?7S3%NWFYU" MYZ'*+JV]9R^+G26H&=R#9KO0)'W-X"8R(3+1%VXBDX/"W6JV*8[Q7':>?.MO'="G;VH=T)=&4/M8B@"-@#$U8-T]>A[V M=JR9]$J4."K*8=:N(DKIG=YYCK6KIHN'=JGS4IR@?=:GR43E88-&. M2PL+)*=%3JN&@JJ\T]KL!C'R6FMXK>56N;CA9*[EGQ-GK-D(4XN,L^PQ/-_;:,-J7-OO^#<<1O3OMFC+,Z]TNJ1 MTYY[(H+229J(@(C@>2+(8Y\^Q>]EN,&MC,'[=CN:JK5?Z9N00BTQQ)6%EI@* MQYO@:L5Z>-P225BSM0[E!CLW<\ICKV?1ZRCVOM=3CXV>@VZ?2))(4E^PB22) M)'>^UZ#;KL>0K41V6Z-!6QG@SLUX?A.N\+FC1F;<&MNN+0/61ZB>.(XRIE"<1QVG)?BR!?.YM PF- D!U%(F+'%!:7EAKO. MJ=HBA:E73-)N=%LTIT5461;KJI;Y$%76B"J-1BL7JBQZ %=NV]UV:!=]W/ 8 MUSVT^04%W/RDN]*Y']^8(\^!BJ-BCO&P9GQ@[%G"R3S, MI0S'\=FC\2G+T<&4Z@%U>"(>4)D<3VK#XXLGD<;GPH(X;!-;=Z:M4*MU-F6K MF=:U3H)KI4?J]9K]&APKE!XDQ"IX(F6+!)3S06;=0L^JT1_A7K-5@Y/Y2(=U M1KA'/%SHZ46%1RJEVT;Y* M"PLDIT5.JX:"JKS3*LMA'!IYK0,?N4?NB]Q7R21![DMG057ON*N#9P/+XE4K MK1(YG757='J=C)^,GXR_H//M*%BF8/E)291H<=]^S&[%8LW+'WB5,=Z)+?QQ M/4+K.HBU:CZRH)U]6BV[[C5K$A[7P8!G@OORD3C7K.L")'KGVT0,1 RY$@-Y M]J*(83LKUB)0UUJZ:3@^]1P>V(X=S#0,RK46H=8>MM9^]'30/-4PPM;:&G\F M(]3+"'NY&2&YQ'(8H191:DU')]]L^2<;XBI=M?U4R(#Y/,CGB"D:?E)T6U*9 M:N5R6\T^.V9&\T3#V+>F5JQC5$S&N]IX>\IX:[)X@HQ7RVA::WFF.5_+GMJ6 M<"TVLX5C:1@S:RU&K2/C.KM0MK3T]*\_VBWC)*>M.Y0)+H?;)+,LNSP/:I;D M-LMAEDO1;/3Q$&=7+@"R#AI;G.F(?^&1>&^6.\.R'WYY$\KC>\XG9Q]L:3J> M#'WQ97B1.=C_FW#PI,$+3P;R9L1]\1[/_O_*9WAWM;P%JW_O>.:?[_[C+XS] MDA1VR7T7E$Q^%7[RCFTR$QH*SW\3PU^//H2^*OZ[ ?_%]?C?;[WOG>^=Z,,1 M"UT[>O!W^,,X.6*6,.TQ=^2O1^VC=ZUFISMO^LK:M&N0D6V0\5*#CF&LWM*L M11]L)PS4O1-[%%OGZ2;%]6G:J+U*K\*M2BELDW:]B^DU)=27/86*E(QVXC*R M&Y9V]ZHO.!'U8+\)Q0;LU4=/RM?LVC6]L6" E,PL/,@\.V[,#HG-? 8.(&Q MY[(;O/!E!*T42TN(%]W-6AW/'CN[%#.6X]39U9)1SY[9 ;34C,J*,4Q4"<_E M95*AN$^(2GPR+QZCC-?_@+JH@Y.](;M3_N*5HY 1CY%Y=73Y]>;H-9ZN'%T? M%)^L',$MK&,^%3Z_%\P-QW?P%A1I1BJHWI?,"P,9CUP9[L(,1?($V*Z'S MD;&JTY,M-'I[*M*W48&9^%=H0V".,4N3K6B]%7,3M'$O+51WR:9-F7@!U&QS M9_$%Z,;(-D?,=DTGM$123##B 1OS&;L3R1G0(6B$KQH3=2<^KQKDXC88E\"* MN.4*Q&-ECIL.?,$AH)O%[XP%0&8UZZJBJ!N1CJ:BB>7]('P\FSL^BUNR5^IL M;B^4\"#(2/PP!?0]TF)\=Z[3%@_XZW4.X:[ZX=2G[6:KT)ME=CIS,TI2-%O= M#<9KBQ6FAW%6\-#JSKXOG]15SV!M_O2";PGS5/= M)*#U6;S1"?)C3YT@+_(Z0;YH)Z>;79*#(P=',M/%P15R'F9M/-R!3YLG5T>N MKA)"(5=7$YE5[T3JU!NW7_#&AM%L:W$Z]?/>N-*:DM,I]40/918ZT0/10Z'G MV%,83F'X.D+9\D2$G,6R'V-VT%&+ M<>+V,F:]JLE9;:=ULJ/")S>9:1C1E,R:RQVWM.%WRPMQF]^Z^<^2X9N;%?V4 M@VWL.?HYK/2J'>6P5T:OT>UT7A/E$>41Y1'E/2F]^ "Y*/AK59_X!HW33D?# M 5W)K)+FW>HUFKZ)3D5Y]4&XWMAV:RY:LH$5W12(6FW,IE MV$2H1*A$J$2H91\(5L:PZS5$K-.4V_]L<1:GAJ%-5>VM&@%,R="E,.6 UYEH MDXUNGS:Z@]/&2;M'_$?\5V5TB?^(_[;COU:O,6B?:C@2*YF%UFN\E<G?""V SR&<* IXW2*-I>QO?G='$ND1 MZ=4*>"*]TI*>T>B?&(U>OZ_AZ$H_<]-BW%6GT=6C>:YX6BN]X8ZVE97,Q&B/ M11GPI5T010<&-.]46>,ANWP"_&@M+ZHI[T6M!JKMD7[/[:>MJ $0\1#RU)IZBQP;Z&8 6HX:2@9_; MP/N].A./)BS*9$#5\-PE0SZS61'9%=E=$ELJ/] M-FM37JO9H4F5\A">%L.CRHQ:\ ;S)H'MN9(%'IN$\!.7@G4:H)GI$7E# M5=2%-YYP=_;_R<7S&QZ$+YCX83HA%C[TO;%Z&IZ9A ''HM.S'^!W5P3)'5@3 MX4-DA+5* MH"M%.=^&/GB[LU3Q?K-',EU3HKR9> IFQS0TV@?^'7^ %:!O\/_S$Q^!A@L7^\ ;:'L6RKRQE0C6 MZ-4P5K*X*K *V^2J;<+D "D:*_0.&P2/C;."''$0T)(H8WF?K6&BX&46?;W1 M@H#]*/%"4:M-X3BQH_WUJ'6D/LL)-Y//<>Q@(IY^&CO$/AWS'M5.0EN/<%I-BBO+?(&M*#0@7-MD2>V*4SG(R]/R.\3^3U-%Q<; M.:U(ZO P\ I-Z?2W#IKZM0B:RBBS?Q[ MZ3S/I__:1C%2O]!^P2\8[69WWU-D)?0+E=84S-(3/1 ]'.@"N#Q&OD0)>Z>$ M%@6!I5U.D=M"F2^9*;Y5$[792;IZN(R:*4"N P8Z@;R8Y:9YS*_0">3[69EX MTNB_<"7] MFV4T6/;#+V]">7S/^>3LDOLNZ)_\*OP;W"1P"YU^[WCFG^_^XR^,_9(^-IXX MWDR(&^%/;5.H1]_C;@7<]"!OO#G<_\[$X_V'+ M[^Z/P/Q^WFX9W2]CU[X+Y;6+^7][*O"Q3P)WAARQT+6C,G^'/XSV$;.$:8^Y M(W\].NX>O>L8AM+"#!!Y]?! 0'Y5&S:N/#_^"I\S%M#]$/KJ[>_&]QC?6V\O M8+_[VOZC_\EH?S@ FBN[N0CQ%;?]_^9.*,ZE%('\**;",6X]]>_VK<]=.12^ M/%=;;)Y1O];S2M0Y>I?1GDWJS*6U1G&M;<=O&@?$]JDZV"5' ''U>R97FVV_7V2E73:%MON^ZP!V!4--F6P)A\+ TN#CI-$^J MN\6F=IL C6:OT(,ERBZMO9]KWZWN+JCJP7W:[! 7'0YN(I,#P]TBN ]))@." MF\A$6[B[A9Y=7"^X#:/9)NTF,M$6;HI,*#+1%6XBDP/#W:GN^275@[M/^=OR MG!%3>#9]3SL8]3^CH&BG4!I!'>)RV&*3Z#6"NN@$>HV@)@+)XS@IPWCAW)"3 M[OX];"&'!-3W$*F-CQ6AR(PBLQH*BB(SC:"FR(PB,QVA+G;BH$90%SUI4.*P MERA%(STO>F%#?: N?%$#48H&X)<"ZK6/G6WUFP,MZ$7K[-$-=,L>VB9W THP ME-ORRKT6H$90%[T.H,3$ML=[9RGW3+GG.@B*5Q2P*U+GE'.J+BPBP]/$\ ;- M4W)\93>\;=>^4\J34IXU%-1A&?2TV:?0A8;+&N@\9>!* C5EX(A2]-!SRL!I M-1"YQEOZ8!SBL.B.2(IB-3$_2L!5POS<24A&IX_14?*M D;WN^MME_>F[%OA MV;=<%.*5NB_9"R5W+?F:V+@.,L]X@>?_VD8;*-=(B0$RRPJ;90Z#)SI_?N_* M/ZCF J'&13*$S=0S$#KB$$HE6_WWK^H)=PGWJ^H)--%+O=;'Z@EW"E;'Z@DTTS2'>ZJ+]@E/-ZUBF!7/[.^(=PL^:=7M5SZ M)^CVC(W504YL"(JGXZ:62AE/-5+F&D):=&)\ARE=5605,"8FT&Z<609(JVX:VW2:W7F$S!@TC'Z78IQJ,%NQB?@R0%HE9BL\F4_, M1LQ6$6:CF*U*S$8Q6Y',MK3N^Z\_VBWC1,=S.\M@EII-7Y0!TDHQ7=%3(,1T MNS%=]>=>RCT)EM],C)J#P;.-F!1FZ-N!+6AK0]7]7]'S-+4"N^@9G/V!37,[ MI.JESB#4"NRB1__$*WJ@7PFP:?,#;7X@7JD4^I4 F^(5BE>(5RJ%?B7 INT1 MM#VBXKQ2_9Q];?9+7'C^Q/-Y(-B=1YLE*L);12?A-82TZ%1[M0F?F$"?8>AF MYSEJB&D.H\U<,=5KR4B[8S1.6P,*1*I@*CEDU^M./WDDT8E^:&VN_I9#P1 % M0YJQ$05#%3*5'%+WM:>?'#+T1#^T?+^029ITDL!H5VV6H$87W.D[VUGTK$&M MP"YZ/D'7J67BE1*"O==A-SA'9GDA[AO;X5*I$L&=FU>NP,$ 10I3KUB\W6TU M^H,3"L*J3I9[G3$ALM3H?"@B2SH[JM+&2X$E<24%EM62M<9S3.6VWG+//A%9 M:G1H%9%E>6?$HH]X3%+ZLF5/L[^NLI#=<7H!)/7@$DS@;V98EW(SB;&5> MZDTC>?,)/=(CRJB0X#2;4*PO\D7/+M87>6*;XI O]L2-^B)?]/$;]46>V*8X MY(L]-ZRVR!=^B%AMD2>VH=BF=LA3;$-L4S_DBSUCK+[(%WW@F([(+\VGO)3Z M7RF8PK/_*Z;;>!AXNXAHYXFU_M:)__1-K1/_9919+7<1U0#UHA/^]42=&"8? MU*$1L$Q=XO> )Z###)K8**%#@7YZG6K>(B"N#O/L5:U=-'E?Q"F M&-\)?ZX5':,Q_]!NM5N[+)>A\(["N_K*;*_DVWZ!>R'HZ)?M[I024B^%(56U MA'+GY.N)>M'Y>.(RSW['P]42]Z9KX:S'? 2\$HD4N)7'UE1O/TU2>TVL[<5U(.Q$*4 M1*\+ZI1$+X<1 G$,9YBI80GER6>=F8$\%^\3]/T4@F>?3>$0_JZ0,<\6L\LL=O#E5 MMR"0.>IGCH/F*3G)"IGCMOL** -+&5B2&65@2T6KE(&MBQR(A2@#6Q?4*0-; M#CD0YU &M@J64)[!Y;4%78*QIV*( M\DBF$EOD.B+X**;"808-!H@Q M*+X@QEB;,=K$&,08A3!&#@EI8HP#,$9G,\;8,!T-BE"!7/3%Q>7EU5799H_V MHQB++5,U7' Y8N)?H0U2 K669_7P&>64LOZKAVN!>PE7"]<"=^(96A]<)]Q+ MN$*X%K@3S]#E>37"O8S7Y]4!=^(9BF=JA3O%,\0S]<*]=,UG/\GZ/F,C=4!:6P(:JCCMJ"JFE(U4OMZHUMT E]O=(D9=!Z\ ME@S=W)SH3SGXS*('P)O*KM/LSL.@UN(B&55'M43*#*-A=+L4#%6.\HJ=%R@9 MNE6BO,+G%HCRB/(J27D4Y564\BC**YCREA;$__5'NV6 P5D$,?3NP!>T TB4PFYX'Z0V)J(1PL#*'KJIZ:X%SYM0\1#Q$,13PUQ MIXBG)((@XJGGM$==<2]ZRJ(&Q%/]*84Z[2*Y\/R)Y_- L#N/MI!4C]"*GAO0 M&]VB9P#T1I>80>>QK=[H%CV"K?O:E_9)I]$['5"\4C&[*3K5KS6ZA2?TZ\Y* MM"A9!S.BT(E")XU)BD*G:MI-T7,&>J-;],Q W5F)-C/D-#U4Q3F)\5CXILT= M-N$3X6OHJ>HZ_UKT=$5=<2]Z(J.NN!//:#."W_GNLEH G\/@OBC@=8NP>XW! MX)1B*6U,+8>I%.*X@F99B.-*DT4@TBNQ[5%@1X$=D1X%=EJ;6@X3/<1Q!5)K"K_O30#I- 1KMJLT"W7L =#;V:WA1:] 2/WN@6/8VCS29%HHHRH+O7 MH3PX.&9Y(1Z#N&ZX53)\,1K]C4(A4.=[;Z[P-\5Z5 MKSHAWJ/+3DIJEA3N$>U1N%<6H;)VM]7HG?:(]RK'>WN=S2'>J_(=)\1[)9CY MB3[BA1GIRY8]S?ZZ M<]X/0"2.K!)?9)>I@V>Y(T&5K,WBRWGV4__/(FE,?W MG$_.KKCM_S=W0O%^]IX[W#7%S4B(X#??"R>@6K>@(.\=S_SSW7_\A;%?'KWU MP9:FX\G0%S)]E)G0,OCP30Q_/?H0^CRP/?>[ ?]MM]K&]UOO>^=[)_IP]"YN M;]K"E]%6'*3FK!2<#T(9QYWG6/G+8=T*5('=)D.I0'GZUVH56 L[9?FV:T$- M9YW>(A7\,Y2!/9Q%7\4? ($ F,BVA'?O\\GH0#I_.Q+LPAM/N#MC(RZ9*?R MVRX;)D Q+J4()/.%B5QI,1ZP(:(^140;[&%DFR-X=2K8G1 N,QUXP1[:^*1D M'\54.,QHL#;S?-9A#W8P@M(#J'5>"!O9PN>^.9KA*Y:0IF_?P?OQ@]PTO= - MP%B@(]RUN&])-H3B,B6,,$OUD1T,;999OY'Z 4 W%C=2L0FOFU"W0 C-P,; M!!1]'X%G8_=L7S00.YFZ@Q0*E^ M@>\"QGW!A*V>L6RPCL"9(8;0X_33'31PBKZNP60(5@+:_:\5$FHPU74A X:G M04H&2LYFMG L9H;^M';"Z&2%\;L[AS'!W\+'O G@&$JD!4#.'BODO"&J MH$O,/G@W4UP24UU"6[X8.B K^,F3(A9K*AON@WW8\'C 'KS0PI/Y%D5:#!;LCLN 5/X>^Q9PI&1WB^:AB.DS%@ /A(NBE(5&X'=4']; M KHZ!L>CJ@%1S@D>_<^_0C L"55"Z?\,K7LD^R8[-]$O@18XLZ24>U\(?#UY M"+J!6YKE(S7 1B25HAYE' IT$HI!G0HBNIS'"\R$K^\]'[#-^+@.-"7C->?/ MSY5Y\%8"+/CP2VXP"S$^Y'@/V)#H9=1QU78 /,(;'I>@0.!U3=36P%LN.>,> MM]3@"BCN1K$CQCU#SP%@4?!J0 (@"B7L8+2,'T">49M%B3Z*E$#'UI,R5WSU M"3^P#L9($+ K[O\@3#&^ \<2?]LZTU9HZP^\DD\X^%J<%FJU?GZ;1N_198RF M<)QX\/[K4>M(?983;B:?X[R#*;"_:=XAS@; 2-CA$RG.DC_>1A5!UV!HGU16 MT76,HV@X9T!'0$X;)CC6UH?%6KRI\(=@:FTE@SN(E,#@QWL2=)U@SNHH^6K!G<1"8'AKO8L[/K!7?A MAVG7"VXB$XI,-(:;(A,B$YWA+O9HZIK!7?19U=K O;0P[*54^DII%)Y-7W%H M! \#;V.Y[+PLL+]U(CU]4^M$>FD$I?\Q #6"NN@$>HV@)@+9(]30"#GA@+5A M'+W@8;LE/)=I*^ S2Q^B:?^"G.ZZ56377:]HZ:+O5HM(YGK0,1KS#[BL9"./ M3I$9168U%!1%9AI!39$9168Z0EWLQ$&-H"YZTJ#$82]1BD9Z7O3"AOI 7?BB M!J(4#< O!=1I_JC]0OJHU6\.M* 7K;-'-_/-8Y1@*+?EE7LM0(V@+GH=0(F) M;1?P*?=,N><:"HIRSQ7EJWIEHRL)/I$,Y:?U@YKRTT0I>NCYVLDDH]WLDQLM M>S(I/H/N:WKX'(T;-+$_2N96P?Z^J",)R>C*;724QRT)U+KD<2EKJXTD*&M; M$4%1UE;K43YE;2G%4@>2H:PM96V)4JH#?BF@IJRM5EFC\^B&D$_Q#2&>3^,& M3>R/LK95L+\OZ4J.K^R&M^W:=TIY4LJSAH(Z+(.>-OL4NM!P M60.=IPQ<2:"F#!Q1BAYZ3ADXK08BU^F%O.?J'D&*8C4Q/TK 5<+\U/VU9'2Z M&!TEWRI@=-G+O2G[5JWL6RX*\4K=E^R%DKN6?$UL7 >99[S \W]MHPV4:Z3$ M )EEAV'\\_U%,A<,,"N6)&RAF M(&Y8P0UMX@;BAL-Q0PYY8>*&O+BALQDW;)@5!NE7("5\<7%Y>755BNF:_6C# M8LM4#1=Z6'W!+N'* M6'W!)AHY*-BEN^-*6[#+>,N5MF 3C5 THBG8%(T0C>@*=ND.=]47[!(>[UI% ML*N?6=\0;I;\TZM:+OT3='O&QNH@)S8$Q=-Q4TNEC*<:*7,-(2TZ,;[#E*XJ ML@H8$Q-H-\XL Z2YN<>?M 04B53"5'++K=:>? M/)+H1#^T-E=_RZ%@B((AS=B(@J$*F4H.J?O:TT\.&7JB'UJ^7\@D33I)8+2K M-DM0HPON])WM+'K6H%9@%SV?H.O4,O%*"<'>Z[ ;G".SO!#WC>UPJ52)X,[- M*U?@8( BA:E7+-[NMAK]P0D%854GR[W.F!!9:G0^%)$EG1U5:>.EP)*XD@++ M:LE:XSFF?B"PU.K2*R+*\,V+11SPF*7W9LJ?97U=9R.XXO0"2>G") MHY(>ILV>9#]!JY>&1RT@I*.D5]%)4*9PG%B!?CUJ':G/,]G(ULRQ)N1G&V,B_UII&\^80>Z1%E5$APFDTHUA?YHF<7ZXL\L4UQR!=[ MXD9]D2_Z^(WZ(D]L4QSRQ9X;5EOD"S]$K+;($]M0;%,[Y"FV(;:I'_+%GC%6 M7^2+/G!,1^27YE->2OVO%$SAV?\5TVT\#+Q=1+3SQ%I_Z\1_^J;6B?\RRJR6 MNXAJ@'K1"?]ZHDX,DP_JT @YX0"[81R]X)B[16\ ST$&F34PT4*'@GSUNE4\ M1$'=8JUJZZ/(_"%.,[X0_UXJ.T9A_:+?:K5V6RU!X1^%=?66V5_)MO\"] M$'3TRW9W2@FIE\*0JEI"N7/R]42]Z'P\<0YQCC:[@PGU2JPX(,XASBE'Q-]O M#G3C'ZV3+3?0+7MHFQP&WC0"KXH]EGMVOIZH%STS7PWF.^"E8)3(I42NOC*C M>?KJ$UIM9^XK*0=B(4JBUP5U2J*70P[$.04GM(QVLT_>MT()K7^$7B L]M6W M32C5=AF-1_2S2DHS5\PJOP0CX9,I5L<4*<-G*I;$,@<]3/'0?.4G&2%S'';?064@:4,+,F,,K"EHE7* MP-9%#L1"E(&M"^J4@2V''(AS* -;!4LHS^#RVH(NP=C28>=2BD#2<$0_HZ0$ M;-6,TIV$9(I:FB(E7ZMEBK^[WG:S(91]+5/V-1?=>&6[+!AYH>2N)5\37==, M_!DW\?Q?VRC&^AZ%#@:FW ,9:T6,-8>1&-V@D*?>W'H!=\BU$UL4P!9Y)%.) M+7(=$7P44^$P@P8#Q!@47Q!CK,T8;6(,8HQ"&".'A#0QQ@$8H[,98VR8C@9% MJ$ N^N+B\O+JJFRS1_M1C,66J1HNN!PQ\:_0!BF!6LNS>OB,QNOSZH [\0S%,[7"G>(9XIEZ MX5ZZ8YIK@7L)#VJN..[5GPG8'GG6JUK._Q/T?,;&ZH T-@0UU'%;4%5-J1JI M?;W1+3J!KS>ZQ PZ#UY+AFYN3O2G''QFT0/@3677:7;G85!K<9&,JJ-:(F6& MT3"Z70J&*D=YQX7,+1'E$>96D/(KR*DIY%.453'E+"^+_^J/= M,DYT/#.W9$:JV>Q)R="M% 46/0-#%+@S!59_RJ]&IA%QP/TAL3<2CA0$4/?53 M4]P+G[8AXB'BH8BGAKA3Q%,201#QU'/:HZZX%SUE40/BJ?Z40IUVD5QX_L3S M>2#8G4=;2*I':$7/#>B-;M$S 'JC2\R@\]A6;W2+'L'6?>U+^Z33Z)T.*%ZI MF-T4G>K7&MW"$_IU9R5:E*R#&5'H1*&3QB1%H5,U[:;H.0.]T2UZ9J#NK$2; M&7*:'JKBG,1X+'S3Y@Z;\(GP-?14=9U_+7JZHJZX%SV145?T&<'O?'=9 M+8#/87!?%/"Z1=B]QF!P2K&4-J:6PU0*<5Q!LRS$<:7)(A#IE=CV*+"CP(Y( MCP([K4TMAXD>XKB"YH"(XTH3V%5_>FB'22"C7;59H%LOX(Z&7DUO"BUZ@D=O M=(N>QM%FDR)111G0W>M0'APT:C MWS$H1*H<[^UUWH9XK\I7G1#OT64G)35+"O>(]BC<*XM06;O;:O1.>\1[E>.] MO<[F$.]5^8X3XKT2S/Q$'_'"C/1ERYYF?UV!:P2C[5K"#@7T!9/;A$7PE$:;\GFO3S=B38A3>><'?&+-N: M=]OU A;XW)5#X3/\E4LI LG&@LO0%Q;C 1MRVT?##P7S7,:9C_>F^&!E[(Y+ M6[([$3P(X3)'3(4CF16JWX*1F%<3C'PAV!A:.9), %P6^\1]<\0Z1H.U6VT# MZK;PCU:3/2,)_ N4C[U95D66_?#+FU >WW,^.;N"EO\W-OR#+4W'PQ[)6Y#& M>\O0AQ-\\][L!_\5&?[_UOG>^=Z(/1RQT[>C!W^$/HWW$+&':8^[(7X^..T?O M.MU^'RQVWLP7ZMY?0XUL0XT7&WK2/]FAH=>NZ8W%+?\Q!S_%?I-6OHNEGLKY M9?I13EE-XBJS>1#*6]QYCG4@>QLT6=1]!OT7G+SSGK5K"*FQA2 M$E ,^'G@FHGO36T)RL$\'XC&%4,;" G^MB-X X0W0SEL Z9Y@OQSG*3/]!0- MP'9#>#WPV)B#B. ?Z/ P=!Q%MLHD&'<<[X&[IF#\'AZ0 ;.!G2T!=(WL#-V/ M&;NYJXYIK%4C#JH088J8P2\33]I(7$H97'&O6 R>@=X@UK8[]9PIJA2BS>]L MQPYF*"A? "#_%D\+(56I3]SE]V(,:*KJ0=P2"O?C^N.6S6.TP5O)1L"GGC]C MWI"9X3ATHD:Y(F# GA*Z"SH?JAJE';72%)-(2Z 7V"2' [7"ZY&")?N"G1FV MVYJA,5FAN=#,Z[1YIA-:JG4<=8R!7Q][OF"._:> N!K5UFF^CW3!?9@@\)& M-AMA@S_&EBJQ,?AY%58L Q'8;"P?N8Y\H F"@TW[8N+Y WKQO,%+XB,AG>R8 #Q<'[)NC.O5+?IW7?>X#(0H[L"7 A&NP4 M-6]L@[TVD/GQ2_4Y*608!A!/--3??.R%@![[,W J#]RW9*3A)JC[G6"A1)U%NP?#26I=\#W-37S' M. MC#PBZ4&HB*H4*PY#=4G4Y-L%\\R(F)H,:5<,A_!8Q$./"WKP0L=";/%E>QQ9 M.OIW]3AWW1!41LDZ\H!>)'"0A")&)3$0:Q#X]ET87>0(G8CL'\V3=0@O'1SQLY!15[A:UE"N3C_=GF# M/RW0"GL %R4!+-!<0,8#/_<0J5KZ/-HD.C )L1-H0B@3(\7*)WSF>^"ET/G, MB3 N(1,C**OX=^RB%Q].M'U>8<0EL>FH5V:)T:FVVD,;2 2"5=N%^ UY$)2= MPXO0_B=I$%"R<"1E95X#'@V4EY31V)@SEX]!@M__YOS9-=J#DVZ[W3U*1\1\ M04)&'/5&$CJ'B !;!9*1)C#Z5P?^/H]L5<7&"^Q^_NWKN?IZ#6&DSR:"L'(4 MQ+RR(H2PQ_S$Y]CH]T_VWEH_%-9' M.QHX3]UZK]T(GUFE2[MW:4#;M?C>'7H'7$3+X"J]]%GLCXB@_O-3:A9JV;\:& MJ'665>'99DSA)^4?K]T/XBX Z.8WK5_^*X2([R:];AU^O(C&B;<^Q^FZ". B M\\0K]I)=J?]L'*KO>[YPG< ]F^!>D7<\P5Q+>NW]7 Y;CFU>P&J7<]DD(P"AAZF97&>.1\(RXO8YK.F& \O+@IMM7Y^FXY7(JA-X3CQ MU#V&?NJSA$ ]^1P7$$_^0Y\=/I'B+/GC;50R]*753$M?9]OBRF4,)X-FO]"- M0Z/(G WH"\AFPR4-:^O 8BW>5/A#4.JSD6V!_68T9*OE"^I-(WGSF937/I8, MG9*TGI'6WE=H&84>K%PSN ?-TT*7&]8,;B(3(A-]X28R(3+1&6XB$R(37>$F M,B$RT1?N0;-7Z$V'VL"]M'NCF@FP%>E1'@;>QG+9.3G:WSKWE;ZI=>ZK-(+: MQ\Y$:(2<<,#:,(Y>,)!^\V3?!W?M?/;A5L!GIAM,@5,+!=G,NE4\/=.UPO34 M$JC,&E>C,?^@UC5M8I!$K$2L-134(;9\%QMIUPCJHH?L)?9:A]!SHI3]QVKM M%T(UH]7LD\Z7/5+[S?>D)#=.-E]N?'H.&1X97LE@ M)\,CPZN8X9W2*+GLAG5.K7+"R5W M+?F:J+MDV9R\,ZO/_[6--A0:UM'2O[TKRX4G Z(%H@6B!:*%[)PWMUVB!:(% MH@6BA8RR?*25,$0+AZ6%O:>HB!;VKBQX?1!3]P?EF:2JS'*2BXO+RZNK[2[( M@W]Z.662]Z,=*XX"O/#\B>?S0+ [S[5JXB"V$W(YI@@.OEAR9\XM$=JYF5$> M%TWFL)&I(%DF-U!.M+A^LMTQ&MU.BZB2J+(/A=AU2!+FGP?9I:U"_W+36%GR+ M%Y%JZ/[*(+1R.[DV_&YY(=Z'LRXSE@'4BOFRO8;Y^8M,/Y>E9WZX#)9(]%8E M8R!ZTX[>],SIEL$*B=JJ9 A$;1J0F:YYV#)8'M%9E4RA DE5BM0.GCN-/N+U MQ>G++]\XO@=@7D#EN0/4TF;3#TAN'0#$F,B$RT1?NHN^>T ;NI31B-1-@U3Y:A&Z; M*,6$#=W0O-DLLGXGK'P0IAC?"7^N"LN7-&^V5I"XE;BUAH*JW H#@KJ\H_82 M.RZZI+E2>DYWI6@5K-&%L61S)82=;(YLKMPA!87.);.J7$>E12?*2\RK=$ES MI6V14CO5]$\4$VH5$](ES61W)85=:[NCNV+)\,H*.QD>&5[%#(\N:2Z]X=$E MS71),UW27'[J+H_,,RZ#KETD]_*\LM ES40+1 M$"W1),]$"T0+1PO/*0I2\KW[O(X!<1:>70^LU!@.ZW)0XCCB..$Y7CEM:8_37'^V6<:+CZ19E,% B MO0J9!I$>D1Z1'I%>#3#-(:%*;)3C,%.+K&E-)T1NO8 [&KJ:,A MHJ3EN\2-Q(T5AKMBW+C7?#,%D7L;<7=;C=YI;Y=D=/21@S#2ERU[FOUUE4FL MD,>5^D^$J.U:P@W..KU%B ]SNNB2!%Z _[FYXQ2?R4MX+#9Z9PQR[_4N"?&1 M8!?>>,+=&0LEO!G %W(B3'MHF\S&3N-?/+ ]EXU%,/(L]C 2+C.Y8X8.?._> ML^2P;';/;5!3;CMH'<=#SS^6'#A+"C/T[< &D*!C-K3(EO"RZ818#Y3B00-\ M_,8;BP9S18 %8:-,#W5"PE,R@':, 2JH9,B\B? 57M#]FB@@F=T.9N>+J2T> M4*D=!_4'===5LF3O M*N_:\Z?EO+TC9A:,[,?40SPNOB>6?\Q,2%T=D<6#\%GN!%0!$( M]3N\&RU$4!E*\L6+ K#:X%$;,RL";+ #YQXA!'X*P:0FS+M#V#@=PP.3-R<_ M9RQ5\,%;I67.D]9\1,@@.4!X>$*O(##@+G;PB?STE?A(*^! KO97# ^-'B4. MA*!N @"]:)DSM@\W>7ZDH=H!"^!1(3)8OBN+*AX,$Y\%;/&!":[S'3$+R/#$ M_8*>+,@]./"86Y317[$3\*5'3Y%_"*F^N 5?+,?G!,CM* "N OD:B@/1-PX0 MO?"]RT ZI_Z6NPZ_YW,JEFC7^ _@*5^Z$]X,<4+,4QD'3OA=\_'M,=K?C 7 MNH23^%N[(6#03 AH QKO\@3!K]L!;&4Q@^O#D$A8I2O4M *=&Y MQ3*QT;MP"1K7^',F[EZ.+4X:(HWM=1"2@]4>A)#H'Z7)@Y21!>"3)&:_'G6. MQ.=PQJST<_* ).D#IKEL%O*3](]W\LDPEDY[_O2=5\X,S':_U,+/1/8*U&$L M()N==A^V.Y"U;JP.RR_T[WDP!A,ZF3@VJ&)&679*5<6=>GIGH:MNC;99:D.% M"@DN]_)=CTRF%,Z/VD:?.%\&YP%M2FU3T%S.$]J4AS8FH4W.G%\IL%!EAZL%R*R MNRYGN'8>Z5!OM%M=VIQ;D;!0E&G5[ZHPRPT MPM1;BP]8F=EGKI.@F*"XLC)3%(K5CNQ)#FI4%4@.:M08FB.';; LHR%>)5^:]TB*'C^!JI)MOC1D''>U.81VA12N!) M:%$D6I1SA*>*H><^1WCF%'P>:V04<7Y\V2&T8E9)F$>8ITBP39C7 M;QFF2=5I9;.LPF3_@4B,G45'>"=ZK>UQ*SFR M0/9*QY[=#TXTR;94ON6//G8+!U3#*271$=Z*@P >"'^&/ K33T%C<-A](YNB%%]0._\+&QS^O I&6_?#+SW%X?,?8[.1B MP?H+[YS?1J>>_5ET/TK.<'PXQD/(N9XUP%#@9P*[IX[H>7Z(3#F M&O3T@^M;W]___6^:]DOZEC\<=NNX7XQO=N#'U&SP? MXTB+/4?^]"?\H1M'FLTM9\K<\->C8_/HO6Z,#!.T:S& S*.W>:>9O%)__97Z M4"CT=J\$3EU%P(>)[X)L0\G(_<9N=OK];O3,>J,>J-\J#M+ M5'X_5>F81N\Y>I(W[$#!YAP9ZL/A=N_WO;MK'DS1#/-A0;\_6*;@Z1MV(6$+ MX]F+@B^^9^7"AV&G_RP5BY?L2,@6W#"'HZWI^,*C,Q9.O@;^/;@)^\/CG^"< M+KQ/C@SY+_. MZ6.SURV2?.DV"^-^SQR8FY"_AHQ"R-^2^_J@W]E(>W:E_U+&0H4IO][IC3;2 MGS6$%#* ;=5?-T>ZGM< +L3Y8'_@,40Y,GDT,)_H^.)-1$0-B;A)'G!SE1XJ M)P-!S! A>8,XX_ABO0"YMD?6.B$_G@NCS75V^V+U2NL3.K4'16+\^ME*ZX]<2*@U)+/ MRBISGDQ1>,KB"Y!P!BJ3:5$/IM[6WBS.'SR;7[3X[OR=EIQQG+WNR=&%Y^_> M:@],'"WL!S,?K%D>+WS.7?; Y-FN5WP6"<^6;9*O]T2IW FU"6?V7S$+(E$( MA^L_<#<*[QT7Z_^?6?#HPH7+IY3"74RS8(R.Q5P0,[OCVJWCSR8LF#*+QQ%^ MKR7U?OSWU(DB>>0HL,C"$U5P%D">\7K/77^&'SWXWFUI8R<((SG"H=$9O7.\ MS 0'D@08@)O M=T( +2V5IW:>#/<1&7LAR,X0<^GAQ,W=X[(R?+KXC6,8AM3V7L6.'X/4_:$\_3BPI&+X$G)2?8/GC,?IV;_) MNUKIB>1B;NHV@?64[JF< L*#?]&]B\-W ^:$8AZ+S1#>6LG,$GR#( .6(\_+ M157A>'*MF)P/M53YDG-VUQY$"O?8P'Q49=M)CEF^C1W73D?@ [.FSG]7QK#\ M$("P&(]"EC0!E8L)&7P$3K_!._"W5!T>Q0'I7!QPFK%+,7BVJ)2,$U#:F/3Y M\_%7,(^II "%]T3/YZJ]ZPGG:X./C7Q!WNLF05L\-SJ.^YQZ4.3(]2Y%XOSO%&;M7'@3^=*CO/CR3'EZ:G7_ <>EHZ7 MI\_)/B9<=[\C9[I!Z<'XN)R CC'"7/B((G]Z#K:'XZ >GCP'*23 M$^OQK'EQ+'P:ZT@&84:HO0$F:E_ 9VC]M\LABY2-\ @.SO9HN/0J\5E^FH-E M#Y_W^!T3!]\O?K58.-'P*+@%#JX1W)/53$4O:B'4$Q1\<\+O4G1_8A"(I1UT M6?OR]/G3QQ,:#-WH&2.%N;=,IVQI??G/B_-C?;0;& ,#,1C1.']?2 M[C#*\B1,3QC@%D3B?B@@>(9PC"*!3YCK!(XEG00,9![M+GP'C#U@."*T)7CG M1#H)$2#&;B2C7"#TSO5O 3TY1),^T M^\,$#!/0RZ1>S@2C@P_P:$8+[%J9/ M::X0)D"=C&0^?N'9AP=XI+PP+YZ ?@L.;*6-J:,.]NX4PS7A X M-!5^4HC0PH08PN(D%,ZN;DN361@Z9A"A \%K;DA>G,[^[C] P+KO% MJ@"DMSS1"ZS_.1"/V%E&13+8 #44CYK+8.J'41)#X&_"@02Q2-=>6@OW''@@ MHFH)O&Z*(MUV$:O5BY,)*G.2!2>5Q*>J_2:[KC)[.41!R*@[D<CGIKV<'8/0,>P2JRZ=$. A<99)VC?CGBV0(:TD8![I!^'R M6E# ( O41]Z3%)%3&M-12JV$%!T,RY*Q7 (9P&RPL]LXO>N>6:(DD$6Q9:3* M0(J5@-2"'$BK'0Z6#I + 1C^-)VY(IZ4^ "A7H!\B)Y(9D$JOB"#;Q*94O8N MF#<5"S03>H!4K$5(<'N4,"90UTD'ED5^++XC1+:6BGS9*Q 8$^[(I3%+5^(K MEZX&1(RPQ.7)"'WI8ML!S,?P-%DB<&5 2^"NMUL,0C MRDR"J>"M()IV4(7GQOBBT:US)"T)O%@TXJ+X A:'.BVP#R 67BG+CS,0@EBG MS,8\>I1**98RVQKW M]UA6$ 4T)(0E*6?YV(2$/# E7&"GWOSL=GRI_UGPU\ MD6 [FSVNDIFBRUH/@J'&D]).2_MR9NK#K7SD'J"JG6(BC3X_$_0 !\9(E!(G MV? )B2R7E19T()8 B?+$>V>0H8IJ9@I'+Q8$7>9Y6)&85^%>+(]MNPP][_G% ME=E+5#BY5#VO):7&L+>\L'7M.W8C8XM%UUUSN!,5*.. 3[@7@M+)2=\_/0CG M78A2[-]]4>?]#5 &9X(OOPHG1-;Z$<9G "8\9=7CR2K;')=8=0S M]*=*_^RK&F;/7"9W(Q+R MIGI+%IO#KM')G>JOR13I5XAR< <<+MB3LXZY+I/K]EZF_%DR"B%_6^5>6>.W M,_7IM(W8$/:5!9>!".5L<6890,W5)-D6N7%TULW2>O'E$\!@N]/1,[1N],Z< MZ'R6I0<@4UP0GL;1!'*Y_\H\;V,VKK@279:Y.L_1M_JN/>EZEFV%DW41AO%^ MK'J%&/F"/0C9E#S=B)"M]JMGC-3J_??Q?0 M"P2L#VF_\'VWI/>&3^#H^7?M1=466V=ZW<%J:+4I4=\ 3&5"<#G&[>RYIJJ# M93!E&RI.UU].TKD6E9@W/EB)6L1]9%.;S!<(>R%5^=%Y;8[LPQS!9ZV MHU),&W(;MS'GTQYCT'E"SM-W[$;&-OO5=J%B><_@J67%TU@LZS[G8\=R]N3, ML:X/^N:JJK_VSAQHW&J+NS3&O4@4:V+1.9X!*0&S(CR*\"P.(W_*@X\_DKE] MC GAOWD6K06L&>83J]V:H$..:+YG]?IQ!B'=:1#@DBDEPFPDN_RZ^ M'>)\"9S7@8)2#UUH+.<);4K3>>GEB?-Y/7I: T6T/\SY@8N^SM/85068;IQQVVA$:;>VM%""70)=$EFRMEW1O0O_[6+8LS]@O&*7]"-=B_O ]<4 M] N5UA0LB!(\$#SD!P\'SWP)$G*'A.U.H:MK$-BPXY:S:SS]6=(2P-=F,>0* M3"Q%6#0&:H;+:)@"%)HP%##!4M/SU-6?7Z&#SO,Y^K#;,KN=EF[V"$YK8VXJ M!KAD;L+PI]X5TL-V\OC7]MTS4L_U7\S^X22$_F_N0'N(]R\8YO MV'@1F[F*1U_C-8SEMGCGW7]1\0 M-5Y0JSU8J"['MF_:GLNND@VWD<"C<]A'TAVUA]5=FMVXS2-Z>T#2.N2.$;VZ M:[BKQ^Y1>Y#W6B)B-X&),NPF,"$PJ2N["4P(3.K+;@(3 I,ZLYO Y*!@TL][ M*UTSV9W'THW2"V Y+5:O_W:TLIV",H+*=>.OKK^RPZL[;'?SGA0N93M'<[?[ M;KT!C("5@+6!@BI\"4CID7:#6%UVRJZPUSJ$GA.DY!^KO;H9O],>DLZK'JG] M%OAA2&Z<;$XMMI/-D'IU \B/+Z2[([L3BVVU]KN%H>CD^&1X:G%=C(\,KR*&=Z LF35#>]C M&#E3/"*OR$484\>V75[73/W@6X75T9XWCJ=%$S\.F6>';PFZ%:OF5*][XF* M8"%W9?G$G$#[)W-C7F21JC++2?;I8S^K8%/M,S^8^0&+N';K>W9#',1N0E9C MBN#@BR5+.J&@6F;T?X4LA,Q](U/)ITW,:M%,V##U5L_;;K6%ES448YENS\5A*:VDRO^\+)J64(%POS#G3=7'Y=5S_JP"I9( M\%8E8R!XJQV\U;.FJX(5$K15R1 (VFH 9G6MPZI@>01G53*%"A15*5([>.U4 M?JSPN>?I)SJA>6L?HOIQ01L8#IW0K(RTU(X&B-UJ'ZK0,'83F!"8U)?=!"8$ M)G5F-X$)@4E=V4U@0F!27W:7??9$;=B]4D:L9@&LVJU%Z+0))29LZ(3F[6:1 MZ]=AY9Q;?'K+@X4JK![2O-U:0<)6PM8&"JIR*PR(U>IF[0H[+CJDN5)Z3F>E MU"I8HP-CR>849#O9'-FIX!(?:MDM 24!) M0%D=26O#7I= DD"ROLPFD"Q%E!6'Q3>#7D/6M<>)Y.>6 YS-5F;,:#&OI$%"CPMS"8*WE>?>P90J.CJ MY=#ZK=&(#C)G" MK)=C-+JCUK"6%5BUK9? DL"2P+):LJ:ENP24"ME6M8R'@)*6[Q(V$C96F-T5 MP\9I5_+?OCEYS@\OF-L=G)E3;@=N_QR?'K/'!='_LD/KIC+K[@5!T[D M\/ ;MWS/,UUZ I'US?^O[^[W_3M%^>/NV,A1/\W\>_8@?,B7M1 M>.K95Q,_B*YY,+WP[GD83?'KY>=I\"I4PV]\_.O1>1R(5][H\(_1,?2;:__& MO#'EAZ/WR6#GP]M 5$+%'<^&-Y^8_66=WZC=ZV%D?3WAVMAW7?\!K%D3"JD% MB1C@E19P5F.>+?_@"QZ++P-@;>!8$4]^G_% B^"!M\QEGL6U<,)YI$6^^/*) MM>1@G&((0"QP.00BMGF%N#6,6,11.31_+(: M'T&$<91R6&J,Q5TW\0B_'G6.Q.=PQJST<^+F9(NAN9M+G \@K,MF(3])_W@G M7P1#Z[3G+]MY!F]@MOMYG_>^50 ZD3V+=!@+B&K;*&A3E5A^BW_/ U3EDXEC M@SIF%&8G/RGNU-,["UWR8[3-4G!"8%) M?=E-8)(3NU=R\]?"S+7'DI0>9C;K6))"#AQ=*]C2G8@R;8#I&"AJL;MB>)]9 M8$T66F#JK5HGAV2*E69[K4WQG%M\>LN#/*R1 J+*!42%Z%2.Y[11;%41F;]R ML (=L;"WTZFT>N"$*$5V! 0$! 0$V[6*WS*H5',RMZ'+V\Z>6P?2#%>@Z-$Y M-9N^::AM%;-TM-RI(5HXNG;AJ-EO]8PB=FK6!C,))ZO.;,))PLF]<=)H#09& M\[*+6MOOMY75XF\8A+ MM,5THV;J+0W+4.+Z=-HC_;;3PF7I,VY%SCUW'XO8T5:VLZ4TI-B"CPI6J/Y2 M,6I=MKD[:W5&VWFS6@)1%0R%P(? IV[@T],;&$I7IXI;F.B+ZJ%8MMNICFC5 M=D[4W:%&I2?J[I";PQRU^OIVY[,U##<)*PDK"2L)*\6$IC':X7SD04>:&+XE0=7$Q;P#RQT+'CBN>/&$;>,!Q/D*VS0FUI47R+8W_L#A6 M*% "XE[LBB,_V2QB;S=I+E-BTY5A+CU7C':GNAOO)3BW.[V#[%+> )P/VWXE M[Q.7ZBJX_ /64D]>;R[G1R5W*&TNYPEM"&V:QGE"F[(XWVD/"6W*;9VC9K:0 MTPZOK(AJU!5'3=>MHLQR[V5CI-'-_W#S\;XR'.W W.')UY.HJ(11R=0V169W[\.AM M(^^*L8+>N-*:4EQO+H('985.\$#P4%#'+@K#*0PO>ZUYT6+)QQC7K(U]\X?(FG/&"1'ZPL *RMBVZ8N M-T,I>K5$9\=9LK48A?*_VEH/< M0EL"5!4MCI".D(Z0[I!(IV#ZIJ;%J18ZUB)/W%W&U>O'\85'VALWFQ4^N\FL MAA&-8M:L=MRRPPYEQ?A;F!45L[\\U^CGL-*K=I2CO='[K9YIOB7((\@CR"/( M>U9Z2>,,&?QUJ@]\H]; -&N8T"EFE33OUJQL6K0^";4WY]SSIXY'4VYE2UKM ML*.^?%>M7D6%Z(I&*C3EII9A$Z 2H!*@$J"JG@A6QK";E2(V:/ MV3T/V!W7O%@<%N6/L=GCU/=D9\90\^,HC)B'C*EA:%-5>ZM& *,8=RE,.800 MZU:--@:MWFC0ZAI]PC_"ORISE_"/\&\W_.OT6Z-"CN@1ZRZ"GMX9=O=4?#FN87=7/W&J1=S4I MNWHRSY5,:^$&,]I6IJ*)T1X+%?A+NR#*#@QHWJFRQD/@1.!4S5,6ZIJ/+5(3FHT*53\W'C9;KQ^"7XU%I8TE>]EKP6I[I+]FIU/VU0#(. A MX&DT\)2=&]3/ &J1-2C&_,(2[P^B)QY-6*AD0-7PW(IQMS +J4!+J$/*KN)U MQC>==K_SEL".P*[*W"6PH_TV&T->IVW2I(HZ@%>+]*@R66MA9G5>Z[5>E9%O MS>*,RO"=(I"RI5KQJ*2VB5AE3)B@DZ"S0=!9P[2NCCW-*V/&NR9\\B.[=?E< M:+9SG_UUS6!RH'F/M65SLF_O__XW3?MES4.F,]=_Y/R* M!_>.Q=,'*N MFT#3KT>=(_$YG#$K_9R@K3S6?HZV"0H",+EL%O*3](]W\D7:4%9XE@?W0ID( MD'JU1F2VN_TRD7S"Y0_M#HII2_3>6!V6W^+?\V#L^@\G$\<&5ZM+*/ULI-:YM&+M';:/4J+)A["8P(3"I+[L)3 [*[D[;H#@R M#W;G,O-;=E2_IC[#XLC?6BY[EV2&.P?T\SMK'= K(Z@\IAZ ",BI@=>]HY?9 M;ICMD6K3$#NQ/5,^D:6#DBQFTU<\2/R\]5U[':7+AG<]"3C7/L,/DU#[Z-G< MU@HI99?KN&IA@>2TR&DU4%"5=UI[MU,DK[5J>9]98$T6:F#JK4)MD=S7X=W7 M%-(]E]?5?6T[)5%HT\>.0>798T+(S\IQJR7RE_??S?^VB#7/G;KSB MW/5.>Y W>JCBW"NM'KBD@X" @(" @("@0_%[+>)W!9=!Y;:@M5KKD[_QD&.^ MK$' K=G\GKO^; I@T0R/JY"$:[;606UF%V9.Q>SM*'<=1>Y[.^JQL6/4*^+H M%@)) DE%F$T@22"Y+TAV>T8S4C:%[+9!29L*["[,>'[C'@^8*S(S9D\=SPDC MW/=VSVL8=Z@@2?6CB^WJB"KPM##K*'1.OX!HHE#1U2MHT%N]7A&57L(XPKA* M60)A7&TQKME/SDU89A4\Y_?:CR!%"B/?^GY\B^U%-"O3 M7T3C/_#O.B9,-:E!E!)F['#PH]KL;G*IMDQAUBLF,5J]#LUI$52J8EW5,A^" MR@9!I=[J% *592=P:MLN]7)85IV.<,_PU,KV2>;1U+; ,(;VK/7[9),6&M]?>&[6YU^T%E&[EN:CKS_BU:Y1H!ZNU^ M=;L;%2ZKW%M)D6$8?2AF]]I#@A&"D1HR>UCEUI958S9I]D&9 MW27-/AR,](G9:G00+;T8D-.^Y%S/=U&]+UO9GD%%F>7:HFWT2O,&VI#R\T(G+. HCYB&S%E_"Y\6'CS]X8#FAJ.=O8\,$RP3+)+.# MK40HNVA;#20^Q(H0TOXRN%YN8;>97"^[PDN80YA3'M?+K@)70_O5R7W^)2[F M-H6\-3' LHO5S>1ZV57K:L!>V:>+4.6$*B>UD!E53JH/:*3]2DSGO-:+N]-O MC\BU4T9#QD@E!3+ 30SP])X'[*Z(A@=D?R4[0[U3ORF%>MOBW5W [UA$JQ24 M,%;*M:LG,\JUU0!5RK6KJOV4:]SO&Y\RQ\-ERF2!5;% M2K;K:HT77A0X7NA8E&RK8*R4;%=/9I1L$Z@NF^"7>'K+@X46^&,RQMD@&?P5<"L*&8NV6!E;)"2_[K:XS^9&S_UAH[^_+.F7_\I?#PHHIE"KFR*]E&B2'A(B$"+LC BEUG0('8I$AZ^!8U%%A\"A MJ'"A@!H3 4*1@/"',^8+C7CS;\Z"<+L4D0!"-2VH2/101 &,P*)(L'CC> OE MB"9^'#+/WA(NMJPH/3T06<5RTCX'(A=7NRX"360[U47W5(V%FC_6SKG%EV?Q M3;VU^&!TC$XSG$K#-*%JM:>2Q)L<2RD$7(>3*K\]ZA%^UM".JU9A(X/.Q:"';8/,N4;AD')=5M7D M>Z7"(06[N!)ZRG"HTQKJVQ6)JE]*W-V4M7[5S/FW@'GU;-JG&"#7;#M=XX&Q M9>IF2^_5L8!>;\LINZ*F&'Z($*]BB%=V<2J?A1O%V4O- MVMG56YG+K@#5F[ME5V)J Q75KX(44>JL7GTD[;=0QPI)98K9-:N=%,+WBF<6 M;\Q>JZ_W&K+(O1%F5G:AI3)\IQ(,S=7E49QI#X8$G[6!S[*K-M6-4FI6SVFJ M 91=Z6DJW\NN 34 >*I?'6I2#>B3'XRY0ZMDJ@=EI?=)4AVQ"BSH=$>MP:!? MQX).O6VF[+*-8MREX@RMC]D8](Q1VZCC[EO%;+)FE1;5@X2:U5/JKWX-84X1^^B??ZI4U%E>^:#MQU+M(I9J,U*\4I MQMU*!;)E%]R:CGIU+:LUQ29KW46[Z<99STJ<8J99LWJ;8MRM5#!2=E6M\7C7 MP-H9U<>3EDX,BQ6-K:*1&AR^OE9)\=8-\_56S]!;HVX=&W=7QJAK5I"K#-\K M%1V77:HC#'W^5)CV8$#X64,[KG5YCPSZ^<)?E\RY1N$0+<&K7SA4=K&0T/,Y M].RW^L.]RHCR(Q:DYC?;SGWVU^0C_CD)TB$D DOTXYW\M]'[Z=V$IS),Z+UU M07A/)2B_/M(2O4.].9I3, F>(V:-3'.0T2L"$A=>3[C&[NX"?L%#A> MZ%AH.3%\#C6+N5;L,K%J+M0BN-QVQF,><,_BVBV/'CCWQ-<\Z>NNS0('?O+' MXEM@#0_<1]S0ZL\BQ_="L?A.W!!&SE0\>,R<('EC^!X3[UG=M[ ?B MR_0!T81%V@.0 /2*'^!2_JC!EZ+LJ)EZ2\,BHWC3.;?X])8'2\5(_+G37E*P MN=;,4B&!C+2?5R6F93_\\G,<'M\Q-CNYLB;CQ&M7S&@SU@PL_OO_[WS3MEY>>]Y4]3KD7G3ZPP,X^ M[Y_ ./&2TS",I_*[Y6<#.SU$A&]\_.O1>1R(JV]T^ ?9='/MWY@WIOQP]#YC M'%KF[XS=+,.HWNG\]&ZNY,+F-(N[;H)AOQYUCL3G<,:L]'-B'A8,AP='*]8' MEN2R6]@O$_53*(&Q@+5NB?0;HX)_SX.Q MZS^<:!/'MKF7@8F=@%S:]#G&X2 [WVYU20\OZ?:9_AA$FH?/1O2 M_0(LL&Q?50L+)*=%3JN!@JJ\T]JN@3YYK0V\UDOK5\E]J6F+Y+[(?9&@2@3- MC+Q?_BM_;2B@&JB*5ZVT2A2TUZ/L\CH9/QD_&?\&QE_$GA *EBE8?E82NRV@ MJ];RN(_SSF4\F#8CM&Z"6*OF(\M=ZUJ3A:[MAH3'33#@1\Z"$DX-WS7&4CT M-G (& @8"@4&\NQE <-N5ER+0+W6TIV'X_>^RR+'=:+'&@;EM19AK3ULH_WH M8-0N8E]]V1%VK:WQ)S+">AEAOS C))>HAA'6(DIM:';RS0F_:V-O@G!,> MA1&PB-5,F1O^>G1L'KW7.YTA"#XS MG+6OW)NLE3:$KY%E]'(CZS0(F'?'41X?'M>+2/P?GAT-)OT5],RW]2T&L_^?14_+H_=?N_]^C06[#2\GQGUB3H ZS3/ZG.9.YTGJ] T[ MC^ZNL696-8RC]]@D,@>>;$JY2HQZV8;48]3MZZ^[W>9UUSR8OFR8*ZKT_FO_ MW_KG_OD*&PJA2XGQKS9[+7?\>:D;SF!^"CB_2.8OMT24FS"(;K[ABP4PXZ?/ M[(ADESCY#">WU89@@F7]T: @EKTX!B5YMT54)G@WJ#3O+E/7 M+T\#@-1&9A37?L39,JWE4)D=Z,9/L';TW16$C!XYO,?)\ M>?W)#\;)@\',YOM&->?A>$,J*,N)0SQ=GGQUB>9PLW%T!(X>#P:CB?/P2XT@/ MI(E/L-34=Z#59O;N86MR.Q!/E7Z7'F]ASGA9".\T[/G4P0^?I78 M$DYXGZ:'$BH1=?7[PWRCKIT9<&@YE!ISZ#U#'W4/RO8B0I'7WZJ@_\03Z0_) M^,.YU:UI>0X4^AN:R@7\@WK]J/!0?Q"]L'RP?T"_GF!?EQH C)I+7T>A_<:H M;6PS'9$S#W*6P(O3GNHQ7S?:W6W"F?R&O$WY\YSQHX%=Y]:EA][8BV^[SJ6 MP\/YYH^MUO8F^U3F.U->WV4C=IGIQB&VVVSU@NRI$_)DB;9V%4^!\$?-'VL9 MWFD+YFDI]Y 2IGF@-;\>,2.YSQ^_R/&C^=X>-O]K_6Z@C=@I=NTYG@W*L9('>FLV1MV/>$!UR;L MGFNWG'N:YVM32%8#A[F:-4$S"K7(UZ()U\*,W-A";K-$!MHLX/>.'X?NHP;T M6:X/)J1!_:M_XS \BS?C8MC:,^Y)2!BZ9@_#6/%]K[R?J*U4A)XPXD3@=PM=60H'@APYH1H2U_! M:X"6"F I7>O5XA%H-C@3%ML.-GX )(:!H4:.'8]Y%NHW)$F1]!*@II8;VUSH M7*+;@K]?8+QGX)HU2*?+I"V@0)IU,8D\6T-POC.7OWV^GIU\7G M\W=O!8&S. AC-,_$8H,8WX6_!/PN=H66B&?BCU?='/,4)C'T M>> 2Y$@B"\&1M<*:1MEDUA;$W6\ZDM MG%. 6;3[V$*6A?PU-0HG?NR"5@#K.;,3=?A/[%EBZ(+ 9]$PU=2U#T;:\$[D M6HA_!1R(WQ->$$XXV.7:Y!49@)7#";!RP,(R6 M!I"!CWJ8.&#(@ KX@25@DI@TX%R ^.NQ*(5RO- #90]##$K1()@V9DZ V#)W MJ"E2KK6OA9G._-"1T#;'UD!8!_H'Y@IL@H'P2+-Q[P&^_J4' P&Q"Z--K73^ MK!1K9R)7 7RZSG@>P)D0!!^$&K\7B(%W0W(3,DNB?C1A ,6\$)C8WB0>/8: M\F[C"/ +7LX3C%B'1O CN(@8S[3R@64^;AO5L(4"O@NNY6(?J87$(YH"&L-U MJ?APX_)4>K< O\=+47TQ\(QP!(+4@/\5.\'24Q?>0HX]Y11PTP>F).XMZY82 M5DEQ^]%$]"4!FLS/'DF>CS2=@HXIC$!L(,4**"3MEWGK$B@6>+74/2?-AX M#!J\#"!L.H]KX7J>A!6NPVYQ5Q$$@A*%%V;V_)49K!.HD?S] "DHPNFM;(LM7T1?B+NN0Y'L$(.BLA0/@*A+-0>TM@N39";9^_?.%;L #PO M)/IGRS>![\'?EA2U4D!PBL)J_<[=>QX!Y+="<(O'ARR(B1!_P X8"77+:5B'W];2<7@7IN#R8%(8F":]%G_ $0 XX/H M_Q*<_H$*?UF.[+4_0Z2)_^ IR"1.?^E] MR:V+WP"K@-0$5M(13X!8[B8G8OI(MUB7,)T!O,S3. ^8"9X6*TK+:)))I\4< M)PO O>,7KN9$$)2DF"F>+9Z: *HPY_DMK21@=+*IN(BAP@@A0=PR?Q2S?3%L M@74"K""5OY<;27%0(+YVME?63LK_5.?5LGT(WS_QVR#&@!G4HB^ENDA\,EAP M-9?,!Q_^M:R\GTZO/BQK;Q)*GE[]*1Y\W#&T-]>0)EC:L&N\;6E_<(:N8.DI MIU=G^.N*FB;?@K#!18#BR%Q9<_$!F CX=YX,U1/1SMVOO+&3OFOQ),N%:%'8 MI_!U:&1.ZLM9\F"9922NV@4;X[)HFKSPO_!JA/AC?WP/.59 F+.P*+4@B98+@>R?J%R'BD?.3K!.T2 M!O"F==BR%E&R):(K+LLW>F?PYO9M2DZ*=AFF.2 W3!Z6&)@>*F*)>Y^4#$>X+,KYV8=+Q9O M\E-*!9" IT)+3XQOC3EZ1V(.@!3 S$_4A*A&T&LB^17V0?G8PT27S"I6** M"&?2[&FNF8FT4W0 BM8"S-J_=@M:%&KTV,0*PP5BM\>S =E3[.X?ZV9KJ40= M1D$L\[1,6]P[MFK =N< MEB=!V_P7:2=IZ<^2KW'E:V1E;EXY2!R>MZC5)=>!!^3N$L#+TK) DI6KI(5E MT2T6(0&8XQ(E:XN0B4$FJ8:D-7#"[Z$,KM@]90$XJX&?YWO'F,2]% 6NQG\CP<%G S^,8[-/:BT8_F+X MM&T<:AA;TX%EM)1QZ6L#L6A6N&M@Q+)[$C KHM"LQ#!RP-AM/I+EJ$^7SWC6 M:8".V:(>)2(=MEB0D?K:;3WJCMB^YO"/3^(_%4#1)X66Q02), J(RQQ+NMI' MJ26+. ;T$$PB3%$TF>-'8,6*HYO4_K.70)@1@H'RQ=3[&)Z\""4WF*$5\3V& M V&*0#9$U<%41(')K(233#JDU .D" N-%B (5^ZE-?/)+)$AK9E?>4F9MFZU MO-$JNI65=]A?=^*[*,J/@(G1XPLM ?31JUN"3$/O#KO+*Y>?O&(O$N:K(:]2 MBY0WH21\#PU4+(],KP).R$R"VY&8^EV<"F=0L/!93*^)]ZQX1",@4+D?TL2S(])?KFI2@WU MCEF M6S>X-PT]4&O $X^W7ER<'/M=4V%QK6GN9J]@4*CV<%:"\#.7:G?U5@' MNMG1BP.=#:S5&)D#H^XDE(883W8SESNN_1!#[_1Z*HE)#*T"Q%:*@-,30BT",G8>U)V"8NF&H,QHU\&)7ZG>&"[.K#SK; MCT,N(#H7J[ODYCNQ3R_\PA_$3R]W\GUFKWA.@LH.LH,VHW>-E>&]2G[N0WYF MAV4Q0S9[?;U7X)"S9VBENRP5:8*]S=#7#F,C-HBM[+OH^NOY\1K?_=K[BR7Y MH%[![%=\^-N[D35!\Z%'O.5I"^__]02P,$% @ W82F4CE>JG._"@ )V( !$ !N>'1C+3(P,C$P M,S,Q+GAS9.U<;6_;NA7^/F#_@88SMNO5+MAH34*2R>,[#P_,=HX0839W*%L=GWBRQJ6-J4GOWSX\Y_>_Z56^WSST$,.MWV/,(5L0; B#GJB M:H[&?+' #-T3(:CKHAM!G1E!Z/*TV3AMG#;?7J!:+42YP1*T.$,&[NRTN4QI MAXB<7:'S^D7]K''61*VKU@7\0\/[I=P]&#BE18+/TKF2]IQX&"DL9D3UL4?D M MOD^F2NU.*J7G]Z>CIEY%G9OB"G-O<,4*/5:IX@K)2@$U^16RZ\#IEBWU7@ M$O;=QZ[)'#SE$NV(-8%8,KB6R2NP8BV[I]8I%S/(J-&L?[[OC8R!D; @TS7A MYXEP(_&+.J0N42'!44O9N-QY/4B,1!EGS/?281TEZNIE0>H@5 ,I(JB]S,+- M-*55_]RC[%LD"7$RPWA1 Y>M6^3+>IA67[I31EHN(.3DH),G$"G+8A"5*7U9 M%]R%0I!5H8M+O%G:37-"HIJ7EY=UDQJ)EHB,B'I:3'V-,JDPLTF<6IKCF$UY MF_M,B9=USTMBG\[X8SU,U''=J#6:-1W9H9HO!%3U++TP-44Q9'2I-\5R8JR+ MJ$Y5T3Z7J3HF)47)(33=-DA($9=J(=+E=0HH--\EC-)1DVZ424G)A9&9;J&* M(]&(+6T3*LL!RZ2TS*!A*M%405N'D&GM,&-<805MN7D7O5TL*)OR\!6\U,%\ MI>T<0\9(/WQZN,O.R)1H!+BFM6MSYA &+?@-=G48CN:$**C4%)Q2)+0T(3+" M(5/*J#$8*D6C@6IHB0'/[4&_T^V/NAUT8_6L?KN+1A^[W?'H?7U3>Q/8A[P' M[(-Y7@@B <_X13=;H78HDJ=I8]?VW1T45Y9EZX5O(QX.3<_RC1Q,!PLB3"FD MQ9PV]\ C(0&MV@P[#Y8X[M!?X2L M?@?$[H?=;%_4&HXKY+9EO8SF_=?E3*9)7POE\OBW-9]L:?42WO<'O M%7$)XCI4VBZ7\.Z!2!A1V-!A: 8Z1&'JAH05">41];;1:C2!G!4&_%C!((V# MWH1(/U4$91-TC\4W<-/$)2,",F $D1DTY8GFD_4V2=8*#*W0X'U%6@G2;C$5 MOV'7)_<$Z]^FDKB"M'7)\H/:BX8Y!&AD2,YE@0 M*YQTZ*9PX()O\J8,H$S)@(K\UK7$K_A+\A>N(T?\PL>@R1=7+'4Q6A6>*$')71C)_R-JX MU$/6""#^B)F# C04@ZOHVG(!8 @M&X,F2U$H4JG5@'6-HJ6!\Y)+ [J374.N M6LXMIXSQ?JC[W8>*46;NF**53VFK]"1R-!ZT__EQT.MT'T9_^^OS6:-Y^0_4 M_=>GN_&7BMM]N2U5;[>!*&(]NR*79KVJX?M-7K%;49%-C:I+9 M#-4+JE#1XD.>(JE\>GY.TF-PPKW7.%+%T(%GH@>9?1;P>_@99Q4&V6$0^'., MGY--9SPIG[++)&4A3T:[\O]V?=A8_RS5DX62>>RTH#]KE5M\?1/ 56..K3NV M=,9R9?,Y^SG)658G5]'V6KU=.JO[0.63_BY)^KYKK55LE-A,X<(CPIH)8N9M MOU,U[[JT1UWW)3P0@-E+UN;*-KKYRZ\7*9LM!ATMX8/CB) !,CF8];TPCVHU M???6V[P=+,P1D R>RROFD[S%Y"5*0CS(H&)X3X83;[O/^I%L3WD14E$,)/99 M"F-@8I+L>!()\JS"8O>PL*3TO1WJ?8I>$>7EAW,U%(.OV'VUT9W%%.U0UU?T MD72G4V*K0VZQ9Z-OO0F[_WZ[-J;FA-8@8LRI(FO+Y9&,Z$B1R&>X8+&D.DE3 MLL[KXPAD,+WQ)65$)FOM9GK^$E8S9=71(" ^16I.4(13<9+3R_J>A\7+8#JB M,T:GU,9,6;;Y3H.RV9"[U$[9HBFIE<_?6;2UVPDZ8N!A53%X"K"]AU_[#<.*34>T=\[)A=Y2H]'T)OH MJ9H"E!Z:I._6I,KD;\.TDHLUB2^+JFV5W<8KZ23EB>9S=9[D*NL+E?\CSO0? MO6+\0*;(?-Y_I3_#OCZ1U%NX^N-Z\VYN;F30'V+7HN^MOT)Q3Y\]-Q+1^#F? MZQO&-ST49AQ!8&$G4!+7#P (7Q"A3R'4(^-/4/U@Q0*7;ENL=19^Q$*Y>+)M MH4"%N#]J>:#";%N>C3IVN%*%EE.EU=NK7)#.1OX=8===%?U]??,J@O#-^I4% MYL("\ (7"K'$=2VYUT $5[WTN&W0 AV9I:0?:BOM4\@VLC7?A/Q+(M)LB$Q( MO2>C3EPEEU@[651T!46&36MJKA!K6C6-4VN>U9H7.QJ2O&>EC!V;6H>T(W[# MS7:V<-8_E#D;-[B4L<.HZ%_+FV*T&2UMQC9ADGY%4$D#(@6=\_E:GJ4J2N): MF-WKB;EH:+.:F.M2RMRR5-IH*=3V!D=*@;'Z9I=]#0UOF#)#0=T1?+UC^M8M MO8L>_'_'.F1*A"#. WDDS">W@GL/Q-65>(B%_G9'E_+Z9!=%ZKIZ.'A]HH0/ MP1KT4>9ZHBN/,Z)@HG:GB*<'5^ A?R*A+_"U?WX5W%]$HA1$H.3F&3H1RIVQ M 7)\$1YX#](FP<=AD$ F5!W 5QTB;4'-'O%@VB=/L7FJX P>[6#4V^?J"U&6 MPQ>Z['I2^3*&,?N-R^UOD?L.A)7JT>""KBL5R1W&I_MZK\VUK5SC/1)+",QF M1F(UC[# .(%M%?EH*XV9TH-ZX?!%\ M*!4O>;2B>$^\"1&1=W;2S(L7AWN8LA_33=99HWD^\!B=^/I, *1!\890O]=] M4BQVK [8+)3^?"U9_D*I8RU^%^8Q_(4$1X.&/H0]=#GI/B@G>JR.,"=0DF>C M5HUCU"_?,2,J;[FXD]+7/:$EAT3HR, S IV.KUTQF,:.T0Q\I0>$^K+.R)O_ MQ?S2*0$^%@'*C]&-/9#O/C6C'$G$X\929]O<MRU,^T#-KU9"@76']L_8C%THYL<[FL[ ?&/.[V<4]G+#?:#^3< M.-[Q.#;8G0N6O3_\!U!+ P04 " #=A*92CB>C:"<+ "0DP %0 &YX M=&,M,C R,3 S,S%?8V%L+GAM;.U=6W/B.!9^WZK]#UKF9>:!<,NED^K,% FD M.U4$**"G9Y^FA!&@'6.QDIS+_/H],@[8P1?9.&V;;%6J".;H^'SG.SJZ6O[\ MV_/*1(^$"\JLZTKCI%Y!Q#+8C%J+ZXHMJE@8E%9^^_6?__C\KVKUCYM1#\V8 M8:^()9'!"99DAIZH7*()6Z^QA1X(Y]0TT0VGLP5!Z/*D43^IGS1.SU&UZFJY MP0)*,0LYZIHGC>TOMZY&9EVAL]IYK5EO-E#KJG4.?VCXL)5[ /G-$[0I-9? M4[@7 HR6N*XLI5Q?U6I/3T\GSU-NGC"^@(+U5NU5L+*1O'H6U"?]U'J5;=3^ M>.B-C259X2JUA,26L2NEU 25:UQ>7M:<7T%4T"OAE.\Q TO'Z[%VH5 )]:WZ M*E95EZJ-9K75.'D6LPKX *'/G)ED1.;(,>!*OJS)=470U=I4ACO7EIS,KRO6 MLS2JRH_UUJ;\3V,)9"BF;YDU(Q:0=H--A7B\)$2*"E*JOXWN?0@L GIL3DX, MMJHI@5JLFEKVAFZOB,%\L";<\;1H6[-;MEISL@0A^DAZ3!R (LD]WAGB+1;+ M.Y,]983&H^Y@PSM4&"83F31X(5M\=*E-;':TM0[/[1*H:<@]MSHH,"1\O M,2=M"0Q/;<=K$P;5:<6LL63&7TMFSJ"M&L@EX:FQ97#+#!TP(7S58]AZP-(? M'08VC69R=''Z7-/5-]MT4E8/#'7-5;H.S>9>9T!I E*S[54JU0V@':W7415M M=<'_MX-^I]L?=SOHIMUK]V^[:/RUVYV,-ZT86&PRPZ?;5.TGXWY/NZ8[C>0< MBZG34D(W9H'Q6G42ZC5B2O%Z17%2K]8;;H/YDWOYS[80'B@FGA+3Z0SY?JSE M9MBMS3DX+=(^5^;/\];%V=EEH]FX/+LX/6N>7YYY+/<$09O[06!NO.J'?_?B MPM\+<25JPEZM'&U5"KR^EI]SMMIWGWLSEL1PQJ$J0B^U@FP!]K"UNAY;3%U.IN4X(B,+ MT&Z,- L=(_Z>;'0D!,H>!]_ZT%Q66X5F=D>0XIRNHT[+K5'R M.!A/"]3E_[3@_+,UX?)E"+UB"=A4Z[96G5P8=X02'UZDJ(P'\YH01RG2M"#JK\2.&XG&:IJ\=!Z@4 M;;@'1/34V[Y@H5G4K)*:J$K1M89TPFQ+BB%^46L#,>LF@<*%IC3*QL"V5Q=@ M6=CE-IEIU]=0^>/B. '&4N3CCCO6'ZG](_!)933-H?)'1',RC*486?68M5#[ MD-1Z;4R[NR]Y1-3JHBO%*&@_3F-70Z**^!UQWFQ=-HM#<^JJ&X.O%$G:&[6Q M% <+'P.Y"9"E3,J?:V]V86:^-3/)%G4O#:'[-IL1^S;'D_:D^]#M3\9H<(<& MP^ZH/;D?],>HW>^ V,-PU/T*DO>_=U%O,,YE8V? %%7,]%YDB=Q6HP.L^F9Q M@DWZ-YE]A:$]M19?,+44LP-KMV6JS:F GSKPU5H,"83D+ ;_>]VN>!E"(S;V M%LI_E&-*,88#!+M9WY!P\LF4/@;BT92BP7=;!FL12U^ 9/%(C&7B9 A,=25=0Q4X*,UD5/LV'\2_$ G^8@*H]6U&+"JF\\TBB.8\I=3RL MIP&:K .7$^_.6*3/+.;/>]&T1QNFX47[1X M874@J4'+2RG=4(KQYGX5>K.I)20X8LM]@,A(YX-23$8&0GNS#R9)9+PI^E&# M0\<-[[RW9/\4''4EP%SOLOH;JC5*'#'#:=&_\_Z2%,1NYU5'Q-DA/L1\[VG& M=$H^,OWZ#BG%KOM]J.[! :^( P\0T&X<=)0=<32]@V/345^,69<9^PM@'NXR3T MA)NPID1;0?%"[$"" YJ:PYP1.ZM5B%5WP&00,A.J&ZY.KP-8[E&L+X-YT&' MX9V09'H^0@!EXI-23(/MU94DH:-3]B.$2VH_Q,Z$%2+5A#CLCEK8,@[H 4H M*%ZT%+8#I.N]9+.M^8V5MQGW7@A;'?0]F'L.^=%HO0++%2^@#J0SNK72]T$I MUNY&9.WFUL%"G';_:-:;C&)?JJ&QN>BTWJHW4!7M=,&7 MG3JD]*&?78V_E&Y3T7OL$?H(Y](7HG9GPOQAA];_H+0>L@2WAS;V+&K=8D=, M]D$N*,CV4?[M>P/\;PMP-TVIR6\A;["@H>]W M2:RF".^7>&/E[NRU+YP)L7LH53V->D/FC).((PVST%V\!)$V/J+>39&=:\HQ MNYD6OUI??*^P\^G^?]@E MNDE>5PPZ4%]2=PH.NT61G:0><*;6P"+_)IC[C#_0->&*_9'WJ=DZ/2U8OF$(EHF(L<_T?)]1^C.N.H/L0Y>+, M6X-B.\"7;K:O ,XR[V^5'E-%S"S#1WNGE-D]+(HRU7VLP?3^3BK<=&7TB\>U MYBO/]NO>EG+$,J2]!DZ_YZ05!5T"U9G)6C+5,[3R=:/0HH7YQZ MG(+-^'4B7<2EV *0RYQ,B4/B(,"%2]-]XCPRLCE.94BX\VQ!6TI.I[;CG@GS M;'1Q7S;B+*$ER^6?]G,YW!K]K&[^"]K<'L']D6, \EJ )$,;&Y#7"-#@V)'O M6M5WASD;Z^FT'C/.]2TX:H#1@QL*22VU(:TD$J46$L>B2+$R#WK MU C62 8T6$=Q4L:!;'O3Q^$>*$6K$@@SS$_MV7]L(2.>ODBI[>,$4$I?%*XY M4N>T]QBV=J,A-[DKW4WMMJ;YMJU1>I%2[.QY>-6]:SJ@HZ?TYWQ(?TCT^T7R M?I/ @>\!*4(M#/)YHM=]E"D39_X6B+(Q&(,CPQSXN:8,F6)!?OT?4$L#!!0 M ( -V$IE*I)6B;<1, /8P 0 5 ;GAT8RTR,#(Q,#,S,5]D968N>&UL M[5U;<^.XL7Y/5?X#CU.52AYD2?;8,YXSDY1LR[.NV-9$UFZR3UNT"$DX0Q(* M /J27W\ 4J)(";P*))OR5FW-RB38Z,L'H!O=)+[\_=6QC6=$&2;NUZ/^<>_( M0.Z46-B=?SWR6,=D4XR/_OZW/_[AR_]T.O^^'-\9%IEZ#G*Y,:7(Y,@R7C!? M&!.R7)JN<8\HQ;9M7%)LS9%A7!SW>\>]X_Z' MN5I1).YGXZQ[WCWIG?2-T\^GY^(_X_M]V.Y>,#C#60UM[/[X+/]Y$AT:0E"7 M?7YE^.O1@O/EYV[WY>7E^.7TF-"Y>+[7[_[[_NYQND".V<$NXZ8[14>&:/^9 M^1?OR-3DOI8BC[\^47M-X+0;]I780O[563?KR$N=_DGGM'_\RJRC%8OR=HY. MULWE78N'#T0;GW6#F]&F.(5T1.R@_0XK*W7U+RXNNO[=(Z%HP_A"B8W&:&;X MUS[SMR7Z>L2PL[0E+?_:@J)9G,F9R9Y\:@)F<]-<2B/VNLCF3%Z1%%E'7NKT M^BL-_0DARSDRY*V?Q[\PXVPE8RY% M=XL)Z;[RJ>2\WSM=\?W(!:SEF+DBKB480E9XA8UFCYQ,?RR(;8EA./R/A_G; MKHR2/1<)PAY%QU/B!#(6IUNCT->836W"!,/W)OV!N"FL\(B$ )ACQ*[%!6RS MO)+F)-:(># M?QNXUA5QQ,S_5E[@0M0;48 _DOQE2[(C!IH_C_A71TOYL[RY"Y"&)OK.U>&K M_(FJT$5F7X"4,V#,[:M,U;?LHKZ>TSD;'"$F)WU>CA^OAP^/PVGB<#";#^^'#Y-$8W8B_1E?_^&ET=ST7?0N$F M$XP1W]\Q[68,M,78=6QIW#),0MN* M#+*[J.:T1AK4HL9)$.<0C/+;^>G'L[.+_DG_XNSC1:__X:)?AYW6:UT=AE** M",!V$;?\/N:Z;=E-T:XJ \4=OG3CI$(O:A0%_P"T/[ L'/3_W<36K7ME+C$W M[51+9#Q3JU5.]K1*ABP0+#2=>HYGRS3(B"\0E4)1M)!3R#,*XMUT:^5_OE;+ MG>YKN?QR ;#B6&XLN,@:FM3%[IREFBRI<:WV^;"G?9*$ &",<$$5X1>Z%3\S M/>M(PXJ,X._:Y/0#=MA6NM K)WM+WT'D_7E*7"X"PJ'M-Q71.YK+'YO[-A'A MY=N4S=&'1EA03 M*B[Z ,Q#),V+':&X6Y#"+Y?28C&1^NN:-#L%/%<_6UU-O*XK N0-2'9SKKB M$0AC3(/MTH6$9L6!]7\>X_Y>X80DN+V^&$_;2:8Q$MI@F*-'1)_Q5*97,+'& M:$KF@?'\['1BL%!UMQ"\5@UHJEY1T!#IJ^B6,0]9UQX5@R9@W.?V ;WX=Y(] MLUS/0O"8=:T2V=*VQ,#!9%G2PCL/0W $"B$YAV%WA-1GV=TDOKSR6U((_;,K M,&OC_R+K)X%7P> WH169:1^YFVJK 173CSN/2O" ^&@V,5^#60UMN^CL#VU'SZY7_=\P4[2*>FO[4/_GX"4[V MO2$<*74" %I7A"X)-3F*3[49J?O49R!$<%6,F/A>8:H*0!C6<<1RB^66DUAW M'XAT16U/^';R!8PKDRWDRQ?B?]*3?1:KJ9 WLV"C+$$(.\350Z*\?@#@1;X9 M:7DV&LVVW:P-O#/SJ\5H-)AZ+2-LU-BY'-.VIFJWQ=D2UB&4RWV**\+XI*O+0A)(FJ M1DI>71P*?.0F657PV:(-(8_4&'RV= $=/M$=RZB .1&2_#B$;()V$"2+VQX[ M^W@=1R:[XK96D8"05*C0WBJ1VV-SB=9[DZ\GKR<1<)E37FJ,J\C4:ON/C8QU ME=AMM;^,F+$[B,(RIXG"PH M\>:+R0N1W+(T3%1 'T)@N@\T*E!)6Z>61^S.;;3Z^^U:^,>E-S3VZP)""%OG M=)-/*P<$*ST^3!KA6B'TJ6&O)DT1;45-; D./PRFT\>)$&V3?Y,]G/;V>"*: M@>[M)"%#,^TV>3GY *)906V=9G:5I7U1:I<_4\WTHM)*CS M;+?H4U(U?+)&E&Y[RCY#M5R^79JV_!KNXP(A_DV,^:6P7UK=9[Y'&RGV4%87 MI-1^ICT I_RSB*UBI1@IT@&8ML=(S#5XRI&E9K1$<&:C./Y!@GU$ M_AT&VR2C%8J?A ?;/[^ 4[59'S24:@" EGOBHK?@E8L;S[72<9#4&$((J /V M46,GR0K 9FTOKDV(T71;\/=B6KC%M F!EGX(M+IX-N*H1J(B?TL[[06LK*<: M\,03AGQ93SQ31 #&^RZS$$*S/&0V_!%Y@S)M-!>B ,39S@G9J#$+B?G>#!OW M&T_[_0^07GJJU-A*T0'8_\JD]$W,3F,DW NQ5 T ?GP# MI:#, *P]9!P[PHD]JYF, C!R9R,*?/V%$A?(6;W?H&=GY M_*W4AQMPNQ+<; UN5ZJDD"P:32?L,IWZ\G)!&O \L!Q85IHWG[SOTISY O=3%^;4)R#X6Z7PK32L2D*@-CLI;+,32+Y3 M)38[@6@SE>\0OMR^.87(#$Z>N\MXRWM_LLV]^*U+)0G.5HJ3UM:7P54?00BO M#1A#G*FDSGJ%9W^RH*80G7#:6S/0RM34V_>*0+-0L8KR>1"^@*81DUW1HE0! M-.L?YON\21-"!;9OXA7?A#IFU7>70.@@ M*)F0P-'=?$_)WQS.J"0;(6 M&BP=)]1!=#"GR'=;90G&T,9WV+;?Y+1%G*7IOA4K)3]7E)+[O1AA-\:+Z,<0 M'1E^3X;I6L:JK[84EV]>AKLBMA@"LJH)/Z,!%;:=!QL,0H$/Q)TFW/9!(- C MHX34LVTKZ*B1+YN*#D:S"%\IZ9N$MG#*U:NS?NRKI&HU %@G=@4UU;*E'W!8 ME J0=$XJE&/^?%$!WZMIX_F+B][%IU,X.9RJS*T4NHI8;HP8DAO<@J=KZ8"0 M97 4?71J6B_-2JN6I@)ADZ8DH,.0KHSV9AS&8CRY'KH1!K@2S,I@RB\"]Q@G(F 8OLK"&VZ3Z8#DH)-^--($:9FBP; MJ_J."0W 1UDSE%H9MMT(2$2H IE*V8#J]$JH.Q:P]'L]\2^<**V8"92B5/(] MH)->_VSDN/C)8[?N5 Q+L9!+7I(#K]83$-S%#+5GB5"3HL]DG\*!'3I+F[RAP*O[[HD@6BQ/I0Q1B"*$S')Q0Q42 ML?+A4])T\.R3D/O-L$\N.0"LXIF.89)?F+6=HX-P@Z?^:%.+>NMF;W^\K3LV MI17K__,+8CP\SKBO&WG*+B LVA6A4:N>*E]0]F-W^+K$U'\BX%BU]NCN 8(; MH1YEPLYP^>U*S,R(12CCS.N.G* MK?%2+Z0:GA& MU)RCM:/TG>(IDOJ?U;5'E)L1$*1!D#?0J0G M%H(H=T.J0+M.#@YLIZM*Q.M4^\&A?BU?H\ OR,2![QSP1DNN9DZ ML*U.>,,EMR4.;;@,+ L'_&_>_<_Z4'7%?=8*]D]MVO+,4!Q(;#YEB_M4>,88 M(VE+<7W]J0[/M">(.B=IB*V;DT/8]Q O&Y-'QKP"_MT2;I)?74,"(.' ML%5:^S#1:8!W,GJ273P@HZ<4@X>PV0IE])0R ,C1HR=,NQ6R8I?AJ?^![NJ3 MR-O]'<(N:CEL5Z//0X-J]B(XF,\IFIL?@YAKQ/*4,BC[T,;"JGU(O[-:Z&%\-R16MY_R\%%JPL]FX)]82T?&MAW M"D0FA,OS>6J8XO-UW>K-_*9@G4^U(+&\=U2^%CD$T_&0AHL]8GE6FU/3:7R#N<^"W2^TQ?Y*/ MWK\BC#\0_BOB8S0E#1Q7LSVAJTNR7=*" M73<3$!*+[0)N@B)!GG*R^!V1,H[=0T'?[3D+)AT_; MYT7\&LVVP2)AE/-83JU]-3&+WKK"Z *38J1*G^=NQ6C*@2FI3T \/Z4"/$1G MKE1] %@G$_A+/?HCXQD@!Z_DP&X.0P$ZED6[J>(GG7SJ??P Z&A-G>93"@K MHNKS(U?+>NHAJKF>A!#'Y )M_%2Z')(!L-TWY")JVH+-@>4([4KG51[7D<=Z M.9^%X,X7ME].V0!84,_*?Y=Q6H;V7IH[.J,BA:G/T=#JE[7U3(V5?,A2B[\: M4PG(R_LPA&FF!FCE50>TV'_ F.<$^\Q%(_W3 I%^I)O6!/7K52DU&M]JI&$8 M,\HC3(J_MAD4EWX;R]R!(E#>N@5<8#IXO>Q_YY\Q%B7O4JF6](X_="48[G).I\ZWZ3D5L"0-8*WN*T M*7V:K^GZC-]OTL7)TF><4P!QT2;8RSH(4-&PP8/]$MF.?U(\OLJU-3(H7;(0 MUJE$'#X1K-\COB 6LNG1*)718P%W%"X@Y M.H2P35KC<-92 I=#K2 QJTO%6X77OQ!;4+.%M&,Q9]0Q<68P &+^;!#3-:GY MH#$^QNS'#47R]1E$$>-U05O=;ZM?^P:$:+5V#QK(ZX7I&C]C"[E674!6]]OJ M=[P! 5FMW>9V[Q\0OR.,!0G3[XCZD@PXI_C)XS+8G)"KS3FD"V(+ PG=<7R- M;<_/D,YF0J!B>_R?=JOY!!_&7R0G?S4"7@S!C.%S8T39,3@Q H:,*$T*3-V(\2! *700)I:%)Y>.,Y*,^DCWUQR2K>*U#5S>AR.MJ;$]I1^X!#/ M34IZ::(-85NV2BAJ4E.I(/Y+-S#<*OC\V_\#4$L#!!0 ( -V$IE(%97Y) M$4( )ML! 5 ;GAT8RTR,#(Q,#,S,5]L86(N>&UL[7U[<^2VE>__M^I^ M!ZR32L95+<]HG'@S=K);K9>C6HVDE61[75.W4FP2+7'#)CLD6R/ETU\\^ ? M($$T2!SVI&HWUG0#Y]4X/QP !P=__L^738"><9SX4?B7KXZ_>?<5PJ$;>7[X M^)>O=LF1D[B^_]5__L?__3]__K>CH_\YN;M"7N3N-CA,D1MC)\4>^NRG3^@A MVFZ=$'W$<>P' 3J)?>\1(_3AF^-WW[S[YO@/WZ&CHXS*B9.07E&(&+GWWQP7 MWYQF%*/P>_3'M]^]??_N_3'Z]OMOOR/_AVX_%NT^$@'7?E_#P ___CW]GQ5A MB(BB8?+]2^+_Y:NG--U^__;MY\^?O_G\[3=1_$CZOSM^^S\?K^[=)[QQCOPP M29W0Q5\ATO[[A'UX%;E.RJPD=']9Q4%.X-NW!2]I"_JOH[S9$?WHZ/C]T;?' MW[PDWE>9B/1K!29Y<_JMW]%>T(6W;]#/;'#\X<.'M^S;KXCU$/IS' 7X#J\1 M^^S[]'6+__)5XF^V :7%/GN*\;J==1#';VG_MR%^I#\IU?4#U?7X.ZKK;[*/ MKYP5#KY"M.5/=Y=2+3Y4:&6=F#I*AGK+]>'C@7:^(G]5U,(O*0X][.6*478= MI)DTI:4H[DR+OWS5]OU JU#9*;%E7%7 B=V<&?FSQQY9B[=N M1 ;:-CT*LE^(=5_'T:9=5,XN:OGR;\%*XQ?.=:DH$N,DVL4N'O33BO++;%W( M2%I0M,3AT4_W X3^#T8-Y>3^S+D.'E#Y>%H[R8IQ(:C]Z#A;/JAPD";Y)_71 ME7W\M_N4>!5%] =G5?IVIK:T$=!QUJT4'6SM+0".N!Y!=8==00Y]8@3_'X"1 M1P 97Y(_DSX3B WG,@(;RK6.PJ+5'$9B4U@#HY$218RJ]I 9<'L Z'; M OBUKX&..)DB^=0J?@=P=$E%U!U3.3%$J4T^E&YQ[$?>>>B=D9'=H6J]W0P& M5ZMJ]5%6:01\N+7+NO>XXV01H8LHX%7:P1Z_,EDW7, 9F01HXL(XV1Q:HB3FWKRW,4Q <\[O(WBE.I$UL:[^I:(0G/ PTU% MT=J,VMH6Z&!4$GG?^9531P5YQ.E//%@OPQ33?6O_&9,UCI-));6)M#GXP=JM M:'6PMK<%/5A[1-YSL K4Z5+8R4?OQ(/UP@]P?$J6XH]1+%^4U%N!'YJM:E5' M9*4)Z('8+NF>XX\113G5B4?=_<8)@I-=XHM2U M2[KGJ&-$44YUXE%WOL'Q(PD+?HRCS^G3:;39.J$<\V2MP8_"3C6KH[&U*>A1 MV2WQGJ,S)XXX=921GWJ8OI"U5ICX-*>*[Y?+K='6%/X E2I8&YV-=K"'IES< M?=K"E-2R!(N&ZB M\#Z-W+_?/SG$7C>[E*9KTCTH^?9"=R?PXU%%Z=H>4$N$_R*G5B> ]'1%/#P[5.P2&65M ,Z5'O%U4YPS78J M.65$24^?$Y$G993J79!/VI;C\I: QV2/>O7DG%HSH".R3]J]$W3$$$LAF6;O*8&9I9 -NW07!()/*9?X+1%G_7O 0_! M5E7R85?Y$NA0:Y=1=W@5U! E!R#?_V9]X8=.Z/K$C2*^X)=<<1K8%>B8U#% MZRV!CGX 1[*6^-K1YLWUV?GU_?D9.EE>+:]/S]']7\_/'^[M#?=EDN TZ1G8 MC4; AW"[4N)@K;8 /"PE@FJC+".'/N4$&[=8C"B4XCC!5U-K9=N)LJ6DDB\U MV\["I20J-CVKUA"\@\GDW6]$+HI$*!@.9UK+7#N'4?_>G@.>.LG3,O3H?\[_ ML?.?G8"(E2S34R>.7_WP\6Z@@TP@.JQ21\ ./$Q^[:%.R",G M]!#[0V"T0$Z*:G8P3N)U4>H$RKM^^]\[INS N-)M M'&UQG+[>$FU2 BAT\;^EYW?76#Z#=G8![F@J"E?G3'E[P&ZH)+;^%,&)+Q C MSV:(@L$"$1:VIL<)E&;:XE+;L*GM=.XKS/_79.QWSHBRML =ME-%T5-;&P)V MT6YY=8=I-5HM"=OQR#%UM#UU'*=U9^P/9ER=S++JD\18%'((+.P^EK3T;'@.[ ?6JH(42O4^T+V"\'JZ [ M[ 5&10A*XC/;22+6]!=9_>XW+^_?'7_X(3,*"%10R^SJ[# ?SU?(\9*WGH=W MF\Z#$DC#2?D:4=])R111E=RR<@8VNYY72MNF&\PUX3=N0&D;:'[XS=JM;\L;TQ;)?L MD7F/\4HIH[8ITYICCJRK,$W:<\\SO,9$+>^.:'9*_NNGW>[9U1ZX>_:J*KJG MM#%@]^R763^!CU-&E#3BM"W[YP3*QNP\)#_99"5KH]#BRC,*'Q]PO*'YB-U. MVMX2N'MVJ%=99#:; 7;)+FFUEY6$YA'QCPVB5,N5Y4_,#>KH =T,5 MA;L#UEDD#2B);39LM9U#,(W*<9[,0Q^;@3-S"A%"KP-+&P-WW6XE9<'L+-RU M1V!3(>WYBQOLV&LV$P6W_<T>UP>S%556 MIIR17:#+)-GAQB,/4^VTCJMI0HG^@+9.C)XI:1J7_O;=-^_>':,MCE%""[7_ M@([?+=Z]8__//TF0LTN?HMC_)R'AT) ]=I_0M\<+1%SLF&7TG6$7;U:$1/;I M.Q+V1GEOGUF47\\L:\"K4K)89:JLE-]94*K9##A&R!2KE(FJM0&,#E)1M?/= M*L\7C(\+_;6>1M(PX1KVXH$!0/@!O?_WQ7?O_K#XP_&_LQ;DGW_\[D^+/[U[ M;P8G%HC0V&+VKF-@,;Y8>AXK(NL$MX[O78:GSM8G:QC)+RMO#1Q#>M2L9$2U M-P6,*'T2:V<(%701)8S\$&6D+>5"C:\G+=%P1/1TV_6<-%]QM]D%3HIY,0KZ MNE*,GW"8$,"X#-UH@Z^B)+G&ZA^K&>66L;C$!*0_5Y3DSTR M!G-^6?66"D?$6:(WE.G7[+XZG:$)9VO%U"P:*"OM4C&0SUC:K*Z6.GZ(O7,G M#DFLD@CRGN&U[_KR4FL*'8%#A[KRU2)L?;T \0 X?5+EW$6*.>!WHA>D+'Y MVE:UMM'U%Y7U.$U(>_[*NZCP_5>N7/?>/F#_[!!V@KW\47QRR]Y=.@^]89OX M>^M]XI".+J;+;S+Q(AR.L_?!U;M/G3BUJ^ */_IAV/(XY32'IB,HR,].$XB' M,'U7S_M/EF7=@&.NJN)#2BT QF-ET]S".LHUD"*8R2 >OGF.1Z?$F M9B]N>6S_^A;'[%%@I4.PCL[ G7V8$>3'L[*>@!U_H +&#G$))Q3%B//B1S?T MY4K^!K6U6KC3FJ)QJE.@P0Y^N*MOGS[SUS'RY M)K1I/[:97#&)NIG_5C(=8'GL39ER,T @0U]>" M^HJ+Z^X>\_%SE65U1_-Y^+7QE675GX&LIB=0&/(ZNJ%^YR):WGINOBM?/DN: MSLEG#:TDV_P5S)V$,32%M6!N*-N_6N[I,C03C:[\<*@>890#W OA^>AL(;CI?\Y! MWAHX5/>H*:*TI"E@@.Z36'O4WER?G5_?GY^A^X?EP_G'\^N'>W1S@6YNS^^6 M#Y7V&3F\^WMZ=_Y6TO/SY'%W=W-_;O&OPC,,=OB __FD4,C/\XJ=/ MISOB>AL<]PQO]=[ A_M ,U2O'BAU!>P.0S70OX3 ^"!J>I1S0I\)*Y3SLEZX M9&);6'SQI$?3HJ@:?:6-_)\GO[ZH1VG>B-!EG@'HT$9FODC1JK %_YB2S8Z.X!'$X4U!5AHZ,Y8'A0D7K/$;Y MW'D[5S^[/8]CI]] MLCK^5#)#E%LC>)CP3>HMCIV4N/?YRY:(A).>$+JK/? QW:MJY7UJ66/ X[E? M9MW17%!&.6GKD>\4RN*,M-6PE\^*R] [*^?$3&?IC-[=![B?*JE<#5H[.@#V M5S6Y]6<@(9X2Z.W-\+ MN \KJBUZ<4\7P'ZL*KGNJ,[HLT%=Y6#7EZ?4VZEP !0OJX8G\'U6JEIG7 S8 M+^6RFHN#[=RR-J\9OU8=-4)? )Y6EM3JLT:EY5R\K:E>J[^5S>;@<2W2[N]S ME4IPEAW/H()9U[7-X$P9=J)!.:HE$)QVY'5HH>]B'SGNWR+ MS@]V]/;<^:W%G+*\CF=^1>Z$BD?W)[EP/0=BZKV!0^M ,XB@J]@5,!P/U4#7 M(8IZML5-T04Z*=PAXV;];&TJ:V1S%IIA".C*FMFJ;VH"=#6T7+E*UG!C\U-;L M*&LZ(PBJ2VP2A#+:,&#(E*)GY8H .!29UA@Z'-6"0+;/=>8G+EG>[>+>O$%] M:C.#LX%F&K",DI&:$1P.U6C49=8B>VY($ #ZRFLT@V7%3W;T)@+!(7IWUW4" MESY!XD- 6JO]@OW')[H>)>CM/.)K5L_D9MVXWMNUAAM* S@::9E$ MQ*!!! CCYX>NNZ3" MMFQ3 &R&I_28S:LMI6%BZFBF$=?5UG%5Y:'0VRBFP;9XU/&C!NF]9POPPIQ4=^%R@329+18GW%#L6J57M6DBXL7E^46>>G M,,9.0$N-_C4**-S_Z/@A-=E->(_=7U;K4>6.WN M 1P9%=2M%7&5-0>,3RI2FXDL.B*U*7..^Q;B8QJ$WY5SY0&7S;?:LR*1-^OF MVZL]JTC5OL#]?9 )JH^\*W0$C '#Y#==-/3^X>;TO_YZR?/%E-V+Z^LQE^'>IW#KLVSK,8;AWRJV=0<"(HI(J M^D3I6JS455/S+-J0R%:61B!I"WSL=JI8R91I:PAXK';+:VJ,HD^-ZYR]AQLZ7D^ MW3!W@EO']R[#4V?KDR57I[/U]0'N>$HJBT[8V0&P0ZK)K3M^2^J(DD>7(HBE 5.E/!JGD""%W3^[P\1DB9_B[ $-GK)Q MA]WH,614V!/WTI77Z&R!8]=4AJ]N3XS+$S Z3J:Z_FY!(2!-TZCOF92;!]F# MO4=,4"1*ND"%K,6K-EQ:)(AK:ZL%N/WYUC$WJBNPMWE.3B3B;Y>+27%,W6O\ MF7TC/R]7ZPL<) >9H'I^KM 1,%P-DW^_,<_9U%-)&2N:2O:9-QBIJ'H?;DQC M"$J&/9$MW(&U>]HBT9O?R-+T_F;G>;J_Q @*_E_K.3\ D"DP!@)P7F AP+0I M9!BP[UW%\"5UJ9Q!/F<3[>BKMNS^3$KSYE=X'<48Q=@-G"3QU[[+J^XXY4)F M0:%B5UXM>Q:Q V[%H%R>:>^=S^/'T'UNA1[2H$Z ?$8]-MWAW.C=;K+K+.X MK36B><>\P@K[=MB8VL[NXNK!7%F=\K;J@N(N@'L\-^M3)WFZ"*+/?05'>[H MAT$5A25WUQKM 0.3DMBF;ZJ=+N__BBZN;GZQ^.8(B:.HPK=Q].Q[V#MY_2G! MWF58/"^W=%/_F3M^]S#7(@1\\.L;I_82U$ J@!UE#V7V>;N'\D0Y4[1Z16]^ MXA5BOT;ELXPE;^O%>"R8B9EH38&K\G0CL8M3,+-8@(>88NVG'0_ 51H !X:F M,J+#E]\"=N06(?=QT%K$3/X9[%@@+*N:=4VL'(4ID3/PV9.,Q*=P8NEA.,/& M %*#H9)_0),'0MY-2WZSI?2C MD92DN45'D/*-FQ=DBH F2]#N6?@,(@#<:X<;H_M6F:PW8._64,+P7:ER>5#4 MB["\-IC0)J=/I!]9#A$["/%ZDF"R J!3>. [*S^P';LW#7(;XZWC>V=XC>,8 M>^N2*:!L745BLP.3(4;J!A852K,"F4$*&0:X$S%[.*WVL(D[2]>E.9S)K?-*]]65 M+=GL-SLTD:C>#1RU3K/"")GLAN$@9X,R/E!B#M/J%WINV_6T[-;QCJ!C&>T, M,5.SZQR=6V* 7O^N]9N;B\O$-^_EE!,26 %R=--&R+4-Y-KN<:NIJ4(>H=SA ML+YOH-8#J,,.4+>X#]3='/IM'D7IM0DY5N:G7N&G[%)>F/@>6PGS MUZ]W(8M.V8MCZ9.3YJ==":*G8]'&=]$*AWCMIVP5O=ZENQC3-[+]R)OZXLW( MQBN@+:=/BVSF'-#=:"]^R"!M"IT+]=H>-!D)PYYQN,,7! #N,"L-=NO$Z>M0 MW65$YHITG491 K]6"G/&PVZ%QH%( G%>[A)9*@!+?HRY""2X)S+P)?PJ\!\Y MC*812F,G3$@_"I_>SDU9DR2K'T.^=W=)2HC%[/W:ST^^^U2#XBAMY')Z7W?%]OUA^+R[_EU6.)977H (<9;=/4KB$-(P(89/1UT3\'YARY MZU">;(V8&AXP+JUO,^4R!!^KI,Q.9@4C^1/> 9H !!"/) M0BM]O26ZI@0@:?G[[:9Y1*=%8&YHT&N,3DB0]IX3+O0K81(<"*!A' 4DZJ,P/4524&0E9"M8SV"4=TTSU M7=)U81=PNZ1YN?:;M?#@ML*.D*P?#Z M]'N84VCO9SP2."^@W.%MMB"[69_AE2QF:&D&W)5EBE4?FZVV >RH4E%U1V9) MD Y&2M+6CH!QU6X%Q=(GC @.;% 0.19O_:M'&7N'*?!=<[@Q]()TP.ZLH<2$ M03FHY?Y8-JDD1+6%X/;0@IJ!_C_="GUV HIE=Y@L/GR70"G]8AEZU0^$EKQ" M>C/[-"N/>?[BLI('=P26S]=K+-TFF%P(X*AEYT<1D6]:"0"CIR5#[+/>7W , M%N2@[\CF(O(OZ=%$_;-*A^R%G98T>+'^;:X!HBH@KH,=1)_9[T1G!+RU^,?C_366.,7_# ,=TX1!\JXD(!T%% D%]T/0\[E[@0S*<" M7K_[SL*N4?<\G*?<&/KL--$.E2*I:5\ SUE - MM"N,"GSXC$,Y(8&5]2-.*Z;P_,0-HF079Z<=^9DGB:8+SE8K*O+7/VX=G[[L M*;%H5:UA5&D"V(5EDNI?'^?T$"6XH.OD;,6<%15E;P'FC1837A7M M+UEDUA ,IEA5%UILP)<\A#/AZ0@9V$2D,K$K](I=W\L4;WHSF@;T!^[ @TU1 M.1I1[0S8Z8?KH+W=PSD)"8\TL"_/0Q@WZY/W=/;HFK[#S%9^Q5; $IL4\XK"#'Y,9H_^V!=U<)Q$7/W%US%1(-(,<-_&C$V8/ MM9Q&81(%ON=D3\3<$HOE!:INUAGV.D'Q?F]?<&**-G#,,6K"RGOU)@@#1BNS M^FD'0PXKVYAE3)WL$C_$R5P]\JP(7A[P2WH2R'.61V!SR'[:85AC+MO"XU"] MMTM574<6!5J@BDAL-A:%HNY>B(5*N5 I&/I$14-,MG%60 JOMX$S,C2TS$K+ MDY78+;&-J_!Z;E<'X C6KVSE)5MI:\"HHB"T_BI_LW%B5DWFWG\,_;7O.B0T M+SFBG*7%\[M2L*8E^J9TY<[ A_DP(U0.[Y1Z A[^ Q70=H7N\3_^U-=_1 M(6: "8WLA5K.0L^$-Z [<%P8:HCJA2>UOH"Q8; *^A>D*HEDC>+:TR9V-A55 M7^0.Z0]\\ \V13TY4ZDSX.$_7(>]#HGIBK&>1CGIZE!A?WLJ@]0 P6;N"CV$ MXXM;O,IK)J6O996UWB>$!Q C@C#C5%-AE'M#1@3-)30K\&I4'#0BB?0YQ68 M[J6(#2L0F,!QZOCA0^S0Q!_^@*?Z1#HBN_EXV2B&EOBD45[S\.!Q5-9/F2L$ MXR^MK-*L*'&! UPZ 0[0&Q8U< E1)F+VM._7T+:6P5H>&-)>.'[\LQ/L<*EK M7Y31TP4XXJDH+*)65WO R*,DMNX8IL01HXX^8H?2WK3=P[([BOLF_;X^,QS' MG=-O9X>9C61S<"P,98$^@/7O9&KOZ\&2=R!/HX#0BFBF_3->QC&]TTUYE.I( MIIGAO8%ZJJ89BBYJAL;:MW!SR%ZVBA MO;TM\D(",V#;VQ.:9!:X42K.*G5N<9BP^21[2?4T2M+D_LF),=7)RTL!]BQ5 M]R8*'%W,&$T$G/TH L8@0XIIIV+0F+B0HGA%G,BP0D^*(^3XJZLS:#Q-L&Q >;)T[ M,:W#0\O(,<5[(H".YL"!ID]1$4%D;0%#0Z_(^U3[>W,5)0E]\L:--IB65^3^ MC99I&ONK'3]^2:-*J?JG*/"(.$9V7U3;5?[F8WMSNE1VGA&H]L<(N>4A5%M M?YH:3]W9>C.7]L%YZ=WP5NL!W*,5U*WF@DB; _9J%:GU,S+8Z";$[29>-33L M3Y[J[#*_<=N3Q"1O/Z^1:S*9*!^ZL/98)U+:ZHL"9,KS>9H3S6&*V*T>'-(K M/^N!"NB.?L:&GE&4C!;\1/EZG(2M,(X9*]1 M9V5JPZQ,K<-5:-2Z&# 2O M[*EW8AJI$2V6%W.?L+<+:*I,\Y4DLH:]?XKB] ''&^%RZ ,]/.PM/6:",-"9 MQ+SQ*B7+]J8*.*HTJ)S9%_388DF\XOV)L;4?E@*PF% 3+<;4+_S YRM,-R^, MH_(P')V>69'0E4,$<3%*GC"9.,A,33],\BJEE2>20$#C\MGQ VK2BRB^)_J5 ME]#O*N88"(S:9&<#B_L9KAT4]6C. A+W5$W;O3,!V%Y:+L+1.HJ/$J=2<@%5 MQ0 (D0 LN"F+521[%:N0+/Y5E/U(:S*SOSHAR00]H%ADS%3%(G\?8M 7]T9T MTW4>0FX7.+'PS%)>3'Q3L&3+_28TE0Z&Z,^.W"A)271!]$)5+&F%_:?Z87] MB1?Q5LU98-&-@.:(\$?W-30O14!U(+>P8H=AM/9Q5@Y$ /5:3EY/>/Q\3\/G M'^-HM_7#1^72+?W=@4*ZKB%:"[KT] 4<+@Y68?]Z)PNT>D49,\2XH9P=F!AP M,K,(B^%R@LEGK.Q*.'\"_<,/2?XLH!,@AY5'@["<+2^_B=?3V!6 &[9CFF2/ MO+X.7-#N01@XYI@S7ONB5ILQ8/J0;8+9H4SLX<:KNG:#RZRRPO*S$WOB?$6C M=&[-)-EM^&?:@>9>3&8#OB:-VA> ZG.8!;F/?I?L:F\@C5EM'<27Z3=!C M[(0I#*BM5Q"@2>#N,O3._&!'1!R(J4.IS08\MBUV-C4MNI7L> D6?I6*'H%G_Z@C?7OJ,B3"L*RE"\?%RPV] M."$Q1T=SX&.T3]%*Q5M)6\#CM%=D_0M*JQ25E!>(TD:Y#E(!]WARD<] MORG"V=%;()0?_ZQR(63BM,Q)#) S01D75)M54<;(0H;E1/I7[_S4AX'=I^-K MUZ=J@53H53\0+UKUU(,S1!LH<(YBPOIS]'L3!AP)F=7/[,W'10.BZ*9B_3/Q MJN2G7"*+[]S;MV;M,E1^:Q'<;4AI"%BSV WA&_-'?#LC0)5N0'%LJ.)"_-?; M!W[XIZZ"ODML>?VII#':J0=$E&.6"(U&PJUX?B2\_H6^/%XCB M%C\0Q"[>K$C#[--W"SK$MIAFH^+@]>O1D%&PT'44*B.CK-M\D+%3<0DRMO:9 M%S)VJV &2OC/8S"HPP)^1&"[27R%*:HPF,%&@D?,/ XCOHWPL^_J/_<=O?< MR[.U^A5,=B38L?79WQ,H[FFH7]^4[^D&>%4Z1/J]MNI+)HNV"A/\Q+FQF)SP M;FU^2Z_/70Z*16 !WC3$,*OJ32?J MG7 4-;4+B^3"L!5X(0XMC-'FU EB(LF__L3ELK3I"1-05K>U>;*(XI;>QZ3UL]AR*Q'(:9( #A:YA1*P82@,P7&BK,B)B M+%#!EU5 & */RC =O'[@A M0_Q(N8\!<&;MV6H>. !7&J1J'D6;=G2?&4SU&:(+B61]9P0VO2J,B"FQ3&P)04'PL7\WHN<6H M06:V@-%M&/6XJ4ECEL#1H\I(X,'"+.$9&ML7"R>W#]T6%PSP/7P(^<5/G_SP M)L2_8B>N'!GL:=-.P@<",_W&TP$>.=4#@"(%Y4;=-,HD>2TJFY/9GMY'N_?# M1X)F^=?HC'RS0)^9M(B(BZB\TQS[F4*U$4W-2:-C]$I(&[RJIPS8:V(EHMG# M4QSM'I\>/D=4QZ0+O\:@#Q3&1C-E<4O0)''HUPE'T77_$WCV-F*T1GZ1RT,O MWWH4 [,-GE>TP0Y]?Y$@7"H^;D51#;E/1 ),^PC?Q.7[#L5-7EH ,<9/.$QH M(4H_)/_&Z$WS5;VO.5RBA"/I)D=2CZ8C4HAU"L"E[:)=VMITD?TS?*0B)+0H M@X=2;E.T]MOBVJ7P;1IE__T_,A09^)GL7W^8>TBF:,M\3R>6'(G%>EK$/Y-M@V2GQ61(+I_H:, MLX!*Z&RW<>2X3U]/? L4U@CN?,.ROH)@(K'Y-Q,*$:G87)Q8G8OAV?4$IY\Q MIG,R&?3OV;"?P0X&#[ORJ(L&7=J)?WNR #J7CVE0G<6)"OT#6*8,4A/0@@5B M6J)5&S]0:84@*2G? ^:O@;0<_^\^%Q0/ --Z% .$9XU=9WGR M"BQ4&\G$0'>;91AEFC90J!K%A*9VF*$ U]B[R^:<[*+5\.SG;75;> M3_[7'K+]<6IN_]C6K K+GH>R;VQ\009WYC5G+#,;'P>P..A0"M#"8&S$&F]G M]\#W<0LX/GD]X>7_[VGU_Q\)9F^)+;K*K2IV!0Y%0PQ0J4NIT \PO P2?_\- MO05:O:*,$6*<4,[*?M'5K )]_7D.>=W5S@[ QWN_LO7G<-I; Q[;"D+O\W - MF^9:GJ*Q6XBU\:!"3?WV3SOK$>Y)$K@CF#!8Q^.M@^@!=B8C:IE\P*3A>?)O M[!9,M&JY#J"R7AOU8Q3B5WZM]V(7>MT@)&T,'%ZZE12!H[TE8$CH$5C[HCW-#\O"I=IH7KQQYF?N$%$Y>V]6Q8Q:E8140/F2VFW!V*XU<_ M?+S+SD#YP^)#T6,X%> (HFF6ZN;2(!* D417$_W5'>>'^X>(J!8,PYG M9 \Y\AI.-VOMH&,@">"8H6,0$3"&] >,%EIJ[%M(C+TF!#ORF-0N$,JJ".D0N_+<+M+$X:;QYU1=7>/N:"#7-U6+&@VGX/G=TAM8#ASZHB3MQS] MCJGR?^\BNDEP&_LNNP& EFY*;R_PPZT$O6'#O?C]G+WX_3 O M?C]++ZY+;=B+WP/T8E,JW_N/H;_V72=,T0V[BW2S2G#\S%*),R-DGOP>@B>W M)986[_7>YY>'3ITM/0/H?533 -FY8,*>AFM?(^O1G .Z[*N:B?3F]MSFA?" M=R$(RB7I?+US0G]M>9V[^&R9)"1 :+-P7PUO V2A^ZLAPU7\=4^:D/W5E&K: M_MKV5KSHHEP(F3/;KPINWX*5J]8D!$>6;KA*^_^\W+^W?''WY(A'O #A,( MVK6.EA,%Z;FE>G_@2#78%/UW0%HZ \:>X3H83[Q>M)^YV3J3G\H>HV6[2DJC ME,]%"8_5-32MF6583Z#.KJ%^4;1$K1OTDB0#M= =TL?3%K"82"OAG36A+$7; MO9IIKW!/:0-^5QM."%, ,@_N^)[P0\1WE1YB)TS6F)5CWH729=@P$D"Q;1^# MM&Z'*/0'',YHJ6%BFR-?(67G!;3R2K;AB JV"TGBW<0;L%.8AO- :48VSBLD M!:5Y^)_O86'(^\P@Q_H8TD%BAAC29Y ^#)'UGQF&]*IA'D/>EQAR#!E#1C-- M-X:\+S&D$79.AR'W[A/V=@&^69]& 1$BBAUZ?KR,8UHTC^U#D6CLFOB>Y&MF M-,=EV]Y=-65&800*HC^U-@3L$MWR:B^8"55Z%% ?S\2UCASA M,]&?K*<<-V' :??\SO2CX52 #WU-LU0J,0XC =A==#71C@(%?FS3KR,[*HGA<4(8:! :MYXE5/:O:D"/C4PJ)SVN:S"66S/4>S5R"DISSA>1=WG M%! ,R8#LI&'(&:(9^Y^?<9*26?H6QW[D'9NV>SN+0T6X#H,:P;H6^H>(>EUJ M6L._10:#F5R("V;GN!:497.#;%L-LL=J=3\MSU^V/D^GYXJVA<'&.0 %MA'- M62R7S9*'OK(>25OMA M&!GU^\MG=$H2S9=?O$Q3[CT\I78/C%QR[/EE[T8TG M!F5^@L((!1$1.4;.L^,'--ENXJ4X,$LR7BWA766>.,GFB:Q=-4[F_UL*9F6F M@&A:P23ZEEZ,:8?'\9)VG>=1N33UD+E]9,]9P8O6(GAA9Z0_D)58+R!%GF8Q9?2-)>'MWPAV,$4]Y%04!^!?JEZ2V[/F9 )^EIC&QD5[V3$^"% MR<@*6]QISP1KH?XA' 0F,J5&O^'*/A\.4A:->U( M(,J9?!GX6=,5&'0NLCAW%,SD6[GGH3<1;AHRM3BS."E;E)%U&'I3+! ;@:E! M:]VG3IS.WEXK_.B'+,.SPVKSF7I^) W3Y#([[?@QCA+C67Z=G Y\^NDPK\D) MJ(7- 4]!7=I"F(2X?'1C@$M(/R$RSC-X'\/8C";NG'^LI *=<*@&?S +3!V[" M$#\ZQ,<[H6EZ2Q:4@&#/GN!\$<5K[--3Y@*A1YH&VCE!1Z_QS&LR>FMA QG_ M1M06 D *\@& 2(#&%@UT$"A*<[FQ1^]!OVRQ2_Y\B.A'4^W*#F!_X'@[](
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end